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The primary aim was to investigate factors associated with post-operative 
morbidity and mortality following liver resection. A secondary aim was to 
analyse the outcome of liver resection for colorectal liver metastases (CRLM) to 
identify factors associated with tumour recurrence and survival. 
Methods  
A retrospective review of a prospectively maintained database of patients 
undergoing liver resection between 2005 and 2012 was performed. 
Results and Conclusions 
Over a seven-year period 504 liver resections were performed.  Liver resection 
for CRLM was performed less frequently among the most socioeconomically 
deprived population. However, socioeconomic deprivation was not associated 
with tumour recurrence (P=0.867). The major complication rate was 18.7% and 
was significantly associated with age, male gender, insulin-dependent diabetes, 
hypoalbuminaemia, synchronous bowel procedures, the extent of resection and 
requirement for blood transfusion.   
The 90-day mortality rate was 2.7% in patients without post-hepatectomy liver 
failure or renal dysfunction, 20% in patients with single organ dysfunction and 
45% in patients with both. Post-operative serum lactate predicted the 90-day 
mortality rate (28% when post-operative lactate ≥6mmol/L compared to 0.7% 
when lactate ≤2mmol/L). In the staging of patients with CRLM, the use of MRI in 
addition to CT showed no association with lower rates of  post-operative intra-
hepatic tumour recurrence (P=0.737) or disease-free survival (P=0.487). 
Recurrence rates were lower in patients when a fibrous tumour pseudocapsule 
was present (P=0.026). There was no association between tumour doubling 
time prior to surgery and post-operative survival. Change in tumour size after 
completion of chemotherapy is variable and sometimes rapid, especially in 
patients who initially respond to treatment. However, disease-free survival is 
determined by tumour behaviour during treatment and not by change in size 
after completion of chemotherapy. 
Clinicians should consider multimodality imaging preoperatively, evaluate the 
role of preoperative MRI in the staging of colorectal liver metastases, and not 
use rate of growth of colorectal liver metastases as a predictor of poor outcome, 
Postoperative lactate should be used to guide level of postoperative care, and 
post hepatectomy liver failure in combination with renal dysfunction used to 
assess clinical progress. Histopathological reporting of the presence of 
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1.1.1 History of liver resection 
 
Documented evidence of the first liver resections dates from the late nineteenth 
century. During this period, surgeons feared operating on such a vascular organ 
due to the risk of catastrophic haemorrhage. Furthermore, the physiology of the 
liver and the effect of removing part of such a vital organ were poorly 
understood. It is therefore not surprising that the first resections were performed 
solely for trauma. In 1716, Berta1 resected a protruding portion of liver following 
a self-inflicted stab wound and in 1870 Von Bruns successfully resected a 
lacerated portion of the liver caused by a gunshot wound during the Franco-
Prussian war2. Following on from these early resections for trauma, the first 
reported resection of a solid liver tumour was performed by Linz in 18862 who 
removed a hepatic adenoma. Although this patient subsequently died from 
haemorrhage, the feasibility of resection had now been demonstrated and in 
1888 Langenbuch recorded the first elective liver resection to remove a 
pedicled tumour from the left lobe3. He was subsequently followed by Tiffany in 
18904 who removed a walnut-sized mass of biliary debris and calculi from the 
left lobe and Lucke in 1891 who removed the first malignant tumour5. Further 
resections were performed by Keen who reported resecting a bile duct 
adenoma in 1891 and an angioma in 1897. He also reported seventy five cases 
of liver resection performed around the world up until 18996 and performed the 





During these early liver resections there was very little understanding of the 
anatomy of the liver. Most surgeons believed that the liver was divided into right 
and left hemi-livers along the line of the falciform ligament1. However, around 
this time detailed anatomical studies of the liver were being performed by 
Cantlie and Rex which established it’s lobar and segmental anatomy7,8. This 
aided liver surgery by allowing it to be performed in a more controlled manner 
with lower risk of haemorrhage. There was however significant variation in 
description of the liver, with some based on surface anatomy and others based 
on the internal features, particularly vascular and biliary anatomy. 
The liver is the largest organ in the body and can be divided visually in its 
simplest form in to a right lobe and smaller left lobe by the falciform ligament 
which, runs from the liver to the umbilicus9. Postero-inferiorly the liver has an 
“H” shaped arrangement of fossae. Anteriorly and to the right lies the gall 
bladder fossa and to the left is the groove for the ligamentum teres. Posteriorly 
and to the right is the groove for the inferior vena cava and to the left is the 
fissure for the ligamentum venosum representing the obliterated fetal ductus 
venosus. The cross-bar of the “H” is the porta hepatis and this marks out the 
quadrate lobe anteriorly and caudate lobe posteriorly9. However, this 
classification does not take in to account the internal and functional anatomy of 
the liver and classifications reflecting this have supervened. For example, the 
quadrate lobe forms part of the right lobe but functionally it belongs to the left 
lobe10. Furthermore the caudate lobe has an independent blood supply and 
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venous drainage of the liver and is functionally separate to the right and left 
lobes11. 
At rest the liver receives a higher proportion of total cardiac output than any 
other organ (25%). It has a unique dual blood supply which is divided between 
the hepatic artery, contributing 25% to 30% of the blood supply, and the portal 
vein, which supplies 70% to 75%. Both blood supplies ultimately mix and then 
drain via the hepatic venous system12. Healey and Schroy were the first to 
divide the liver in to functional parts based upon hepatic artery branches and 
biliary ducts13. Further work was carried out by Goldsmith and Woodburne who 
developed a system of division based on the portal and hepatic veins14. 
Couinaud first suggested that the liver can be divided in to eight functionally 
independent segments based on the arrangement of portal and hepatic veins15 
and this work was extended by Bismuth who developed a new system based on 
a composite of the earlier descriptions of Goldsmith and Woodburne and 
Couinaud16. This divided the liver in to right and left hemilivers which could each 
be divided in to two sectors (right anteromedial, right posterolateral, left anterior 
and left posterior). Each right sector could be further divided in to two segments 
as could the left anterior sector. The left posterior sector formed a single 
segment and the caudate lobe was an independent segment. 
In 1998 the International Hepato-Pancreato-Biliary Association sought to 
standardise the terminology of liver anatomy. This resulted in the Brisbane 
Terminology of hepatic anatomy and resections being adopted17. This consists 
of three orders of classification.  
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1. 1st Order – Separated by the midplane of the liver (plane that 
intersects the gallbladder fossa and the fossa for the inferior vena 
cava) 
• Right liver – segments 5-8 (+/- 1) – right hemihepatectomy 
• Left Liver – segments 2-4 (+/- 1) – left hemihepatectomy 
 
2. 2nd Order – Separated by left intersectional plane between 
umbilical fissure and attachment of falciform ligament. No surface 
marking of right intersectional plane  
• Right anterior section – segments 5, 8 – Right anterior 
sectionectomy/sectorectomy 
• Right posterior section – segments 6, 7 – Right posterior 
sectionectomy/sectorectomy 
• Left medial section – segment 4 – Left medial 
sectionectomy/sectorectomy 
• Left lateral section – segments 2, 3 – Left lateral 
sectionectomy/sectorectomy 
• Right hemiliver plus left medial section – segments 4-8 (+/- 
1) – Extended right hemihepatectomy/sectorectomy 
• Left hemiliver plus right anterior section – segments 2-5, 8  
(+-1 1) – Extended left hemihepatectomy/sectorectomy 
 
3. 3rd Order 
• Segments 1 – 8 – Segmentectomy 







The liver has six broad functions: 
1. Digestion 
Bile is secreted by hepatocytes and ductular epithelial cells. Bile consists 
of bile acids, cholesterol, lecithins, bile pigments which are end products 
of the breakdown of the haemoglobin in red blood cells, and an isotonic 
fluid with similar electrolyte concentrations to plasma containing sodium, 
potassium and chloride ions. Each day between 250-1500ml of bile 
enters the duodenum. The primary role of bile in digestion is the 
emulsification of lipids to permit digestion of lipids by lipases. The 
products of this digestion then form mixed micelles with bile acids which 
aid in the absorption of lipids and lipid-soluble molecules including the 
fat-soluble vitamins A, D E and K. Cholesterol is insoluble in water and 
bile provides the major route for its excretion18.  
2. Metabolism 
Carbohydrates, lipids and proteins are all metabolised by the liver. Insulin 
regulates blood glucose concentration by balancing peripheral glucose 
utilisation and hepatic glucose production19. Glucose enters hepatocytes 
via a plasma membrane transporter called GLUT2 and is used to 
synthesize glycogen20.  
During the fasted state glycogenolysis occurs in the liver during which 
glycogen is hydrolysed by glycogen phosphorylase to produce glucose21. 
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However, during prolonged fasting glycogen stores may become 
depleted. Gluconeogenesis allows the synthesis of glucose using lactate, 
pyruvate, glycerol, and amino acids. These substrates are either 
generated in the liver or transported from other tissues21. 
The role of the liver in lipid metabolism involves the uptake and 
degradation of chylomicron remnants. Hepatocytes also synthesise and 
secrete lipoproteins. The liver is the principle source of cholesterol in the 
body, and also its excretion via the secretion of bile18. 
The catabolism of proteins results in the production of ammonia which is 
converted to urea within the liver18. Urea is less toxic than ammonia and 
can be excreted easily in the urine. The remaining substances formed by 
the breakdown of amino acids can form the substrates for 
gluconeogenesis or be converted to Adenosine Triphosphate (ATP). 
 
3. Detoxification 
The smooth endoplasmic reticulum of hepatocytes contains systems of 
enzymes and cofactors which are responsible for the transformation and 
excretion of many hormones, drugs and toxins18. This results in the 
inactivation of drugs and toxins and performs an important homeostatic 
role in the control of hormone levels. Conjugation of other compounds 




In addition to the storage of glucose as glycogen the liver also stores 
fatty acids from the breakdown of triglycerides. It is also an important site 







As well as being involved in the synthesis of glucose and cholesterol and 
the breakdown of proteins, the liver also synthesises amino acids and 
proteins. These include the clotting factors I, II, V, VII, VIII, IX, X, XI and 
XII22. Protein C, Protein S and antithrombin are also synthesised in the 
liver which regulate anticoagulation22. The liver is also a site of 
thrombopoietin synthesis which regulates platelet production23. The liver 
is a major source of insulin-like growth factors and IGF binding proteins 
which have important endocrine activities relating to energy metabolism, 
body size, carcinogenesis, and various organ-specific functions24. 
 
6. Immunity 
The liver functions as a major part of the immune system. Kupffer cells in 
the liver are a critical component of the mononuclear phagocytic system. 
Due to the large volume of blood that passes through the hepatic portal 
system they play a pivotal role in both the hepatic and systemic response 
to pathogens25.  
1.1.4 Pathology of liver tumours 
 
Primary liver malignancy includes one of the world’s most common malignant 
neoplasms, hepatocellular carcinoma (HCC) as well as the less common 
cholangiocarcinoma and angiosarcoma26.  
Worldwide hepatocellular carcinoma is the fifth most common cancer in males 
and the seventh most common cancer in females, and is the third leading cause 
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of cancer-related death27,28. Risk factors for the development of HCC include 
hepatitis B and C infection29 alcoholic cirrhosis and non-alcoholic fatty liver 
disease (NAFLD)30. Treatment of early stage HCC includes surgical resection 
+/- adjuvant chemotherapy, liver transplantation and locoregional therapy, whilst 
intermediate disease is often treated with transarterial chemoembolisation 
(TACE) and advanced disease may be treated with systemic therapy, cytotoxic 
chemotherapy, immunotherapy, or oncolytic virus therapy31, or patients may 
receive palliative and best supportive care. 
Cholangiocarcinoma is an epithelial cell malignancy which can arise from 
varying locations within the biliary tree. These can be classified by location as 
intrahepatic, perihilar, and distal cholangiocarcinoma32. Perihilar disease 
represents about half of all cases, distal disease 40%, and intrahepatic disease 
less than 10% of cholangiocarcinoma cases33. Mixed hepatocellular-
cholangiocellular carcinomas have recently been acknowledged as a distinct 
subtype of cholangiocarcinoma34. In the majority no risk factor are identified for 
the development of cholangiocarcinoma but hepatitis B, C, cirrhosis and an 
association with primary sclerosing cholangitis have been identified32. 
Treatment includes cytotoxic therapies, liver resection and liver transplantation. 
Angiosarcoma is a rare, aggressive tumour that grows into the lumen of pre-
existing vascular spaces like sinusoids and terminal hepatic venules. Worldwide 
approximately 200 new cases are diagnosed annually and it is the most 
common primary malignant mesenchymal tumour of the liver in adults 
accounting for 2% of all primary hepatic malignancies35. There are few 




Benign liver lesions include haemangiomas, focal nodular hyperplasia and 
hepatocellular adenoma. Haemangiomas are the most common benign hepatic 
tumours and are often discovered incidentally36. Asymptomatic haemangiomas 
do not require surgical resection and the role of surgery is debatable even when 
symptomatic37. Focal nodular hyperplasia is the second most common benign 
liver tumour and is far more common in females (up to 90%) with an average 
age at presentation between 35 and 50 years36. Treatment is not recommended 
but if patients are symptomatic or imaging appearances are atypical surgery 
can be considered36. 
Hepatocellular adenomas have an even lower incidence and encompass 
various types of clonal benign hepatocellular proliferations36 and are linked with 
the use of the oral contraceptive pill. However, they have the potential for both 
haemorrhage and malignant transformation and surgical resection has been 
recommended38,39. Guidelines suggest that the treatment of choice of 
adenomas in men is resection, but in women a period of six-month observation 
is recommended after lifestyle changes including weight loss and stopping the 
oral contraceptive pill36. 
Secondary malignancy of the liver accounts for 95% of all hepatic 
malignancies40 and of these colorectal liver metastases (CRLM) are by far the 
most common26.  Up until the 1980s patients with CRLM were often left 
untreated, but now they form the bulk of all resections performed. 
Colorectal cancer is the third most common cause of cancer death and in the 
UK 39,000 new cases are diagnosed each year and over half of these develop 
liver metastases41. Globally it is estimated that 40-70% of patients with 
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colorectal cancer will develop CRLM40. Surgery provides a potential cure for 
these patients, but only 10-20% of patients with CRLM are considered suitable 
for resection.  
1.1.5 Liver resection as a potential cure for malignant tumours 
 
In terms of surgery offering a potential cure for malignant liver tumours the 
outcomes vary according to tumour type. Five year survival rates for patients 
undergoing liver resection for hepatocellular carcinoma have been reported 
between 34-91%42–44. 
In patients undergoing surgical resection for cholangiocarcinoma curative 
treatment with negative tumour margins can be achieved in less than 30% of 
patients33. The median survival time by of patients with lesions considered to be 
surgically resectable is 36 months33,45. 
Liver resection provides a potential cure for patients with colorectal liver 
metastases (CRLM), Five year survival rates currently range from 32% to 
65%40,41, a stark comparison to the five year survival rate of those without 
resection which approaches zero40. However surgery is not without risk and 
review of published studies suggests a 30 day mortality rate of 0-6.6% (median 
2.8%)41. Untreated the prognosis for these patients is poor, with a median 
survival of less than nine months46. In patients with unresectable liver 
metastases survival has improved from 12 months in patients treated with 
fluorouracil therapy to approximately 2 years in those treated with combinations 
of oxaliplatin, fluorouracil and folinic acid (FOLFOX), capecitabine and 




Published guidelines for the management of metastases of unknown origin 
(MUO) recommend a range of chemotherapy regimens51, and surgery is rarely 
appropriate in the treatment of MUO due to the high rate of recurrence from the 
unknown primary. 
 
1.1.6 Liver resections in the twentieth century 
 
Advances in surgical technique as well as peri-operative care have led to a 
much wider application of liver resection. The first successful right sided 
lobectomy was performed by Wendell in 1911 52, but the significance of this 
achievement and its relationship with segmental anatomy was not recognised 
until the work of Couinaud in 195453. In 1949 a right hemihepatectomy was 
successfully performed by Honjo54 in Japan and three years later the first true 
anatomic resection with vascular control was performed by Lortat-Jacob and 
Robert55. This anatomic resection paved the way for many other case reports of 
liver resection and this rise in the number of resections led to research into liver 
regeneration following resection.  Regeneration of the liver was described in 
1962 suggesting that complete regeneration could occur within three to six 
months of surgery56.  
During the following decades, the techniques of liver resection were modified 
and improved to improve patient safety. This included methods for anatomically-
based segmental resections, the use of subcostal incisions rather than 
laparothoracotomies, the use of surgical drains, modern techniques for 
transecting the liver parenchyma, low central venous pressure anaesthesia57 
and improvements in postoperative support. However, there was a paucity of 
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large published series to support the widespread practice of liver resection. 
Instead there were numerous published single case reports often with few or no 
details of follow up. A review of published data in 1970 attempted to consolidate 
those case reports and small series to provide meaningful information regarding 
morbidity and mortality from liver resection. In these early reports in-hospital 
mortality following resection for primary liver carcinomas was observed to be 
24% and 17% for metastatic liver tumours, with five year survival rates between 
14% for primary liver carcinomas and 21% for metastases58. When compared to 
survival without treatment these results clearly suggested that liver resection 
offered a viable treatment option for such tumours. 
1.1.7 Modern day liver resection techniques. 
 
Whilst a better understanding of the anatomy and physiology of the liver has led 
to advances in liver resection surgeons still face the challenge of deciding upon 
anatomic, non-anatomic or wedge resections. The decision process must take 
in to account factors including tumour burden, risk of recurrence as well as the 
effect of preoperative chemotherapy and pre-existing liver disease as all of 
these factors can influence outcome after surgery59. 
1.1.7.1 Control of vascular inflow 
 
Blood loss60,61 and the requirement for blood transfusion62,63 are associated with 
worse outcome after liver resection in terms of morbidity and mortality and 
blood transfusion has been associated with tumour recurrence64,65. Attempts 
that have been made to control vascular inflow include use of the Pringle 
manoeuvre66, selective67 and total hepatic vascular exclusion68, total hepatic 
vascular exclusion with caval flow preservation69, ischaemic pre-conditioning70 
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and use of the hanging manoeuvre71 during hepatic mobilisation. A Cochrane 
review of these techniques concluded that intermittent vascular occlusion did 
not decrease morbidity after liver resection72. Among the different methods of 
vascular occlusion, intermittent portal triad clamping has most evidence to 
support the clinical application. Hepatic vascular exclusion was not 
recommended routinely. Ischaemic preconditioning before continuous portal 
triad clamping was felt to be of clinical benefit in reducing intensive therapy unit 
and hospital stay after liver resection. 
1.1.7.2 Transection of liver parenchyma 
 
In an attempt to reduce blood loss further various techniques for liver 
transection have been developed. These include: basic finger or clamp-
fracturing (Kelly-Clasia) of parenchyma to expose vessels and biliary radicals, 
use of the Cavitron Ultrasound Surgical Aspirator (CUSA, Tyco Healthcare, 
Mansfield, MA, USA) which combines ultrasonic energy with aspiration to 
skeletonise these structures. Both the Harmonic Scalpel (Ethicon Endo-
Surgery, Cincinnati, OH, USA) and the Ligasure Vessel Sealing System 
(Medtronic, Mansfield, MA, USA) are often used in laparoscopic liver resections 
but can also be used in open surgery to seal and divide vessels and biliary 
radicals73,74. Radiofrequency dissecting sealers (RFDS) link radiofrequency 
energy with cool saline to achieve blunt parenchymal dissection and 
haemostatic sealing of small vessels75 and water jet dissection uses a high-
pressure water jet to isolate vessels and biliary radicals which are then ligated76. 
Vascular surgical staplers have also been employed to quickly transect the liver 
parenchyma77. The use of these methods was also the subject of a Cochrane 
review which concluded that the clamp-crush technique is advocated as the 
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method of choice in liver parenchymal transection because it avoided special 
equipment, whereas the newer methods did not offer any benefit in decreasing 
the morbidity or transfusion requirement78. Furthermore the most recent 
Cochrane review in 2016 suggested that using special equipment for liver 
resection is not of any benefit in decreasing the mortality, morbidity, or blood 
transfusion requirements79. Importantly this review recommended the use of a 
radiofrequency dissecting sealer only in the clinical trial setting since there was 
low-quality evidence for increased harm without any evidence of benefits. 
1.1.7.3 Laparoscopic liver surgery 
 
Early attempts at laparoscopic liver surgery were in the 1990s and mainly 
involved laparoscopic wedge resections80. More recently major resections 
including hemihepatectomies are performed laparoscopically81. A recent meta-
analysis82 concluded that blood loss was lower, need for transfusion, pulmonary 
and cardiac complications, PHLF was less as was length of stay in those 
undergoing laparoscopic surgery. However, none of the studies included were 
randomised controlled trials and there was significant heterogeneity between 
patient groups making comparisons difficult. The results of a randomised 
controlled trial compared laparoscopic versus open liver resection for colorectal 
liver metastases demonstrated a lower rate of postoperative complication and 
length of stay but no difference in blood loss, operative time, mortality or 
positive resection margins83. 
1.1.7.4 Radio- and microwave- ablation of liver tumours 
 
Radiofrequency ablation (RFA) is a minimally invasive treatment which uses 
heat to destroy cancer cells. A needle electrode is passed into the tumour under 
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image guidance either percutaneously or intra-operatively. High-frequency 
electrical currents are then passed through the tumour creating frictional heat 
produced by the ionic agitation of particles within the tumour that destroys the 
cancer cells surrounding the electrode84. Microwave ablation (MWA) uses 
microwaves to heat and destroy the tumour and is used for the same indications 
as RFA85. The procedure is less invasive than surgery and can be used to treat 
multiple lesions and can be repeated if necessary as tumours recur. In the liver, 
RFA and MWA are most commonly used to treat hepatocellular carcinoma84 
and colorectal liver metastases86. They are more effective at treating smaller 
tumours due to the risk of thermal damage to surrounding structures and 
limitations of the burn zone size. A recent randomised controlled trial has shown 
no difference in efficacy between the two techniques87. Ablation may be an 
alternative to resection in patients deemed not fit enough for surgery88, in those 
with multilobar tumours that cannot be removed surgically and in those with 
impaired liver function86,89. It may also be used as an adjunct to surgical 
resection either as a separate procedure or performed intraoperatively86. 
1.1.8 Oncosurgery and colorectal liver metastases 
 
The primary aim of tumour resection is to remove the tumour with an uninvolved 
margin (R0 resection)90. Without neoadjuvant chemotherapy however surgical 
resection is not possible in 70%–90% of patients with liver metastases from 
CRC due to excessive tumour burden. Neoadjuvant chemotherapy with either 
oxaliplatin or irinotecan based regimes can lead to down-sizing of tumour 
nodules leading to improved resectability91. 
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First line chemotherapy with doublet (two chemotherapy agents) or triplet 
regimens (three agents) for a minimum of four courses is also used in patients 
with potentially resectable disease. In such patients neoadjuvant chemotherapy 
is associated with improved progression-free survival in patients with 
synchronous metastases92. In patients with metachronous disease the benefits 
of neoadjuvant chemotherapy are less clear93. Although the proportion of 
patients with CRLM who respond to liver directed chemotherapy (LDC) has 
been defined in many studies92,94 the duration over which the changes are 
sustained following completion of treatment has not been described, and the 
consequences of tumour progression in the interval between completion of 
chemotherapy and surgery are unknown. This issue is addressed in greater 
detail in Chapter 5. 
 
1.1.9 Liver resection within the South West Peninsula 
 
The Peninsula Hepato-Pancreatico-Biliary (HPB) multidisciplinary team (MDT) 
was founded in July 2005. It was set up to serve the population of the South 
West Peninsula (1.8 million) and receives referrals from five hospitals: Royal 
Cornwall, University Hospital Plymouth (PHNT), Royal Devon and Exeter, 
Torbay and North Devon District Hospitals. The MDT meets weekly and is 
attended by radiologists, oncologists, surgeons and physicians. The MDT 






















1.1.10 Preoperative imaging of colorectal liver metastases 
 
Cancer staging is a method for describing the location, size and extent of 
spread of malignant tumours. This is used to facilitate the planning of treatment. 
Prior to liver resection for CRLM most patients undergo imaging of the thorax, 
abdomen and pelvis by CT scan. Modern helical CT scans have a per-lesion 
sensitivity and specificity of 51.8-84.6% and 77.2-98.0%. However, MRI scans 
have been recommended in pre-operative staging95,96 due to their greater 
sensitivity and specificity (86.9-100% and 80.2-98.0%) particularly for the 
detection of sub-centimetre lesions97,98 which may lead to a lower rate of 
intrahepatic recurrence after resection. Intraoperative ultrasound is also widely 
used for the detection of CRLM99 but it is operator dependent and accurate 
figures for sensitivity and specificity are difficult to obtain and direct comparison 
with preoperative imaging is difficult to perform. However figures of 84.3% and 
76.5% respectively have been reported100. This issue is addressed in greater 
detail in Chapter 3. 
 
1.1.11 Tumour kinetics and doubling time 
 
The growth rate of tumours provides an indication of the proportion of viable 
tumour cells and their proliferation rate. The growth rate therefore potentially 
gives an indication of tumour behaviour and responsiveness, as radiation and 
drug effectiveness are both strongly influenced by kinetic parameters101. 
Tumour growth rate is also an important indicator of prognosis102–106. The 
growth rate can be assessed by sequential measurement of  
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tumour size and is commonly expressed as the tumour doubling time (DT). 
Tumour DT can be calculated using the equation: 
DT=Ti x Log2 / (3 x Log(Dp/Dr) 
where Ti = time interval between radiological diagnosis and surgery, Dp = 
diameter at pathology and Dr = diameter at radiological diagnosis 107 
Although the survival of patients with untreated metastatic colorectal cancer has 
been described108 the rate of growth of untreated colorectal liver metastases 
(CRLM) is not well defined, and little information is available regarding the 
influence of the pre-operative rate of growth of CRLM on survival following liver 
resection. This issue is addressed in greater detail in Chapter 4. 
 
1.1.12 Obesity, diabetes, steatosis and liver surgery 
 
Obesity, diabetes and hepatic steatosis often coexist in the metabolic 
syndrome109. Non-alcoholic fatty liver disease (NAFLD) is the commonest cause 
of liver disease in Western countries110. It has been suggested that hepatic 
steatosis is associated with increased risk of postoperative complications after 
liver resection111. and both diabetes and obesity have been shown to be 
independent risk factors for postoperative complications following major surgery 
at other sites112,113. This issue is addressed in greater detail in Chapter 6. 
1.1.13 Anaerobic metabolism and liver surgery 
 
Lactic acid is a by-product of anaerobic metabolism which is subsequently 
metabolised in the liver114. It is produced when pyruvate (an intermediate 
metabolite from glycolysis) is metabolised under anaerobic conditions for 
Adenosine Triphosphate (ATP) generation and increased production occurs 
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when there is inadequate oxygen delivery. Intra-operative causes for this 
include: decreased cardiac output (e.g. general anaesthesia, reduced venous 
return, hypovolaemia), anaemia (blood loss), disturbances in gas exchange 
(ventilation/perfusion mismatch) and localised ischaemia (organ manipulation, 
vessel clamping, hypotension)115.  Increased lactate may also be a result of 
reduced liver metabolism, which accounts for 40-50% of whole body lactate 
clearance115 and may be affected by liver ischaemia, the Pringle manoeuvre 
(clamping of the hepatoduodenal ligament interrupting the flow of blood through 
the hepatic artery and portal vein)116 and potentially from reduced metabolic 
capacity due to extensive resections.  However no change in glucose and 
lactate metabolism following partial hepatectomy has been demonstrated in 
post-operative tests in either rats117 or humans114, implying that the liver has a 
large functional reserve under physiological conditions of lactate production. 
Finally, exogenous sources of lactate can raise the lactate level e.g. lactate 
containing fluids like Hartmann’s solution and packed red cells.  
Hyperlactataemia is associated with increased morbidity and mortality in a 
critical care setting118, in patients with liver failure119 and sepsis120 and in those 
undergoing abdominal surgery121 but it’s association with outcome following 
liver surgery is less well described.  
1.1.14 Pathological features of colorectal liver metastases 
 
Liver specimens are routinely sent for pathological analysis after resection and 
the UK Royal College of Pathologists (RCPath) minimum dataset for liver 
specimens with colorectal metastases includes details of tumour number, size, 
location, resection margin clearance, capsular invasion, degree of 
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differentiation, the presence of tumour necrosis, vascular and lymphatic 
invasion, the presence of satellite lesions, invasion of adherent tissue, and 
lymph node status if sampled122. Other features whose prognostic significance 
has not been thoroughly assessed, include the presence of a fibrous 
pseudocapsule around the tumour and the degree of tumour necrosis. The 
presence of a pseudocapsule has been associated with better overall survival 
after resection of CRLM123–125. This issue is discussed in more detail in Chapter 
9. Tumour necrosis can result from chemotherapy use126 and is also seen in 
tumours with high rates of cellular turnover in rapidly expanding tumours127. 
Therefore, tumour necrosis may be associated with more aggressive tumours 
and a worse prognosis. 
 
1.1.15 Socioeconomic status and outcomes in surgery 
 
Lower socioeconomic status is associated with an increased risk of all-cause 
mortality and disease128,129  It is also associated with poorer outcome from the 
treatment of disease. This may be due to many factors including unhealthy 
behaviour, environmental exposures or psychosocial factors128. There is also 
disparity in access to healthcare between populations of higher and lower 
socioeconomic status in the UK130,131. 
The incidence of primary colorectal cancer is associated with low 
socioeconomic status (SES) in the UK, where the age standardised incidence is 
11% higher in men living in the most deprived areas of England compared with 
those living in the least deprived132. Population studies have also shown that 
low SES is associated with worse outcome amongst patients with colorectal 
cancer133–135.  Little is known about the association between socioeconomic 
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status and outcome following liver resection for colorectal metastases and this 
is discussed further in Chapter 10. 
 
1.1.16 Complications of liver surgery 
 
Despite advances in both operative technique and perioperative care hepatic 
resection is associated with significant postoperative complications and 
mortality. Postoperative morbidity rates of between 12.5% and 66% (median 
36%)136,137 have been reported which include liver137–139 and renal failure140,141 
and bile leak142. Similarly, mortality rates of between zero and 22% (median 
3.7%)136 are reported. Attempts have been made both to identify prognostic 
factors and develop prognostic scoring systems for both perioperative 
complications and death. Preoperative patient factors associated with adverse 
outcome are shown in Table 1.1. 
 
 





Preoperative factor Study reference 
Hospital volume 143,144 






Renal dysfunction 63,148,153,163,164 
Comorbidity 143,147,148,155,165,166 
Diabetes mellitus 60,163,164 






Operative factors associated with adverse outcome are displayed in Table 1.2. 
 
 
Table 1.2 Operative factors associated with adverse outcome following liver 
resection 
 
1.1.16.1 Post hepatectomy liver failure 
 
Post-operative liver dysfunction is a major contributor to both morbidity and 
mortality with an incidence between 1.2% and 32% in published series137–
139,172,181–185.  It has been defined by the “50-50 criteria” as a prothrombin index 
of less than 50% (mean normal prothrombin time (PT) divided by patient's 
observed PT) and a serum bilirubin of >50µmol/L on the fifth postoperative day, 
which has been shown to predict liver failure and death after hepatectomy186. 
More recently post-hepatectomy liver failure (PHLF) and has been defined by 
the International Study Group of Liver Surgery (ISGLS) as a postoperatively 
acquired deterioration in the ability of the liver to maintain its synthetic, 
excretory, and detoxifying functions, characterized by an increased INR (or 
need of clotting factors to maintain normal INR) and hyperbilirubinaemia on or 




Operative factor Study reference 




Extent of resection 62,63,167,169,173–175,143,145,147–149,151,156,158 









1.1.16.2 Postoperative renal dysfunction 
 
Newly developed postoperative renal dysfunction has also been shown to be 
associated with increased mortality following liver resection188, with a reported 
incidence between 5-15%140,141,189. Post-hepatectomy renal failure may occur in 
conjunction with liver failure when maldistributive circulatory changes occur 
causing intravascular hypovolaemia140,190, but is also related to operative stress 
and blood loss148,152. 
 
1.1.16.3 Bile leak 
 
Bile leak following liver resection is a major cause of postoperative morbidity 
leading to longer hospital stay, the need for diagnostic tests and radiological or 
surgical intervention191. The incidence of bile leakage after liver resection 
without biliary reconstruction ranges from 3.6% to 12%192,193 and after 
hepaticojejunostomy ranges from 0.4% to 31.8%193,194. Bile leak has been 
defined as discharge of fluid with an increased bilirubin concentration via the 
intra-abdominal drains on or after postoperative day 3 or as the need for 
radiological drainage or laparotomy for biliary complications. Increased bilirubin 
concentration in the intra-abdominal drain or within biliary collections are 
defined as a bilirubin concentration at least 3 times the serum bilirubin 
concentration measured at the same time. This may originate from the cut 
surface of the liver, from injury of the bile ducts, or from anastomotic leakage 





1.2  Problems to be investigated 
 
1.2.1 How accurate is the regional Multidisciplinary Team (MDT) in 
determining tumour type and resectability? 
 
Despite MDT assessment we have experienced cases where the histological 
diagnosis has either differed from the presumed preoperative diagnosis or 
where the available imaging does not allow a certain diagnosis to be made. 
Furthermore, despite advanced imaging techniques some patients undergo 
surgery without proceeding to resection due to unexpected operative findings. 
The aim of this study was to assess the performance of the MDT in its ability to 
determine accurately tumour type as well as resectability 
 
1.2.2 What is the value of Magnetic Resonance Imaging (MRI) in 
addition to CT in the preoperative staging of colorectal liver 
metastases? 
 
The aim was to measure the accuracy of CT and MRI in the detection of CRLM 
and to compare disease-free survival amongst those patients staged with CT 




1.2.3 Is there an association between the tumour doubling time of 
CRLM prior to liver resection and postoperative tumour recurrence 
and survival? 
 
The aim of this study was to assess the DT of CRLM in patients not receiving 
liver-directed chemotherapy between radiological diagnosis and liver resection 
and to explore potential associations with tumour recurrence and survival after 
resection. 
 
1.2.4 What happens to the size of CRLM in the interval between 
finishing liver-directed chemotherapy and liver resection and is this 
associated with tumour recurrence and survival? 
 
Patients are allowed a period of recovery between completion of pre-operative 
chemotherapy for CRLM and liver resection196 due to the potential 
hepatotoxicity of such agents197. During this period there is the potential for 
uninhibited tumour progression which may be associated with an increased 
chance of post-operative recurrence.  
The aim of this study was to assess the change in size of CRLM between post-
chemotherapy imaging and liver resection and to measure potential 




1.2.5 What is the association between hepatic steatosis, diabetes 
and obesity in patients undergoing liver resection and are these risk 
factors for major post-operative complications? 
 
The aim of this study was to assess the relationship between diabetes, obesity 
and hepatic steatosis and identify any associations between these risk factors 
and major complications following liver resection 
 
1.2.6 Does postoperative arterial lactate concentration predict post-
operative organ dysfunction and mortality following liver resection? 
  
The aim of this study was to determine whether the first post-operative lactate 
concentration is associated with 90-day mortality, length of hospital stay and 
organ dysfunction. It also aimed to identify which pre-operative and intra-
operative factors are associated with the postoperative lactate concentration. 
 
1.2.7 Can the International Study Group for Liver Surgery (ISGLS) 
definition of PHLF and postoperative renal dysfunction predict 
mortality after liver resection? 
 
This study aimed to test the ability of the new definition of PHLF to predict 
mortality following liver resection. It also aimed to assess the incidence of renal 




1.2.8 Is the presence of a tumour pseudocapsule or tumour necrosis 
associated with recurrence after liver resection for colorectal liver 
metastases? 
 
The aim of this study was to analyse the relative significance of factors reported 
in the minimum histopathology dataset and the presence of tumour 
pseudocapsules and necrosis on tumour recurrence one year after resection of 
CRLM.   
 
1.2.9 Is socio-economic deprivation associated with the likelihood of 
undergoing liver resection for hepatic colorectal metastases and is it 
associated with outcome following surgery? 
 
The primary aim of this study was to compare levels of socioeconomic 
deprivation in patients undergoing liver resection for CRLM in a regional HPB 
unit with those of the local population. A secondary aim was to determine if SES 
is associated with disease-free and overall survival. 
 
1.3  Data collection 
 
Since the inception of Peninsula HPB unit a detailed database of all cases 
undergoing surgery liver including those resected and those not resected. This 
database records many aspects of each patient’s journey from referral to follow-
up imaging and death. The database records routine data of use in clinical 
practice but also has been designed to answer specific questions by recording 
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novel aspects of the patient journey. Preoperative and operative data is entered 
by the operating surgeon at the end of resection. Details of postoperative 
complications, length of hospital stay, blood results and details of surveillance 
imaging are also recorded. Confirmation was obtained from the regional health 
research authority that under the harmonized Guidance Approval for Research 
Ethics Committees (REC), REC review was not required because patient data 
were collected during their normal hospital care and was anonymised for 
research purposes. No patient consent was required for this study. 





Chapter 2 : The preoperative assessment of 
hepatic tumours - evaluation of UK regional 
multidisciplinary team performance  
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In the UK patients where liver resection is contemplated are discussed at 
hepatobiliary multi-disciplinary team (MDT) meetings. The aim was to assess 
MDT performance by identification of patients where radiological and 
pathological diagnoses differed. 
Methods 
A retrospective review of a prospectively maintained database of all cases 
undergoing liver resection from March 2006 to January 2012 was performed. 
The presumed diagnosis as a result of radiological investigation and MDT 
discussion is recorded at the time of surgery. Imaging was reviewed by 






Four hundred and thirty-eight patients were studied. There was a significant 
increase in the use of preoperative imaging modalities (p=<0.01) but no change 
in the rate of discrepant diagnosis over time. 42 individuals were identified 
whose final histological diagnosis was different to that following MDT discussion 
(9.6%). These included 30% of patients diagnosed pre-operatively with 
hepatocellular carcinoma and 25% with cholangiocarcinoma of a major duct. 
Discussion  
MDT assessment of patients pre-operatively is accurate in terms of diagnosis. 
The highest rate of discrepancies occurred in patients with focal lesions without 
chronic liver disease or primary cancer, where hepatocellular carcinoma was 
over-diagnosed and peripheral cholangiocarcinoma under-diagnosed, where 
particular care should be taken.  Additional care should be taken in these 




Cancer care in the UK has undergone a major change in recent years with the 
centralisation of care in a network of Cancer Centres198. This has led to the 
establishment of regional Hepato-Pancreatico-Biliary (HPB) Units where 
patients in whom liver resection is contemplated are discussed at a Multi-
Disciplinary Team (MDT) meeting in the presence of radiologists, oncologists, 
surgeons and physicians. This is intended to provide greater clinical input into 
the diagnosis of the wide spectrum of disease processes for which liver 
resection is appropriate199. During the same period increasing awareness of the 
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complimentary role of different imaging modalities in diagnosing liver 
disease200–202 has led to many patients having multiple investigations prior to 
surgery. Although the accuracy of single imaging modalities including 
Ultrasound200,203,204, Computerised Tomography (CT)97,98,200,204,205, Magnetic 
Resonance Imaging (MRI)97,98,200,204,206 and Positron Emission Tomography 
(PET)200,205 scans in assessing hepatic malignancies have been well reported, 
the performance of MDT review of multiple pre-operative imaging techniques 
with input from clinicians in the diagnosis of malignancy and planning of 
treatment has not been described. The Peninsula HPB unit was founded in July 
2005 to serve the Devon and Cornwall region of England (population 1.9 
million). Imaging from referring hospitals is imported and discussed in a weekly 
MDT meeting and treatment recommendations made and recorded. After 
resection histology of the excised sample is also discussed at the MDT meeting. 
Despite MDT assessment we have experienced cases where the histological 
diagnosis has either differed from the presumed preoperative diagnosis or 
where the available imaging does not allow a certain diagnosis to be made. In 
this situation, a list of differential diagnoses is made from which treatment is 
recommended. Furthermore, despite advanced imaging techniques some 
patients undergo surgery without proceeding to resection due to unexpected 
operative findings. The primary aim of this study was to identify patients where 
the diagnosis determined by the MDT differed from the final histological 
diagnosis. A secondary aim was to identify recurring areas of confusion to guide 
future MDT assessment and to determine if the rate of inaccurate diagnosis of 






The Peninsula HPB unit has maintained a prospective database since the 
inception of the unit where the outcome of MDT discussion is recorded prior to 
surgery. A review of all patients undergoing surgery from March 2006 to 
January 2012 was performed. Details of pre-operative diagnosis, imaging 
modalities performed, operative findings and final histology were retrieved. 
Patients were identified where the MDT was unable to make a definitive 
diagnosis leading to differential options. All imaging was re-reviewed by a 
specialist gastrointestinal radiologist and results agreed by consensus. For 
comparison of utilisation of imaging modalities, the group was split in to two 
halves consisting of 219 patients each. The dataset was also divided to 
compare the earlier with later experience. Statistical analysis was performed 
using a chi square test or Mann-Whitney U test and a P-value of <0.05 was 
considered statistically significant. Analyses were performed using SPSS® 




Four hundred and thirty-eight patients were identified including 248 males and 
190 females with median age 65 years (range 21-90). The indications for 
surgery are shown in Table 2.1. Four hundred and seventeen patients 
underwent liver resection (95%) and 21 patients (5%) underwent surgery 




2.4.1 Patient population 
 
 
Table 2.1 MDT indications for resection and number with discrepant histological 
diagnoses in 438 patients undergoing liver resection between March 2006 and January 
2012 
  







Colorectal Liver Metastases 
(CRLM) 
279      
(64) 
67           
(33-90) 
176/103 10         
(3.6) 
Hepatocellular carcinoma 
44      
(10) 
63           
(33-84) 
31/13 13         
(30) 
Hilar Cholangiocarcinoma 
28        
(7) 
67           
(32-77) 
14/14 7         
(25) 
Other metastases 
24        
(5) 




Gall Bladder carcinoma 
20        
(5) 




Neuroendocrine tumour (NET) 
11        
(3) 
51           
(41-77) 
8/3 0            
- 
Metastasis of unknown origin 
6        
(1) 
63           
(43-73) 
4/2 5          
(83) 
Biliary cystadenoma 
6        
(1) 
34           
(21-43) 
0/6 0            
- 
Focal Nodular Hyperplasia 
(FNH) 
5        
(1) 
34           
(30-38) 
0/5 0            
- 
Hepatocellular Adenoma 
4       
(<1) 
31           
(30-39) 
0/4 0            
- 
Benign cyst 
3       
(<1) 
52           
(47-65) 
0/3 1         
(33) 
Breast metastases 
3       
(<1) 
67           
(45-78) 
0/3 3         
(100) 
Peripheral Cholangiocarcinoma 
3       
(<1) 
70                
- 
2/1 1         
(33) 
Primary Sarcoma 
1       
(<1) 
71                
- 
0/1 0            
- 
Haemangioma 
1       
(<1) 
33                
- 
0/1 0            
- 
Total 438 65           
(21-90) 





Table 2.2 Reasons for non-resection in 21 patients undergoing surgery for planned liver 
resection between March 2006 and January 2012 
 
 
2.4.2 Imaging performed 
 
In total 969 imaging investigations (excluding repeat investigations of the same 
modality) were performed for the 438 patients including CT (432), MRI (227), 
PET (200), US (93), Octreotide scan (7) and ERCP (10). Only five patients did 
not have a CT scan. The number of MRI scans undertaken increased from 96 in 
the first half of the study (219 patients) to 131 in the second (P=0.001). 
Similarly, the number of PET scans undertaken increased from 85 to 115 
(P=0.005).  
The total number of investigations performed increased significantly during the 
study period from 442 in the first cohort to 525 in the second. Similarly, the 
median number of scans performed per patient increased from two (1-4) to 



















7 (2.6) 4 3 0 
Hepatocellular carcinoma 33 2 (6) 0 2 0 
Hilar Cholangiocarcinoma 23 4 (17) 0 4 0 
Gall Bladder Carcinoma 
(GBC) 
19 
2 (11) 2 0 0 




1 (8) 0 1 0 
Haemangioma 9 1 (11) 0 0 1 
Normal Liver - 1  0 0 1 
Total 
 21          
(4.8) 




2.4.3 Correlation of MDT assessment with operative findings 
 
A decision not to resect at the time of surgery was made in 21 patients (4.8%) 
either because of peritoneal disease, tumour progression or because no 
malignant lesion could be identified (Table 2.2). 
There was no change in the rate of non-resection over time (10/219 vs. 11/219).  
MDT assessment of operability was most accurate for CRLM where only 7/270 
patients (2.6%) were not resected and least accurate for patients with hilar 
cholangiocarcinomas where 4/23 patients were not resected (P<0.001) 
2.4.4 Correlation of MDT diagnosis with final pathology 
 
Of the 438 patients operated on in this period 42 individuals were identified 
whose final histological diagnosis was different to the outcome of the MDT 


















Table 2.3 Discrepant diagnoses in 42 of 438 patients undergoing liver resection between March 2006 and January 2012 
Total number of each diagnosis in the series (438) shown in brackets. All MDT diagnoses of Neuroendocrine Tumours (NET) (11), Focal Nodular 












































































































































































































































































13 1 - - - - 5 1 - 1 2 - 2 - - 1 - - 
Colorectal Metastases 
(CRLM) (279) 
10 - - - - 2 1 - - - 4 1 - 2 - - - - 
Hilar cholangiocarcinoma 
(31) 
7 - 2 3 1 1 - - - - - - - - - - - - 
Metastases of unknown 
origin (6) 
5 - - - - - 3 - - - 1 - - - 1 - - - 
Breast metastases (3) 3 - - - - - - - - 1 1 1 - - - - - - 
Peripheral 
cholangiocarcinoma (3) 
1 - - - - - - - 1 - - - - - - - - - 
Anal metastases (7) 1 - - - - - - - - - - 1 - - - - - - 
Benign cyst (3) 1 - - - - - - - - - - - - - - - 1 - 
Gall Bladder Carcinoma 
(20) 
1 - - - - - - - - - - - - - - - - 1 
Total 42 1 2 3 1 3 9 1 1 2 8 3 2 2 1 1 1 1 
57 
 
There was no change in the rate of discrepant diagnosis between the two study 
periods (23/219 vs. 19/219) (P=0.629). The median number of lesions per 
patient was one in both the first (range 0-9) and second (range 0-20) half of the 
series (P=0.057). Similarly, there was no difference in maximum tumour size 
with a median of 35mm (range 6-210) in the first half and 35mm (range 3-230) 
in the second (P=0.936). The median number of imaging modalities used was 
three in patients with discrepant diagnoses compared to two in those with 
correct diagnoses (P=0.003). The only difference occurred in the use of MRI 
where 31/42 (73.8%) patients with discrepant diagnoses had additional MRI 
compared to 196/396 (49.5%) patients where the diagnosis was correct 
(P=0.003). In total twenty-two patients (5%) underwent hepatic resection for 
what proved to be benign disease having been diagnosed with malignancy 
preoperatively. The difficult areas of MDT assessment fell into the following 
categories.  
2.4.5 Hepatocellular cancer  
 
Thirteen of 44 patients diagnosed as having hepatocellular carcinoma at MDT 
and proceeding to resection had different histological diagnoses after surgery, 
of which three were benign. There was no significant difference in the rate of 
discrepant diagnosis in those with and without a history of chronic liver disease 
(CLD) (6/19 vs. 7/25) (Table 2.4). In six patients with CLD the final histology 
revealed a mixed type of tumour with features of both hepatocellular carcinoma 
and cholangiocarcinoma. For the purposes of this study these have been 

























































- 2 - - - - 1 - 3 
Total 18 9 2 1 1 1 1 1 34 
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2.4.6 Cholangiocarcinoma of major hepatic duct 
  
All patients with suspected cholangiocarcinoma of a major hepatic duct 
underwent cholangiography (percutaneous, endoscopic or MR) in addition to 
cross sectional imaging. Seven of 28 patients diagnosed with 
cholangiocarcinoma at MDT had a different histological diagnosis after 
resection (Table 2.3). There was no significant difference in the rate of incorrect 
diagnosis in those who presented with obstructive jaundice (3/19) and those 
without (4/9). Of those patients diagnosed with cholangiocarcinoma without 
obstructive jaundice the diagnosis was confirmed in five patients on final 
histology. 
2.4.7 Colorectal metastases 
 
All patients diagnosed with CRLM had a history of colorectal cancer, but 10 
(3.6%) had different histological diagnoses after resection (Table 2.3), of which 
six were benign. Six of these were metachronous lesions and four were 
synchronous with their colorectal cancer diagnosis (P=0.539). 
2.4.8 Solid liver lesions with no history of chronic liver disease or 
primary malignancy 
 
Thirty-four patients underwent resection of peripheral liver lesions (including 
hepatomas) with no history of CLD or primary malignancy of whom 13 had 
discrepant diagnoses (Table 2.4).  
Peripheral cholangiocarcinoma was rarely diagnosed correctly pre-operatively. 
Of eleven patients with a diagnosis of peripheral cholangiocarcinoma at 
histology, only two had been diagnosed correctly preoperatively, both by 
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percutaneous biopsy. The remainder were inaccurately diagnosed as 
hepatocellular carcinomas or metastases (Table 2.3). 
2.4.9 Adenoma/FNH/hepatocellular carcinoma 
 
A group of 10, predominantly young, female patients (median age 33, range 33-
63) was identified in whom the MDT differential list included FNH, adenoma or 
hepatocellular carcinoma. After resection, all patients had a histological 
diagnosis that was included in the alternatives made at MDT. In five patients, 





This study reveals a number of important features of the MDT assessment of 
patients with focal liver lesions during the six-year development of a regional 
HPB unit. Firstly, there has been a 50% increase in the number of imaging 
modalities used in the assessment of these patients over a short time interval. 
This has been caused by an increased utilisation of PET scans and MRI due to 
an increased awareness of their role and improved access. Although PET 
scans have poor sensitivity for detecting multiple liver lesions they are valuable 
in the pre-operative assessment of patients with CRLM to exclude extra-hepatic 
disease207,208. MRI scans with diffusion-weighted imaging have been shown to 
have greater sensitivity than CT in the detection of CRLM205,209, hepatoma210 
and metastatic NET211, although these scans have only been available to this 
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department since 2011. The policy of the unit is not to biopsy potentially 
resectable liver lesions due to the potential risk of tumour seeding212,213. 
In this series 21 patients (5%) did not undergo surgical resection, and the rate 
of non-resection did not change significantly over time. The rate of non-
resection of liver lesions following assessment has been described previously 
with a reported rates of 3-12%214,215. The commonest cause of non-resection in 
our series was disease progression. The time interval between imaging and 
surgery may have a major impact on this outcome, limiting the value of modern 
imaging. Peritoneal disease was noted in seven of the unresected patients, 
which is not readily identified by any imaging modality216. 
The highest rate of discrepancies in our series occurred in the group of patients 
with focal liver lesions without a history of chronic liver disease or primary 
cancer. This finding emphasises the importance of assessing imaging in the 
context of the clinical history (13/34). Two observations arise from this group of 
significance in clinical practice. Firstly, the majority of patients (5/6) diagnosed 
with metastases of unknown origin (MUO) have defined histology after 
resection, of which the most common is peripheral cholangiocarcinoma. These 
lesions typically have hypovascular appearances on imaging with ring-like 
enhancement217 and can easily be misdiagnosed as colorectal or breast 
metastases218. Published guidelines for the management of MUO recommend a 
range of chemotherapy regimens51, none of which have been shown to be of 
benefit in the treatment of cholangiocarcinoma, whereas surgical resection of 
peripheral cholangiocarcinoma is of proven benefit219, but is rarely appropriate 
in the treatment of MUO. Similarly, 4/25 patients diagnosed as having 
hepatocellular carcinoma in this setting are ultimately shown to have peripheral 
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cholangiocarcinoma. Peripheral cholangiocarcinoma is less common than 
hepatocellular carcinoma220 which may lead to a low index of suspicion in MDT 
diagnosis. 
In patients with a history of CLD and focal liver lesions there remains a high rate 
of patients found not to have hepatocellular carcinoma after excision (7/19). 
These include neuroendocrine metastases which are hypervascular lesions 
having similar radiological appearances to hepatoma. This has implications for 
this patient group where treatment is often recommended without a histological 
diagnosis.  
The commonest indication for liver resection in our series has been CRLM and 
the rate of discrepant diagnoses for this group is low (3.6%). The most common 
alternative diagnosis after resection in this group was haemangioma. The 
radiological characteristics of this group have been described elsewhere221 and 
can be difficult to distinguish from metastases. Interestingly two patients in this 
group were found to have breast cancer metastases after primary breast 
surgery two and ten years previously. Breast metastases can have similar 
radiological features to CRLM and can occur many years after the primary 
diagnosis. A further breast metastasis occurred as an obstructing lesion of the 
left hepatic duct sixteen years after primary surgery and was diagnosed as a 
hilar cholangiocarcinoma.  
The high rate of discrepant diagnoses in patients with major duct 
cholangiocarcinoma has been shown previously222–224. These lesions are 
usually sclerosing adenocarcinomas causing biliary obstruction and are often 
not visible as a mass lesion217. In this situation, the presence of the lesion is 
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inferred by the radiological finding of ductal dilation along with clinical features 
of obstruction. The most common alternative diagnosis in this series was ductal 
fibrosis. This condition may be a manifestation of an autoimmune process and 
can have similar radiological features to cholangiocarcinoma225.  Peribiliary 
cysts can often be diagnosed preoperatively by the presence of multiple cysts, 
but can also mimic cholangiocarcinoma217 as in the two cases experienced in 
this series. The most difficult lesions to both assess and make treatment 
recommendations for are peripheral ductal lesions which do not cause jaundice 
but are found coincidentally or cause cholestasis. In these patients, often the 
only finding is a short segment of dilated intrahepatic duct. In this series 5/9 of 
these patients were found to have a cholangiocarcinoma on final histology and 
surgery for these lesions is therefore justified, particularly as these lesions can 
usually be resected safely without the need for resection of the extra-hepatic 
biliary tree. 
A particularly difficult group of patients to assess and make treatment 
recommendations for is the group of predominantly young women with primary 
liver lesions where the differential diagnosis includes hepatocellular carcinoma, 
adenoma and focal nodular hyperplasia. These lesions are usually single but 
may be multi-focal and often occur on a background of obesity or oral 
contraceptive use226. In this series 6/10 lesions were shown to be neoplastic on 
final histology (adenoma or hepatocellular carcinoma) and surgery appears 
justified in this patient group.  
Overall 5% of patients underwent surgery for misdiagnosed benign lesions, 
which is similar to earlier experience227. The most common benign lesions were 
haemangiomas which can be hypo-, iso- or hyper-attenuating on imaging and 
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can sometimes increase in size221, making distinction from malignant tumours 
difficult. 
In conclusion, approximately 10% of patients proceeding to surgery following 
discussion at the HPB MDT are subsequently shown to have an inaccurate 
diagnosis and 5% are understaged. Despite an increase in the number of 
imaging modalities used there has been no change in this rate over time.  
These discrepancies must be considered by clinicians in the context of the risk 
of over-staging resectable disease or misdiagnosing malignant lesions as 
benign. The implications of this should be discussed with patients prior to 
embarking on liver resection to better enable them to make informed decisions 
about their management. Furthermore, MDTs should keep record of cases with 





Chapter 3 : Assessment of the value of MRI scan 
in addition to CT in the pre-operative staging of 
colorectal liver metastases    
 
Wiggans MG, Shahtahmassebi G, Aroori S, Bowles MJ, Jackson SA, 
Stell DA. (2014) Assessment of the value of MRI scan in addition to CT 
in the pre-operative staging of colorectal liver metastases. Journal of 







The aim of this study was to measure the accuracy of CT and MRI scans in 
detecting colorectal liver metastases (CRLM) and to determine if patients who 
are staged with MRI in addition to CT have a longer liver recurrence-free 
survival compared to those having CT alone in a unit performing routine intra-
operative ultrasound.  
Methods 
A retrospective analysis of patients undergoing liver resection for CRLM was 
performed. Patients staged preoperatively with CT or with additional MRI were 
included and those with additional PET imaging were excluded from survival 
analysis. Timing and site of tumour recurrence were recorded.  
Results  
During a seven-year period 303 patients underwent resection for CRLM of 
whom 47 (15.5%) were staged with CT alone, 36 (11.9%) with additional MRI. 
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The overall accuracy of CT (63%) and MRI (61.9%) was similar in the detection 
of tumour nodules (P=0.905). There was no difference in the rate of intra-
hepatic recurrence between groups with 13/47 and 8/36 cases respectively 
(P=0.737). There was no difference in the disease-free survival curves between 
the groups (P=0.487). 
Discussion 
Our recommendation is that MRI should not be a mandatory imaging modality in 
referral guidelines for patients with hepatic CRLM, as the cost and delay 
associated with the scan outweigh any potential benefit in terms of improved 




Pre-operative imaging is undertaken in the preparation of patients for resection 
of hepatic colorectal metastases (CRLM) to exclude extra-hepatic disease and 
to define the site, size and number of hepatic lesions. Most patients have 
computerised tomography (CT) scans undertaken as an initial investigation, 
which has a been shown in a meta-analysis to have a sensitivity of 63.8% (95% 
CI 54.4-72.2) for the detection of metastatic lesions205. Magnetic Resonance 
Imaging (MRI) scans with hepatobiliary contrast media have been shown to 
have greater sensitivity for the detection of sub-centimetre lesions97 and have 
therefore been recommended in the pre-operative staging of such patients in 
the most recent guidelines adopted by International Hepatopancreatobiliary 
Association (IHPBA)95. Use of this imaging modality allows detection and 
treatment of smaller lesions within the liver which would potentially be 
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overlooked by CT. Additional use of MRI potentially therefore may lead to a 
lower rate of intrahepatic recurrence after resection compared to patients 
staged with CT alone. This hypothesis has not however been formally tested. In 
addition, many surgeons use intra-operative ultrasound (IOUS) to define hepatic 
lesions prior to resection. Although IOUS is operator-dependent, it has high 
sensitivity in the detection of sub-centimetre hepatic lesions and has been 
shown to influence operative planning228. Therefore, the use of IOUS may 
remove any added benefit of performing MRI scans in addition to CT scans 
during preoperative staging.  
The aim of this study was to measure the accuracy of CT and MRI scans in 
detecting hepatic metastases and to determine if patients who are staged with 
MRI in addition to CT have a longer liver recurrence-free survival compared to 




A retrospective analysis of data retrieved from a prospectively maintained 
database of all patients undergoing liver resection for CRLM between July 2005 
and September 2012 was performed. Patients are referred from five hospitals 
within the South West Peninsula and all imaging is performed at the local 
hospital. Peninsula Hepatopancreatobiliary (HPB) unit referral guidelines for 
CRLM do not mandate the use of pre-operative MRI or PET scans, although 
these are often undertaken at the discretion of referring clinicians, according to 
personal preference. As CT and MRI scans were performed over a seven-year 
period at five hospitals a number of different liver protocols were used. Pre-
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operative imaging of all patients was reviewed at the regional HPB meeting by 
specialist HPB radiologists and outcomes recorded in the database, including 
tumour size and number. For patients undergoing liver surgery IOUS was 
performed using a Toshiba Nemio®.  Liver resection was undertaken using 
standard techniques, to remove all abnormalities observed with IOUS. The 
exact number of lesions observed with IOUS was not however recorded. The 
size and number of lesions found on pathological examination of the resection 
specimen was recorded. The number of lesions detected on pre-operative 
imaging with CT and MRI scans was compared to the number found on 
histological examination in patients undergoing resection. Patients were 
considered to be accurately staged when an identical number of lesions were 
found at histology as was seen at imaging, understaged when more lesions 
were found on histology and overstaged when lesions were identified on 
imaging which were not confirmed to be CRLM by histological examination. 
Routine data relating to primary tumour pathology, the use of adjuvant 
chemotherapy, and pre-operative blood tests were also recorded. Patients were 
followed-up postoperatively by clinical review and telephone contact. Post-
operative surveillance CT scans were performed at six-monthly intervals for 
three years and annually to five years after resection. The timing and site of 
tumour recurrence were recorded as well as dates of death. Follow-up was 
completed at March 2013. 
PET scans have a high sensitivity in the detection of hepatic metastases205 and 
to avoid potential bias patients were excluded from survival analysis if they had 
a PET scan undertaken as part of pre-operative staging. Patients were also 
excluded if they died without undergoing surveillance imaging, or underwent 
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planned palliative resections. Patients who developed cut surface recurrences 
following a resection with a positive margin (R1) were also excluded as these 
were deemed to have been due to technical failure.  
Survival curves were constructed using SPSS® by the Kaplan-Meier method 
and differences in survival were assessed using the log rank method. In 
analysis of intra-hepatic recurrence survival time was censored if patients 
developed extra-hepatic recurrence as no further surveillance imaging was 
recorded.  Comparison between groups was performed using chi square or 
Mann Whitney U test as appropriate. Potential associations between pre- and 
intra-operative factors, as well as histological outcome and tumour recurrence 
were tested using univariate logistic regression or chi-square test at the level of 
P< 0.25229, as appropriate. Significant variables in the univariate analysis were 
included in the multivariate logistic regression model and were considered to be 
significant if P< 0.05.  Univariate and multivariate analyses were carried out 












Data relating to 303 patients were analysed. All patients underwent a pre-
operative CT scan, 168 patients (55.4%) also had an MRI scan, 209 patients 
(69.0%) had a PET scan and 135 patients had a CT only (44.6%). In the subset 
of patients who had an MRI in addition to CT the median number of lesions 
identified on pre-operative imaging was greater than in those having CT alone 










Table 3.1 Accuracy of CT and MRI in 303 patients undergoing liver resection for CRLM 
staged preoperatively with either CT alone or with additional MRI.  
*Significant at the level of 0.05 
 
However, there was no difference in the proportion of patients accurately staged 
in terms of tumour number by each modality. A similar proportion of patients 
were understaged by CT (27.4%) as were over staged by MRI (22.0%). During 
the study period, a decision not to resect was made at the time of surgery in five 
patients (1.6%) due to either the presence of peritoneal disease (n=4) or 
intrahepatic disease progression (n=1). Three of these patients were staged 















































P-Value <0.001* 0.063 0.905 0.001* 
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In the survival analysis 209 patients who had a PET scan as part of tumour 
staging were excluded. An additional 11 patients were excluded either because 
they died before their first surveillance scan (n=4), had a non-curative resection 
(n=3), or had cut surface recurrence after an R1 liver resections (n=4), leaving 
83 patients for analysis. Of these, 47 (56.7%) were staged with CT alone and 
36 (43.4%) with additional MRI. The median interval from CT to surgery was 57 
days (20-148) in patients staged with CT alone compared to 91.5 days (21-189) 
in those staged with additional MRI (P=0.037). Characteristics of the 83 patients 
used in survival analysis are shown in Table 3.2.  
The median follow up time was 1.67 years for those staged with CT alone 
(range 0.19-7.19) and 1.67 for those with CT and MRI (range 0.37-6.71) 
(P=0.900). The median number of post-operative surveillance scans performed 
was three (range 1-9) in the CT alone group and 2.5 (range 1-9) in the group 









Table 3.2 Characteristics of 47 patients staged preoperatively with CT alone and 36 












Age 69 (33-87)  68 (36-87)  0.840 
Gender 
Female  16 (34.0)  10 (27.8) 
0.636 
Male  31 (66.0)  26 (72.2) 
T stage 
1  1 (2.1)  0 (0.0) 
0.614 
2  1 (2.1)  2 (5.6) 
3  37 (78.7)  26 (72.2) 
4  6 (12.8)  7 (19.4) 
Unavailable  2 (4.3)  1 (2.8) 
N stage 
0  21 (44.7)  18 (50.0) 
0.915 
1  14 (29.8)  10 (27.8) 
2  10 (21.3)  7 (19.4) 
Unavailable  2 (4.3)  1 (2.8) 
Apical node 
-ve  36 (76.6)  24 (66.7) 
1.000 +ve  5 (10.6)  3 (8.3) 




Right  11 (23.4)  7 (19.4) 
0.712 Left  10 (21.3)  6 (16.7) 
Rectum  26 (55.3)  23 (63.9) 
Timing 
Synchronous  24 (51.1)  17 (47.2) 
0.826 
Metachronous  23 (48.9)  19 (52.8) 
Preoperative 
chemotherapy 
No  26 (55.3)  18 (50.0) 
0.663 











Open  44 (93.6)  35 (97.2) 
0.629 
Laparoscopic  3 (6.4)  1 (2.8) 
RFA included 
No  46 (97.9)  35 (97.2) 
1.000 




No  38 (80.9)  24 (66.7) 
0.203 
Yes  9 (19.1)  12 (33.3) 
Extent of 
resection 
Minor  19 (40.4)  11 (30.6) 
0.490 
Major  28 (59.6)  25 (69.4) 
Repeat 
operation 
No  44 (93.6)  36 (100.0) 
0.254 
Yes  3 (6.4)  0 (0.0) 
Number of liver lesions 1 (0-7)  1 (1-7)  0.932 
Diameter of largest tumour 
(mm) 
37 (3-119)  30 (6-95)  0.085 
Resection 
margin <1mm 
No  43 (91.4)  31(86.1) 
0.496 
Yes  4 (8.6)  5 (13.9) 
Hepatic 
steatosis 
<33%  38 (80.9)  29 (80.6) 
1.000 
33-66%  8 (17.0)  6 (16.7) 
>66%  1 (2.1)  0 (0.0) 











Table 3.3 Details of tumour recurrence and death in 47 patients staged preoperatively 
with CT alone and 36 patients staged with additional MRI undergoing liver resection for 
CRLM 
 
Forty-nine patients (59.0%) suffered tumour recurrence during follow-up (Table 
3.3) with a median time to recurrence of 7 months (range 71 days – 3.5 years).   
There was no significant difference in the overall recurrence rates of those 
staged preoperatively with CT alone (29/47) and those who had additional MRI 
(20/36) (P=0.573). The median time to recurrence was also similar between 
groups (0.54 vs 0.76 years) (P=0.682). Similarly, there was no significant 
difference in the disease-free survival between groups (P=0.548) (Figure 3.1).  
N=83 
CT only (n=47) CT and MRI (n=36) 
P-value 
Count (%) Count (%) 
Tumour Recurrence 
Yes 29 (61.7) 20 (55.6) 
0.573 
No 18 (38.3) 16 (44.4) 
Intrahepatic recurrence 
Yes 13 (27.7) 8 (22.2) 
0.573 
No 34 (72.3) 28 (77.8) 
Extrahepatic recurrence 
Yes 20 (42.6) 15 (41.7) 
1.000 
No 27 (57.4) 21 (58.3) 
  Death 
Yes 18 (38.3) 14 (38.9) 
1.000 




Figure 3.1 Kaplan–Meier disease free survival curves following liver resection for CRLM 
for 47 patients staged preoperatively with CT alone and 36 patients staged with 






The majority of tumour recurrences in both those staged with CT alone (20/29) 
and those with additional MRI (15/20) were extra-hepatic (P=1.000). There was 
no significant difference in the rate of intra-hepatic recurrence between those 
staged with CT alone (13/47) and those staged with CT and MRI (8/36) 
(P=0.573). The liver recurrence-free survival curves for those staged with CT 
alone and those with additional MRI revealed a 5.5% difference at five years, 
which did not reach significance (P=0.491) (Figure 3.2). A sample size of 1942 
patients would be needed to confirm the significance of this observed difference 






Figure 3.2 Kaplan–Meier liver survival curves of liver recurrence free survival following 
liver resection for CRLM for 47 patients staged preoperatively with CT alone and 36 
patients staged with additional MRI (Log rank P=0.487) In cases where patients 
developed only extrahepatic recurrence, liver recurrence free survival was censored at 





There were 32 deaths during the study period with a similar proportion of deaths 
within each group (18/47 vs 14/36) (P=1.000). There was no difference in 
overall survival between patients staged preoperatively with CT alone or with 







Figure 3.3 Kaplan–Meier liver overall survival curves following liver resection for CRLM 
for 47 patients staged preoperatively with CT alone and 36 patients staged with 





Multivariate analysis of factors associated with overall tumour recurrence (Table 
3.4) demonstrated no association between the additional use of MRI during 
preoperative staging and tumour recurrence (P=0.573). Only the site of the 
primary colorectal cancer was associated with overall tumour recurrence with 
rectal cancer more than trebling the risk of recurrence compared to colonic 
cancer (P=0.036). Analysis of factors associated with intra-hepatic recurrence 
did not demonstrate any association with the pre-operative use of MRI 
(P=0.573) but revealed that the nodal stage of the primary tumour and inclusion 
of a wedge resection were associated with intra- hepatic recurrence (Table 3.4). 
Positive nodal stage increased the risk of recurrence by a factor of 3.9 
(P=0.038) and the inclusion of a wedge resection had the greatest effect 



















Table 3.4 Univariate and multivariate analysis of factors associated with tumour recurrence following liver resection for CRLM in 83 patients staged with 
either CT alone (n=47) or with additional MRI (n=36) 
*Significant at the level of 0.25 for univariate analysis and included in multivariate analysis **Significant at the level of 0.05 for multivariate analysis 
 Any recurrence Intrahepatic recurrence 
N=83 Univariate Multivariate Univariate Multivariate 
P-Value P-Value Coef (95% CI) P-Value P-Value Coef (95% CI) 
Age 0.363   0.363   
Gender 0.866   0.094* 0.111  
 T stage of primary 





2 vs 3 0.995    
3 vs 4 0.995    
N stage of primary 




0.038** 3.86 (1.17-12.75) 
1 vs 2     0.837  
 Apical node positive 0.890   0.598   
 Site of primary 
colorectal tumour 











 0.283   
 Preoperative chemotherapy 0.366   0.749   






 0.546   
Wedge resection included 0.071* 0.138  0.003* 0.002** 5.99 (1.92-18.67) 
Extent of resection Major vs minor 0.289 
 
 0.633   
Redo operation 0.378   0.726   
Number of liver lesions 0.977   0.029* 0.234  
Diameter of largest tumour (mm) 0.324   0.794   
Resection margin <1mm 0.369   0.805   
Hepatic steatosis <33% vs >33% 0.206* 0.254  0.451   





There are two main findings to the study. Firstly, CT and MRI have similar rates 
of accuracy in identifying the number of CRLM in patients undergoing hepatic 
resection while CT has a greater tendency to understage, and MRI to overstage 
patients in terms of tumour number. Secondly there is no benefit in terms of 
overall or intra-hepatic tumour recurrence rate, and overall or intra-hepatic 
recurrence-free survival following liver resection of patients undergoing staging 
with MRI scan in addition to CT, when IOUS is used.  
Although guidelines for the preoperative assessment of patients with colorectal 
liver metastases state that all patients should undergo CT of the chest, 
abdomen and pelvis122, the role of liver MRI in this context is less clearly 
defined. A consensus statement recommended that when expertise is available 
contrast-enhanced MRI is better for detecting and characterising liver lesions, 
particularly those that are sub-centimetre in diameter95, as two meta-analyses 
demonstrated a clear benefit of MRI over CT in the detection of these 
lesions231,232 a finding that has been demonstrated more recently in patients 
who have undergone neoadjuvant chemotherapy233. However, the 
disadvantages of the use of MRI were not considered in this recommendation. 
The average cost of an abdominal MRI scan in the USA is $2625234 which must 
be considered when measuring its potential benefit. More importantly the 
current study revealed that the median time to resection was 35 days longer in 
patients who were staged with additional MRI. This delay is contributed to by 
resource issues in a publicly-funded healthcare system and the need for further 
MDT discussion, has the potential to allow tumour progression prior to surgery 
and probably contributes to patient anxiety. 
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This study used accuracy in patient staging rather than lesion-based sensitivity 
and specificity as a measure of test utility. The results demonstrate that fewer 
patients were understaged with MRI as fewer lesions were missed compared to 
CT but also revealed that MRI tended to overstage patients. The ability of MRI 
to identify lesions not seen on CT conferred no measurable benefit in our series 
as these small lesions are likely to be identified at the time of surgery either by 
palpation or the use of IOUS. In this context, the tendency of MRI to overstage 
hepatic CRLM may be more significant as patients may potentially be denied 
surgery if lesions are falsely identified. 
This study is unusual in that in addition to an assessment of the accuracy of 
imaging compared with histology we have attempted to assess the clinical value 
of an imaging modality in terms of tumour recurrence and patient survival, and 
have shown no clinical benefit in the use of MRI. This is a more compelling 
assessment of the value of an imaging modality than a correlative study with 
pathology. It should be noted that 68% of patients undergoing resection were 
staged preoperatively with PET in addition to CT. PET has similar sensitivity 
and specificity to MRI in the detection of liver lesions232. To avoid bias these 
patients were excluded from survival analysis. One other study has attempted 
to assess the value of MRI in terms of patient outcome235, and found a benefit in 
terms of hepatic recurrence. This study however did not exclude patients who 
had PET scans as part of pre-operative staging, undermining the strength the 
finding.  
A weakness of the study is the lack of consistent details relating to MRI and CT 
scan protocols due to geographical variation and improving technology during 
the study period. The question of determining the additional value of MRI scans 
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in CRLM staging can only accurately be assessed by a randomised controlled 
trial. Such a study is unlikely ever to take place due to the huge number of 
patients required and the fact that improving technology would very rapidly 
render the results obsolete. The question can therefore best be addressed by 
retrospective assessment, in which context heterogeneity of the imaging 
protocols undertaken adds to the value of the study as the standards required in 
clinical trials may not be routinely reproduced in all hospitals.   
It is likely that the decision to request an MRI scan in addition to CT is taken in 
potentially more difficult cases, for example where there has been difficulty in 
accurate characterisation of liver lesions or where a large number of small 
lesions is suspected.  This is a potential source of bias in the interpretation of 
crude survival data. To allow for this problem a multivariate analysis was 
performed to include commonly identified risk factors for recurrence and 
survival after liver resection, along with the additional use of MRI in pre-
operative staging. This analysis revealed that the additional use of MRI scans in 
pre-operative imaging has no association with tumour recurrence at any site, or 
with patient survival. 
Our recommendation is that MRI should not be a mandatory imaging modality in 
referral guidelines for patients with hepatic CRLM, as the cost and delay 
associated with the scan outweigh the potential small benefit in terms of 
improved sensitivity compared to CT. This recommendation depends upon the 
use of IOUS, which can be performed with low cost and does not impose any 
delay in the patient pathway prior to surgery. Further studies should be carried 
out to assess the impact of the use of MRI on patient outcomes rather than the 
ability of MRI to detect individual lesions and these should consider how the 
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Chapter 4 : The pre-operative rate of growth of 
colorectal metastases in patients selected for 
liver resection does not influence post-operative 
disease-free survival 
 
Wiggans MG, Shahtahmassebi G, Aroori S, Bowles MJ, Briggs C, Stell 
DA. (2016) The pre-operative rate of growth of colorectal metastases in 
patients selected for liver resection does not influence post-operative 








To assess the potential association between the change in diameter of 
colorectal liver metastases between pre-operative imaging and liver resection 
and disease-free survival in patients who do not receive pre-operative liver-
directed chemotherapy.  
 
Methods 
Analysis of a prospectively maintained database of patients undergoing liver 
resection for colorectal liver metastases between 2005 and 2012 was 
undertaken. Change in tumour size was assessed by comparing the maximum 
tumour diameter at radiological diagnosis determined by imaging and the 
maximum tumour diameter measured at examination of the resected specimen 







The median interval from first scan to surgery was 99 days and the median 
increase in tumour diameter in this interval was 38%, equivalent to a tumour 
doubling time (DT) of 47 days. Tumour DT prior to liver resection was longer in 
patients with T1 primary tumours (119 days) than T2-4 tumours (44 days) and 
shorter in patients undergoing repeat surgery for intra-hepatic recurrence (33 
days) than before primary resection (49 days). The median disease-free 
survival of the whole cohort was 1.57 years (0.2-7.3) and multivariate analysis 




The rate of growth of colorectal liver metastases prior to surgery should not be 





Although the survival of patients with untreated metastatic colorectal cancer has 
been described108 the rate of growth of untreated colorectal liver metastases 
(CRLM) has not been defined, as patients will either receive active treatment or 
be treated with palliative intent where assessment of tumour progression is 
rarely undertaken. CRLM may sustain a period of growth between diagnosis 
and treatment, and assessment of change in tumour size in this period allows 
an estimate of growth rate. Liver resection provides a potential cure for patients 
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with CRLM with five-year survival rates ranging from 32-65%40,41. Factors 
shown to affect survival include CEA estimation236, tumour number236–238, 
tumour size236,238,239, resection margin involvement236,238,240, the presence of 
satellite lesions241, the ratio of neutrophils to lymphocytes in peripheral white 
blood cells168 and the response to liver-directed chemotherapy242.  Little 
information however is available regarding the influence of the pre-operative 
rate of growth of CRLM, often expressed as tumour doubling-time (DT), on 
survival following liver resection.  
The aim of this study was to assess the DT of CRLM in patients not receiving 
liver-directed chemotherapy between radiological diagnosis and liver resection 





Analysis of data retrieved from a prospectively maintained database of 319 
patients undergoing liver resection for CRLM between May 2004 and December 
2012 was performed. One hundred and fifty-five patients receiving liver-directed 
chemotherapy were excluded. Imaging was performed with either computerised 
tomography (CT) or magnetic resonance imaging (MRI) and reviewed at the 
specialist HPB MDT. The diameter of the largest lesion was measured and 
recorded in the database for research purposes.  Change in tumour size was 
assessed by comparing the maximum tumour diameter at radiological diagnosis 
and the maximum tumour diameter measured at examination of the resected 
specimen. Change in size was expressed as a function of time. Tumour DT was 
calculated using the equation: 
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DT=Ti x Log2 / (3 x Log(Dp/Dr) 
where Ti = time interval between radiological diagnosis and surgery, Dp = 
diameter at pathology and Dr = diameter at radiological diagnosis 107. 
Data relating to primary and secondary tumour pathology and other routine 
clinical information were retrieved. Liver resections were defined according to 
the Brisbane classification 17 and undertaken using standard techniques. Major 
resections were defined as resections of four or more segments 243. 
Synchronous metastases were defined as those diagnosed prior to or within two 
months of primary surgery. Post-operative follow-up included surveillance CT 
scans at six-monthly intervals for three years and annually to five years after 
resection. The timing and site of tumour recurrence were recorded as well as 
dates of death. Follow-up was completed at March 2014. 
Patients were excluded from survival analysis if they died without undergoing 
surveillance imaging or underwent palliative resections. Patients who developed 
tumour recurrence at the resection surface following a resection with a positive 
margin (R1) were excluded as these were deemed to have been due to 
technical failure rather than tumour recurrence. 
Survival curves were constructed by the Kaplan-Meier method and differences 
in survival were assessed using the log rank method. Comparison between 
groups was performed using chi square for categorical variables or Kruskal 
Wallis test for continuous variables. Potential associations between pre- and 
intra-operative factors, as well as histological outcome and tumour recurrence 
were tested using univariate logistic regression for continuous variables or chi-
square for discrete variables test at the level of P<0.25229. Significant variables 
in the univariate analysis were included in the multivariate logistic regression 
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model and were considered to be significant if P<0.05.  Univariate and 
multivariate analyses were carried out using the statistical package R 2.1.14230.  
Ethical approval for the study was obtained from the South West Health 
Research Authority. Formal Research Ethics Committee review was not 
required because patient data were collected during their normal hospital care 
and were anonymised for research purposes. No patient consent was required 




During the study period 164 liver resections were performed for CRLM in 160 
patients who did not receive pre-resection liver-directed chemotherapy. In 
seven cases, no preoperative imaging was available, leaving 157 resections for 
analysis, including 79 (50.3%) major and 78 (49.7%) minor resections. Details 





Table 4.1 Characteristics of 157 patients undergoing resection for CRLM 












Age 69 (34-90)   -0.041 0.613 
Gender 
Female  52 (33.1) 45 (-398 to +1081)  
0.632 
Male  105 (66.9) 48 (-743 to +803)  
T stage of 
primary 
0  1 (0.6) 231   
0.035* 
1  6 (3.8) 119 (69 to 190)  
2  10 (6.4) 40 (-166 to +278)  
3  96 (61.1) 47 (-493 to +511)  
4  38 (24.2) 44 (-743 to +1081)  
Not available  6 (3.8)   
N stage of 
primary 
0  79 (50.3) 45 (-602 to +511)  
0.070 
1  49 (31.2) 58 (-509 to +1081)  
2  25 (15.9) 35 (-743 to +803)  
Not available  4 (2.5)   
V stage of 
primary 
0  78 (49.7) 45 (-743 to +803)  
0.215 1  41 (26.1) 49 (-167 to +1081)  
Not available  38 (24.2)   
Duke's Stage of 
primary 
A  11 (7.0) 73 (-52 to +231)  
0.054 
B  65 (41.4) 44 (-603 to 511)  
C  77 (49.0) 48 (-743 to +1081)  
Not available  10 (6.4)   
Apical node 
status of primary 
Positive  13 (8.3) 34 (-166 to +803)  
0.284 Negative  121 (77.1) 47 (-743 to +511)  
Not available  23 (14.6)   
Differentiation of 
primary 
Well/moderate  39 (24.8) 51 (-493 to +803)  
0.462 
Moderate  59 (37.6) 46 (-509 to + 511)  
Moderate/poor  4 (2.5) 32 (-743 to +44)  
Poor  8 (5.1) 34 (-167 to +169)  
Not available  47 (29.9)   
Site of primary 
Colonic  74 (47.1) 47 (-743 to +803)  
0.613 
Rectal  83 (52.9) 48 (-493 to +1081)  
Timing of liver 
metastases 
Synchronous  28 (17.8) 38 (-336 to +189)  
0.444 
Metachronous  129 (82.2) 48 (-743 to +1081)  
 Previous   
adjuvant 
chemotherapy 
Yes  66 (42.0) 48 (-743 to +803)  
0.979 
No  91 (58.0) 44 (-603 to +1081)  
Repeat operation 
Yes  23 (14.6) 33 (-743 to +1081)  
0.050* 
No  134 (85.4) 49 (-603 to +803)  
Number of liver 
lesions 





 25 (5-110)   0.019 0.816 
Differentiation of 
liver metastases 
Well  1 (0.6) 69 
 0.768 
Well/moderate  33 (21.0) 54 (-202 to +278) 
Moderate  77 (49.0) 43 (-743 to +1081) 
Moderate/poor  1 (0.6) 60 
Poor  2 (1.3) 145 (+10 to +280) 





Yes  28 (17.8) 45 (-603 to +189)  
0.715 
No  129 (82.2) 47 (-743 to +1081)  
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In sixty-six cases (42.0%), patients received adjuvant chemotherapy following 
primary colorectal surgery, of whom 19 (28.8%) were treated with 5-FU, 18 
(27.3%) with capecitabine, 10 (15.2%) with capecitabine and oxaliplatin, two 
with capecitabine and bevacizumab and one with 5-FU and oxaliplatin. Details 
of the post-primary surgery adjuvant regime were not available in 16 patients 
(25%). The median number of cycles of adjuvant chemotherapy was six (1-8). 
The median interval between primary colorectal resection and the diagnosis of 
metachronous tumours was 15 months (3 months – 7.9 years). 
The median interval from diagnosis of CRLM to liver resection was 99 days (20-
548 days). CRLM were diagnosed by MRI in one patient and by CT in 156 
patients (99%). The median diameter of the largest tumour was 25mm (5-110) 
at diagnosis and 35mm (3-155) in the resection specimen (P<0.001). The 
median change in diameter during this interval was +38% (-92% to +518%) and 
the median rate of increase in maximum tumour diameter was 2.92% per week 
(-7.0% to +37.7%) (Figure 4.1). In 27 patients (17.2%) the maximum tumour 
diameter in the resection specimen was smaller than that determined by pre-






Figure 4.1 Rate of change in tumour size from diagnosis to resection in 157 patients with 
colorectal liver metastases   
Median change in size = +2.9% per week (-7.0% to +37.7%).  
 
 
Assessment of potential associations between tumour DT and other patient 
factors revealed an association with primary tumour stage (P=0.035). The 
median tumour DT was longer in patients with T1 tumours (119 days) compared 
to those with T2 (40 days), T3 (47 days) and T4 (44 days) tumours. Tumour DT 
was shorter in patients undergoing repeat liver resection (33 vs. 49 days) (Table 
4.1). 
 
Seventeen patients were excluded from survival analysis because they 
underwent non-curative resection (n=7), developed cut surface recurrence after 
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an R1 resection (n=3) or did not undergo surveillance imaging (n=7), leaving 
140 patients for analysis. At closure of the study the median follow-up was 1.2 
years (0.2-7.3). Eighty-one patients (57.9%) suffered tumour recurrence within 
the study period, and there were 48 deaths (34.3%). The median disease-free 
survival of the group was 1.57 years. Analysis of quartiles determined by 
tumour DT prior to surgery revealed that DT was not associated with disease-




Figure 4.2 Kaplan–Meier disease-free survival curves according to tumour doubling time 
quartiles among 140 patients with CRLM not treated with liver-directed chemotherapy 






Multivariate analysis of pre-operative factors including rate of growth of CRLM 
revealed that the only significant predictor of tumour recurrence was the number 
of metastases resected (Table 4.2). For each extra metastasis, the risk of 
recurrence increased by a factor of 1.3 (P=0.013). Tumour DT was not found to 




Table 4.2 Univariate and multivariate analysis of factors associated with tumour recurrence following liver resection for CRLM in 140 patients not treated 
with liver-directed chemotherapy 
N=140 
Not recurred (n=59) Recurred (n=81) Univariate Multivariate analysis 
Median (range) Count (%) Median (range) Count (%) P-value Odds ratio 
(95% CI) 
P-value Odds ratio  
(95% CI) 
Age 69 (51-84)  68 (34-87)  0.786    
Gender 
Male  43 (72.9)  53 (65.4) 
0.349    
Female  16 (27.1)  28 (34.6) 
T stage of primary 
0  1 (1.7)  0 
0.560    
1  0  5 (6.2) 
2  4 (6.8)  6 (7.4) 
3  35 (59.3)  48 (59.3) 
4  17 (28.8)  19 (23.5) 
NA  2 (3.4)  3 (3.7) 
N stage of primary 
0  29 (49.2)  42 (51.9) 
0.635    
1  21 (35.6)  23 (28.4) 
2  8 (13.6)  14 (17.3) 
NA  1 (1.7)  2 (2.5) 
V stage of primary 
0  26 (44.1)  46 (56.8) 
0.133*  0.203 
0.52 
(0.19-1.42) 
1  18 (30.5)  17 (21.0) 
NA  15 (25.4)  18 (22.2) 
Duke's Stage of primary 
A  4 (6.8)  6 (7.4) 
1.000    
B  24 (40.7)  34 (42.0) 
C  29 (49.2)  39 (48.1) 
NA  2 (3.4))  2 (2.5) 
Apical node of primary 
Positive  3 (5.1)  9 (15.3) 0.313 
   Negative  43 (72.9)  64 (79.0)  
NA  13 (22.0)  8 (9.9)  
Site of primary 
Colon  29 (49.2)  36 (44.4) 0.704 
   
Rectum  30 (50.8)  45 (55.6)  
Timing of metastases 
Syn  8 (13.6)  16 (19.8) 0.339 
   
Met  51 (86.4)  65 (80.2)  




Table 4.2 continued. 
N=140 
Not recurred (n=59) Recurred (n=81) Univariate Multivariate analysis 
Median (range) Count (%) Median (range) Count (%) P-value Odds ratio 
(95% CI) 
P-value Odds ratio  
(95% CI) 
Repeat operation  9 (15.3)  11 (13.6) 0.780    
Wedge resection included  22 (37.3)  33 (40.7) 0.812    
Radiofrequency ablation included  1 (1.7)  1 (1.2) 0.821    














Number of liver lesions 1 (1-3)  1 (1-9)  0.073* 
1.54 (0.96-
2.46) 
0.013** 1.30 (1.06-1.59) 
Diameter of largest metastasis at 
diagnosis (mm) 
35 (8-155)  40 (3-120)  0.202* 
1.01 (1.00-
1.02) 
0.854 1.00 (0.98-1.02) 




Well/mod  10 (16.9)  15 (19.8) 
0.801 
   
Mod  33 (55.9)  38 (46.9)    
Mod/poor  0  1 (1.2)    
Poor  0  2 (2.5)    






Yes  8 (13.6)  15 (18.5) 
0.495 
   
No  51 (86.4)  66 (81.5)    
 
NA = no data available 
* Significant at the level of 0.25 for univariate analysis and included in multivariate analysis 





4.5 Discussion  
Despite the wealth of information relating to prognostic factors which affect 
survival after resection of CRLM the lack of data relating to tumour DT is 
surprising. Tumour DT has been shown to be a significant prognostic factor in 
the treatment of many solid tumours in including hepatocellular carcinoma102, 
sarcoma103, renal cancer104, lung cancer105  and gynaecological cancer106. A 
study estimating the rate of growth of CRLM used early CT scans in patients not 
undergoing treatment and found a DT of 112 days244. More recently DT of 
CRLM was estimated by serial scans prior to resection in eight patients and a 
median DT of 63 days was found245. Tumour DT was found to be associated 
with poorer survival after resection. Estimates of DT of CRLM have also been 
made by measuring the rise in CEA concentration245–247, which have revealed a 
DT of 10-411 days245,247. The tumour DT determined by CEA was found to be 
the most significant marker of outcome following resection in 144 patients246. A 
correlation of increasing CEA secretion with tumour growth has been 
demonstrated only in animal studies248, and many CRLM do not secrete the 
marker23. Estimation of DT in pulmonary CR metastases is commonly 
performed, as serial imaging is frequently undertaken in this situation. The 
range of DT has been reported as 29-385 days250,251 and a tumour DT of less 
than 100 days has been shown to be associated with increased risk of 
intrapulmonary recurrence following lung resection252. Other studies have 
shown the difficulty of estimating DT in primary colorectal cancer based on 
changes in tumour size253.  
The main finding of clinical significance from this study is that, in contrast to the 
treatment of many other solid tumours, and colorectal metastases in the lung, 
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the rate of growth of CRLM has no influence on survival after resection. The 
proportion of patients with CRLM who are offered liver resection is small (10-
20%)254,255 and patients undergo a selection process before being offered liver 
resection. In the majority of cases this involves exclusion of patients with extra-
hepatic disease, rapidly progressive disease and where there is extensive 
replacement of the liver with tumour. Furthermore, this selection process may 
have involved a ‘trial of time’ in the early part of this study, which may account 
for the relatively long interval between diagnosis of liver metastases and liver 
resection. It is likely that this selection process retains a subset of patients with 
low-volume, liver-only metastases, whose disease remains temporarily localised 
to the liver. This finding supports the view that the liver provides a special site of 
containment of metastatic disease in some patients, in whom surgical resection 
is likely to be effective256. Studies of genetic biomarkers and apoptosis have 
also revealed that CRLM generally have lower rates of cellular proliferation than 
primary colorectal cancer257,258.  
A weakness of the study is the comparison of tumour diameter measured 
radiologically with pathological findings. This method may be subject to error as 
the accuracy of CT scan in determining diameter of CRLM has not been 
demonstrated. Correlation of CT measurement with pathological findings has 
been performed for hepatoma, and CT scans have been shown to overestimate 
the size of these lesions259. The tumour margin of CRLM may be infiltrative and 
less clearly defined than that of hepatoma260,261, although some lesions have a 
clearly defined capsular margin262. A degree of subjectivity may be necessary in 
undertaking a comparison of radiological and pathological findings and it is 
possible that CT scans underestimate the size of CRLM, which may account for 
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some of the difference in size seen between imaging and pathological 
examination. Measurement of a single tumour diameter is however a valid 
technique and has been shown to correlate well with tumour volume263. The 
large change in tumour diameter (38%) over a long time period (99 days) and 
the normal appearance of the frequency distribution of changes in diameter in 
our study however support the validity of the method. Survival after liver 
resection may be affected by further chemotherapy, and details of 
chemotherapy administered to patients between liver resection and death are 
not available, as this treatment may have been administered in other centres. 
The rate of growth of tumours prior to resection is however not measured in this 
unit and this feature is unlikely to have led to bias by influencing oncologists in 
the administration of chemotherapy. Adjuvant chemotherapy following liver 
resection is also unlikely to have been administered to this patient group as it is 
not included in our local protocol for the treatment of CRLM without a trial of 
liver-directed neo-adjuvant treatment.   
Although resection for CRLM is mainly offered to patients with disease confined 
to the liver, tumour recurrence occurs in the majority. Attempts to predict 
outcome based on morphological characteristics of the liver metastases have 
met with limited success as they rely on these characteristics being a surrogate 
for biological behaviour and metastatic potential. Few studies have been 
undertaken to correlate tumour characteristics with biological markers of 
aggressiveness, although a long tumour DT has been shown to be associated 
with a favourable host immune response245.  
This study reveals that among selected patients with liver-only disease the rate 
of tumour growth of CRLM prior to surgery does not influence post-operative 
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survival, and should not be regarded as an adverse factor when considering the 
role of liver resection in this patient group. Clinicians should take this into 
consideration when discussing patients at MDT and deciding on further 
management. Furthermore, clinicians can use this evidence to counsel patients 
preoperatively who may be concerned regarding the increase in size of liver 











Chapter 5 : Rebound growth of hepatic colorectal 
metastases after neo-adjuvant chemotherapy: 
effect on survival after resection 
 
Lim E*, Wiggans MG*, Shahtahmassebi G, Aroori S, Bowles MJ, Briggs 
CD, Stell DA (2016) Rebound growth of hepatic colorectal metastases 
after neo-adjuvant chemotherapy: effect on survival after resection – 








A period of recovery is commonly allowed between completion of chemotherapy 
for colorectal liver metastases (CRLM) and resection, during which tumour 
progression may occur. The study-aim is to assess the growth of CRLM in this 
interval and association with outcome. 
Methods 
Data on 146 patients were analysed. Change in tumour size was assessed by 
comparing size determined by imaging performed on completion of 
chemotherapy with that determined by examination of the resected specimen, 
categorised by RECIST criteria. 
Results 
In the interval before surgery sixteen patients (11%) fulfilled criteria for partial 
response (PR), 48 (33%) had stable disease (SD) and 82 (56%) had 
progressive disease (PD). Among patients with PD following chemotherapy the 
median disease-free survival of patients who initially responded (26 months) 
was longer than in those who initially had stable disease (7 months) (P=0.002). 
103 
 
No association was noted between rate of tumour growth after completion of 
chemotherapy and disease-free survival. 
Discussion 
Change in tumour size after completion of chemotherapy is variable and can be 
rapid, especially in patients who initially respond to treatment. However, 
disease-free survival is determined by tumour behaviour during treatment and 




Liver resection provides a potential cure for patients with colorectal liver 
metastases (CRLM), with five-year survival rates ranging from 32-65%41. Neo-
adjuvant systemic chemotherapy has been advocated in patients with initially 
resectable92,264 and unresectable265–267 CRLM. Tumour response to 
chemotherapy is usually assessed by imaging techniques performed before and 
after treatment and some studies have suggested that surgery should not be 
performed when progression on chemotherapy occurs, as the outcome is 
poor268,269. Although the proportion of patients with CRLM who respond to liver 
directed chemotherapy (LDC) has been defined in many studies92,94 the 
duration over which the changes are sustained following completion of 
treatment has not been described, and the consequences of tumour 
progression in the interval between completion of chemotherapy and surgery 
are unknown. As chemotherapy can cause significant hepatotoxicity197,270 it is 
common practice to allow a chemotherapy-free interval for these changes to 
reverse before undertaking liver resection196, potentially allowing uninhibited 
tumour progression.  The aim of this study was to assess the change in size of 
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CRLM between post-chemotherapy imaging and liver resection and to measure 




Analysis of data retrieved from a database of all patients undergoing liver 
resection for CRLM between May 2004 and December 2012 was performed. 
Systemic chemotherapy was administered to patients with radiological evidence 
of CRLM, where liver resection was planned, according to local protocols. The 
diameter of the largest metastasis was measured by CT scan and response to 
chemotherapy  graded by RECIST criteria271. Any further change in tumour size 
between completion of chemotherapy and liver resection was measured by 
comparing the maximum diameter of lesions determined by post-chemotherapy 
imaging and the maximum diameter determined by examination of the resected 
specimen, expressed as a function of time. Time intervals are expressed in 
weeks with inter-quartile range (IQR). For purposes of comparison changes in 
size during this interval were also graded by RECIST criteria. Tumour doubling-
time (DT) was calculated using the equation  
   DT=Ti x Log2 / (3 x Log(Dp/Dr) 
where Ti = time interval between post-chemotherapy imaging and surgery, Dp = 
diameter at pathology and Dr = diameter measured by imaging107. 
Data relating to primary tumour pathology, the use of adjuvant chemotherapy 
for primary colorectal cancer, systemic chemotherapy administered for CRLM 
and other clinical information were retrieved. Synchronous metastases were 
defined as those diagnosed prior to, or within two months of primary surgery. 
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Liver resections were described according to the Brisbane classification272 and 
undertaken using standard techniques. 
Post-operative follow-up included surveillance CT scans performed at six-
monthly intervals for three years and annually to five years after resection. The 
timing and site of tumour recurrence were recorded as well as dates of death. 
Follow-up was completed at March 2014. 
Patients were excluded from disease-free survival analysis if they died without 
undergoing surveillance imaging, or underwent planned non-curative 
resections. Patients who developed resection-margin recurrence following a 
resection with margin-involvement (R1) were also excluded as these were 
deemed to have been due to technical failure rather than tumour recurrence.  
Survival curves were constructed by the Kaplan-Meier method and differences 
in survival assessed using the log rank method. Comparison between groups 
was performed using chi square for discrete variables and Mann Whitney U test 
for continuous variables. In survival analyses patients who suffered PD after 
completion of chemotherapy were split into quartiles according to the rate of 
increase in size of the largest tumour. 
Ethical approval for the study was obtained from the South West Health 
Research Authority. Formal Research Ethics Committee review was not 
required because patient data were collected in the course of normal hospital 









During the study period 155 patients were treated with neo-adjuvant 
chemotherapy prior to liver resection. Details of patients undergoing surgery are 











Table 5.1 Characteristics of 155 consecutive patients undergoing resection for colorectal 








Age 65 (33-83)  
Gender 
Female  67 (43.2) 
Male  88 (56.8) 
Timing of liver 
metastases 
Synchronous  120 (77.4) 
Metachronous  35 (22.6) 
Previous   
adjuvant 
chemotherapy 
Yes  23 (14.8) 
No 
 132 (85.2) 
Repeat operation 
Yes  5 (3.2) 
No  150 (96.8) 
Number of liver 
lesions 























Table 5.2 Systemic chemotherapy regimens and response to treatment for 155 patients 




The median number of cycles of chemotherapy administered was 4 (IQR 4-6). 
Three patients received second-line chemotherapy. Nine patients were 
excluded from response analysis because imaging was not available, leaving 
146 patients. The median interval between pre- and post-chemotherapy scans 
in patients was 15.3 weeks (IQR 12.0-20.4 weeks) and the median change in 
diameter of the largest liver metastases during this period was a reduction of 
24% (-100% to +342%), or -1.3% (-9.6% to +12.6%) per week. Sixty-four 
patients (43.8%) fulfilled the RECIST criteria for partial response (PR) and eight 
patients (5.4%) had a complete response to treatment. Forty-eight patients 
(32.8%) had stable disease (SD) and twenty-six patients (17.8%) suffered 
N=155 Count (%) 
Chemotherapy regime 
Oxaliplatin and capecitabine 118 (76.1) 
5-FU alone 1 (0.6) 
Oxaliplatin and 5-FU 15 (9.7) 
Irinotecan 6 (3.9) 
Capecitabine alone 11 (7.1) 
Notes unavailable 4 (2.6) 
Number of cycles 4 (1-18) 
Biological agent 
Yes 
Cetuximab 7 (4.5) 
Bevacizumab 2 (1.3) 
No 142 (91.6) 
Unknown 4 (2.6) 
Dose reduction 
Yes 21 (13.5) 
No 134 (86.5) 
Change in size of 
largest tumour on 
imaging according to 
RECIST 
Complete or partial response 72 (46.5) 
Stable disease 48 (31.0) 
Progressive disease 26 (16.8) 
No imaging available 9 (5.8) 
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progressive disease (PD). The median reduction in tumour size in patients who 
responded to treatment was -3.2% (-9.6% to -0.9%) per week. 
The median interval between post-chemotherapy imaging and liver resection 
was 10.4 weeks (7.1-17.6 weeks), and was similar across patient groups  
regardless of response to chemotherapy (Table 5.3).  
 
 
Table 5.3 Change in maximum diameter of liver metastases among 146 patients during 
interval between post-chemotherapy imaging and liver resection, categorised according 
to initial response 
 
During this period, the largest tumour diameter increased in 102 patients 
(69.9%) and decreased in 37 (25.3%) with a median change of +2.3% per week 
(-11.1 to +28.0%). By RECIST criteria 16 patients (10.9%) had PR, 48 patients 
(32.9%) had SD and 82 patients (56.2%) had PD in the interval before surgery. 
The increase in tumour diameter was greatest in patients who had a partial or 
complete response while receiving chemotherapy (Table 5.3). Of the 120 
patients who had either PR or SD whilst receiving chemotherapy only 51 
(42.5%) remained in either of these two categories whilst awaiting surgery. 
















and PR vs PD 
Median interval in weeks from 
post chemotherapy imaging to 








Median % change in diameter 
(range) +42 





(-38 to +156) 
<0.001 
Change in diameter 



























suffered continued disease progression in the interval to surgery (P=0.352), and 
only one patient had a late response. The rate of change in size of largest 
tumour during this interval was 2.3% per week, (-11.1 to +28.0%) which was 
significantly greater than during the treatment interval (-1.3%, -9.6% to +12.6%) 
(P=0.007). The median doubling time of tumours which increased in size during 
this period was 45.5 days (0.7-1869). 
In survival analysis 11 patients were excluded because surgery was deemed 
non-curative or a staged resection was not completed, and three patients were 
excluded because they died without undergoing surveillance imaging. Seven 
patients were excluded because they developed cut surface recurrence after R1 
resection leaving 125 patients for analysis, of whom 104 patients initially had 
PR or SD. At closure of the study the median follow-up was 36 months (1-97 
months). Seventy-nine patients (63.2%) suffered tumour recurrence and there 
were 45 deaths (36%). Tumour response whilst receiving chemotherapy was 
associated with significantly longer disease-free survival than PD or SD (Figure 
5.1). 
Among the 60 patients who initially responded and the 44 patients who had 
stable disease whilst receiving chemotherapy disease-free survival was similar 
regardless of tumour behaviour after completion of treatment (Figure 5.2 and 
5.3 respectively). Among the patients who suffered PD in the interval after 
completing chemotherapy, survival was determined by initial response to 
treatment. In 35 patients who initially responded the median disease-free 
survival was 26 months (range 2-84) compared to seven months (range 1-54) in 
22 patients who initially had stable disease (P=0.002). Among the total group of 
66 patients who suffered PD after completion of chemotherapy in whom survival 
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analysis was undertaken the rate of increase in size of largest tumour was not 







Figure 5.1 Kaplan–Meier disease-free survival curves following liver resection for 
colorectal liver metastases for 125 patients treated with preoperative systemic 




Figure 5.2 Kaplan–Meier disease-free survival curves following liver resection for 
colorectal liver metastases for 60 patients who initially had partial or complete response 
to chemotherapy categorised according to tumour behaviour after completion of 





Figure 5.3 Kaplan–Meier disease-free survival curves following liver resection for 
colorectal liver metastases for 44 patients who initially had stable disease categorised 





Figure 5.4 Kaplan–Meier disease-free survival curves following liver resection for 
colorectal liver metastases for 66 patients who suffered tumour progression (PD) after 






The principle findings of this study are that: 
a) tumour response to chemotherapy is associated with improved disease-free 
survival after resection of CRLM  
b) in a large proportion of these patients the treatment effect is transient and 
disease progression occurs rapidly after stopping therapy 
c) the change in tumour size is more rapid after completion of chemotherapy 
than during treatment 
d) relative change in tumour size after completion of chemotherapy is not 
associated with disease-free survival  
Although a regime of six cycles of oxaliplatin and capecitabine has 
recommended as a neoadjuvant chemotherapy treatment prior to liver 
resection92, the most common regime adopted in this series was four cycles. 
This regime has been used to minimise complications due to hepatotoxicity 
which can occur following use of these agents197. The association of response 
to neo-adjuvant chemotherapy estimated by RECIST criteria with improved 
disease-free survival compared to progressive disease has been shown 
previously268,269,273, though others have shown no independent association94.    
In keeping with other units, a period of recovery after completion of 
chemotherapy is allowed to minimise the risks of hepatotoxicity. The optimum 
period of recovery has not been defined but four weeks has been 
recommended based on studies of the recovery of hepatic clearance of 
indocyanine green274.  In the present study, the median interval between 
completion of chemotherapy and surgery was 10 weeks. This period includes 
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the time needed for notification of completion of chemotherapy, MDT 
discussion, clinic appointments and preparation for surgery. No previous study 
has addressed the change in tumour size during this period and potential 
associations with outcomes for patients after surgery. The majority of patients 
who initially responded to chemotherapy or had stable disease will suffer 
disease progression after completion of chemotherapy. For tumours which 
increase in size in this interval the rate of tumour growth is very rapid (2.3% per 
week), with a calculated tumour DT of 46 days. The DT of untreated CRLM has 
been reported previously as between 63 and112 days244,245. This rapid tumour 
growth does not however appear to influence disease-free survival after 
resection which is determined by the initial response to chemotherapy. Among 
the group of patients who suffer disease progression in the interval to surgery 
the median disease-free survival of patients who initially responded (26 
months), is greater than that of patients who initially had stable disease (7 
months) (P=0.002). 
The lack of effect of rebound growth in tumour size after completion of 
chemotherapy is unusual in the context of the expected behaviour of solid 
tumours. There is evidence that rapid tumour proliferation is associated with 
poor outcome in colorectal cancer, although these studies have usually 
employed molecular kinetic markers275–277. Despite these findings there is little 
evidence that in vitro markers of tumour proliferation correlate with macroscopic 
tumour growth or that the growth rate of CRLM correlates with poor outcome 
after resection. It is possible that the increase in tumour size noted after 
cessation of chemotherapy represents tumour swelling, rather than growth of 
viable tumour cells, and tumour expansion may be associated with cell death278. 
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The change in size of CRLM may also not be representative of extra-hepatic 
effects. Tumour recurrence after resection of CRLM is caused by micro-
metastases not detected at the time of initial treatment279,280, and response to 
treatment of these malignant cells may be more sustained than that by large 
liver metastases. In this context change in size of CRLM can be seen as a 
surrogate marker for the effects of chemotherapy on peripheral 
micrometastases only during treatment. Decrease in size of these lesions may 
indicate a beneficial effect in terms of micrometastatic disease, whereas 
rebound growth after cessation of treatment may not indicate recovery of 
peripheral micrometastases. 
An important question raised by these findings relates to the length of time 
allowed between completion of chemotherapy and liver resection. No trial has 
been undertaken to address this issue and the risks are not uniform between 
patients, being affected by the extent of the planned resection and the size of 
the future liver remnant. Our findings suggest that when chemotherapy is 
administered to patients with resectable tumours, disease progression after 
cessation of chemotherapy has no adverse effect on outcome and should not 
influence the timing of surgery. When chemotherapy is used specifically to 
down-size CRLM of borderline resectability however, rapid tumour progression 
after cessation of treatment may render the lesions unresectable, and earlier 
liver resection may be desirable in this group. 
The potential weakness of this study relates to the measurement of tumour size. 
We have compared the maximum tumour diameter measured by imaging with 
that noted on macroscopic measurement of the resection specimen using a 
unidimensional measurement, as this has been shown to be representative of 
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tumour volume263. This method has not however been previously validated by a 
direct comparison of the assessment of tumour size by imaging and pathology, 
and no data is available regarding the accuracy of CT scans in determining the 
size of CRLM. CT scan measurements however have been shown to be 
accurate in the measurement of hepatoma281. Also, the time point at which post-
chemotherapy imaging was undertaken was variable, and some change in size 
may have occurred in the interval between completion of chemotherapy and 
final imaging. Another potential source of inaccuracy is that data relating to the 
use of chemotherapy after surgery was not included in survival analyses. 
Uptake of adjuvant chemotherapy after liver resection is generally poor, though 
many patients will have received palliative treatment. Measurement of tumour 
growth after completion of chemotherapy is not undertaken in clinical practice 
and this factor is unlikely to have led to bias in the administration of 
chemotherapy to individual patients. The sample size used in this study is not 
large, and a study with greater power may reveal differences in survival 
between groups not apparent in this analysis. 
 
5.6 Conclusion 
Change in tumour size after completion of chemotherapy is variable and can be 
rapid, especially in patients who initially responded to treatment. It does not 
appear to affect outcome and should not be considered an adverse factor when 
counselling patients or determining treatment options. Clinicians should be 
aware of these findings when discussing patients at MDTs and use them to 
guide decision making.  
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Chapter 6 : The interaction between diabetes, 
body mass index, hepatic steatosis and risk of 
liver resection: insulin dependent diabetes is the 
greatest risk for major complications. 
 
Wiggans MG, Lordan JT, Shahtahmassebi G, Aroori S, Bowles MJ, Stell 
D A. (2014) The interaction between diabetes, body mass index, hepatic 
steatosis, and risk of liver resection: Insulin dependent diabetes is the 








This study aimed to assess the relationship between diabetes, obesity and 
hepatic steatosis in patients undergoing liver resection and to determine if these 
factors are independent predictors of major complications. 
Methods 
 Analysis of a prospectively maintained database of patients undergoing liver 
resection between 2005 and 2012 was undertaken. Background liver was 
assessed for steatosis and classified as <33% and ≥33%. Major complications 
were defined as Grade III-V complications using the Dindo-Clavien 
classification. 
Results 
504 patients underwent liver resection, of whom 56 had diabetes and 61 had 
steatosis ≥33%. Median BMI was 26 kg/m2 (16-54 kg/m2). 94 patients 
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developed a major complication (18.7%). BMI ≥ 25 kg/m2 (P = 0.001) and 
diabetes (P = 0.018) were associated with steatosis ≥33% Only insulin 
dependent diabetes was a risk factor for major complications (P = 0.028). Age, 
male gender, hypoalbuminaemia, synchronous bowel procedures, extent of 
resection and blood transfusion were also independent risk factors. 
Conclusions:  Liver surgery in the presence of steatosis, elevated BMI, and 
non-insulin dependent diabetes is not associated with major complications. 
Although diabetes requiring insulin therapy was a significant risk factor, the 
major risk factors relate to technical aspects of surgery, particularly 




Liver failure occurs in up to 32% of patients following liver resection137,181–183,282 
and is a major contributor to both morbidity63 and mortality148. Liver resection is 
technically more difficult in patients with parenchymal liver disease283 and the 
risks of liver resection are increased due to impaired hepatic regeneration284.  
Non-alcoholic fatty liver disease (NAFLD) is the commonest cause of liver 
disease in the West110 and is also the commonest cause of a sustained rise in 
serum transaminases in patients with no history of chronic liver disease285. 
NAFLD encompasses steatosis (excess accumulation of triglycerides), 
steatohepatitis (hepatocyte damage, inflammatory infiltrate and fibrosis) and 
cirrhosis286  and can be demonstrated with routine histological staining. NAFLD  
is associated  with diabetes mellitus and obesity287,288 which are also 
undergoing a global epidemic289,290. However, not all patients with obesity and 
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diabetes develop NAFLD and similarly not all patients with NAFLD suffer either 
diabetes or obesity291. 
Liver-directed chemotherapy is also associated with hepatotoxicity. 
Steatohepatitis has been shown to occur in 20% of patients who receive 
irinotecan and 5% of those who receive fluorouracil (5FU)270, with a resulting 
increase in complications after surgery. Oxaliplatin is associated with sinusoidal 
obstruction syndrome197,270. Recreational alcohol use is also a major cause of 
hepatic steatosis292.  
A meta-analysis has shown that hepatic steatosis is associated with increased 
risk of postoperative complications and that moderate and severe steatosis are 
associated with increased mortality compared to patients with normal liver 
parenchyma or mild steatosis111. However, this analysis is based on four 
studies, only two of which included both BMI and diabetes in multivariate 
analyses62,184,283,293. Obesity, diabetes and hepatic steatosis often coexist in the 
metabolic syndrome109, and the increased risk of operating in the presence of 
steatosis may be due to associated co-morbidity.  Diabetes mellitus and obesity 
are independent risk factors for postoperative complications following other 
types of major surgery, including infectious112,113,294, cardiovascular294,295 and 
renal complications113,294,295.  Furthermore, in the four studies included in the 
meta-analysis heterogeneous definitions of post-operative complications were 
used, and often relatively minor complications included. Recently complications 
after liver surgery have been classified by the Dindo-Clavien system296, which 




The aim of this study was to assess the relationship between the incidence of 
diabetes, obesity and hepatic steatosis in patients undergoing liver resection 
after a period of abstention from alcohol consumption and to determine if these 
factors are independent predictors of major complications following liver 




A retrospective analysis of a prospectively maintained database of all patients 
undergoing liver resection between July 2005 and September 2012 was 
undertaken. Patient characteristics, laboratory data and intra-operative details 
were retrieved. BMI was recorded pre-operatively and the cohort divided into 
three categories; 18.5-24.99 kg/m2 (normal), 25-29.99 kg/m2 (overweight), and 
≥30 kg/m2 (obese). Diabetes was categorised according to the requirement for 
insulin. The presence of pre-existing chronic liver disease was confirmed by 
histology. American Association of Anesthesiologists (ASA) grade was 
determined by the responsible anaesthetist and the physiologic score calculated 
according to the POSSUM system297. Selected patients were treated with 
neoadjuvant chemotherapy. All patients underwent pre-operative counselling by 
a nurse specialist where abstention from alcohol was mandated. This instruction 
was also contained in a patient information sheet. The normal interval from pre-
operative counselling to surgery in our series is approximately 30 days. 
Liver resections were defined according to the Brisbane classification17 and 
undertaken using standard techniques, using hepatic inflow occlusion 
selectively. Major resections were defined as resections of three or more 
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segments. Synchronous liver and bile-duct resections were performed in the 
presence of hilar cholangiocarcinoma.  Radiofrequency ablation was used 
where small lesions were not accessible for surgical resection. 
Major complications were defined as Grade III-V complications using the Dindo-
Clavien classification where grade III complications are those requiring surgical, 
endoscopic or radiological intervention, grade IV includes life threatening 
complications including organ failure and grade V is death296.  Post-
hepatectomy liver failure (PHLF) was defined in accordance with the 
International Study Group of Liver Surgery (ISGLS)187 as an increased 
prothrombin time (PT) and serum bilirubin concentration on or after 
postoperative day five. In patients with preoperatively increased PT or serum 
bilirubin concentration PHLF was defined as an increasing serum bilirubin 
concentration and PT on or after postoperative day 5, compared with the values 
of the previous day. Renal dysfunction was defined as an increase in serum 
creatinine of ≥1·5-fold from the preoperative baseline, according to RIFLE 
criteria298. 
Serum biochemistry tests and coagulation assays were performed pre-
operatively, in the first 24 post-operative hours and then repeated according to 
clinical course. The peak measurement of bilirubin, prothrombin time (PT) and 
creatinine was recorded. Clotting factors were not administered between 
postoperative days (POD) 1-5. At histological examination the background liver 
parenchyma at least 1cm from the tumour edge was assessed for degree of 
steatosis using the Brunt classification (the proportion of hepatocytes containing 
fat droplets; 1: <33%, 2: 33–66%, 3: >66%)299. For analysis, the data was 
divided into <33% (mild or none) and ≥33% (moderate or severe). 
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The minimum post-operative follow-up was 90 days and mortality was recorded 
along with details of postoperative intervention and complications.  
To determine potential associations between patient characteristics and 
steatosis, and between patient, operative and histological characteristics and 
major complications univariate logistic regression or chi-square test at the level 
of P<0.25229 was performed, as appropriate. Significant variables in the 
univariate analysis were included in the multivariate logistic regression model 
and were considered to be significant if P<0.05. All analyses were carried out 




Of 504 patients treated in the study period surgery was undertaken for 
metastatic disease in 358 (71.0%), of whom 308 (61.1%) had colorectal liver 
metastases. Resections were performed for primary hepatic malignancy in 106 
patients (21.0%) including hepatocellular carcinoma in 39 (7.7%) and 
cholangiocarcinoma in 31 (6.2%) patients. In 40 patients (7.9%) resection was 
performed for benign tumours. Major resection was undertaken in 299 patients 
(59.3%). In twenty-three patients, a synchronous bowel procedure was 
performed including 10 colonic resections, 11 small bowel procedures, one 
gastric resection and one Whipple’s procedure. Fifty-six patients were diabetic 
(11.1%) of whom 15 were insulin-dependent (26.8%). The median BMI of 
patients undergoing resection was 26 kg/m2 (range 16-54 kg/m2). Elevated BMI 
(≥25kg/m2) was noted in 332 patients (65.9%) and 123 patients (24.4%) were 
obese (≥30kg/m2). Five patients had no BMI recorded and were excluded from 
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analysis. Preoperative liver-directed chemotherapy was used in 168 patients 
(33.3%). The most commonly used regime was oxaliplatin and capecitabine 
which was used in 118 patients (70.2%). Irinotecan was used in six patients 
(3.6%). 
Histopathological examination revealed zero, mild, moderate and severe 
steatosis in 199 (39.5%), 179 (35.5%), 54 (10.7%) and seven (1.4%) patients 
respectively. Degree of steatosis was not recorded in 65 patients (12.9%). The 
distribution of BMI, diabetes and steatosis is shown in Figure 6.1.  
 
Figure 6.1 Box plot of body mass index (BMI), diabetic status and degree of hepatic 
steatosis in 439 patients undergoing liver resection. 




The median BMI of patients with no steatosis (25kg/m2, range 16-45) was lower 
than those with mild steatosis (27kg/m2, range 18-44) (P<0.001), which was 
lower than patients with moderate/severe steatosis (29kg/m2, range 22-42) 
(P=0.001). The median BMI of diabetic patients was 29kg/m2 (16-40) compared 
to 26kg/m2 (17-54) in non-diabetic patients (P=0.002).  There was no difference 
in the median BMI of patients with insulin-dependent diabetes (IDDM) (29kg/m2, 
range 16-40) and those with non-insulin dependent diabetes (NIDDM) (29kg/m2, 
range 20-39) (P=0.816).  The rate of mild steatosis among diabetics was 16/52 
(30.8%) compared to 45/387 (11.6%) in non-diabetics (P=0.001), but there was 
no significant difference in the rates of mild steatosis in patients with NIDDM 
(11/37) and those with IDDM (5/15). The rate of moderate/severe steatosis was 
6/135 (4.4%) in normal weight, non-diabetic patients, 39/249 (15.6%) in 
overweight non-diabetics (P=0.001), 0/12 in normal weight diabetics and 15/39 
(38.5%) in overweight diabetics (P<0.001). 
Elevated pre-operative transaminase levels were noted in 18 of 60 patients 
(30%) with moderate/severe steatosis and 61 of 369 patients (16.5%) with 
steatosis <33% (P=0.019). The sensitivity and specificity of elevated 
transaminases for predicting the presence of moderate or severe steatosis were 
30% and 83% respectively. 
Multivariate analysis revealed that elevated BMI ≥25kg/m2 (P=0.001) and the 
presence of diabetes (P=0.018) were significantly associated with 




Table 6.1 Analysis of factors associated with hepatic steatosis (≥33%) in 439 patients undergoing liver resection. 
*Significant at the level of 0.25 for univariate analysis and included in multivariate analysis **Significant at the level of 0.05 for multivariate analysis 
N=439 Steatosis <33% (n=378) Steatosis ≥33% (n=61) Univariate Multivariate 
Median (range) Count (%) Median 
(range) 
Count (%) P-value Comparison Odds ratio  
(95% CI) 
P-value 
Age 65 (21-90)  65 (41-87)  0.622    
Gender 
Female  168 (44.4)  24 (39.3) 
0.544    
Male  210 (55.6)  37 (60.7) 
Liver directed chemotherapy 
Yes  132 (34.9)  20 (32.8) 
1.000    
No  246 (65.1)  41 (67.2) 
Pre-existing chronic liver 
disease 
Yes  6 (1.6)  3 (4.9) 
0.228*   0.869 
No  372 (98.4)  58 (95.1) 
Preoperative jaundice 
(≥50micromol/L) 
Yes  5 (1.3)  0 
0.800    
No  373 (98.7)  61 (100) 
Hypoalbuminaemia (<35g/L) 
Yes  15 (4.0)  1 (1.6) 
0.602    No  360 (95.2)  59 (96.7) 
Not recorded  3 (0.8)  1 (1.6) 
Raised preoperative alkaline 
phosphatase  





0.001** No  283 (74.9)  55 (90.2) 
Not recorded  3 (0.8)  1 (1.6) 
Raised preoperative 
transaminase 




<0.001** No  308 (81.5)  42 (68.9) 
Not recorded  9 (2.4)  1 (1.6) 
Diabetic status 








 26 (6.9)  11 (18.0) 
Insulin 
dependent 








Body mass index (kg/m2) 
<25  141 (37.3)  6 (10) 
<0.001* 




25-29.9  153 (40.5)  27 (45.0) 
≥30  81 (21.4)  27 (45.0) 25-29.9 vs 
≥30 
 0.144 
Not recorded  3 (0.8)  1 (1.6) 
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Body Mass Index ≥25kg/m2 increased the risk by a factor of 2.97 and diabetes 
increased the risk by a factor of 2.69. Among diabetic patients, insulin-
dependence increased the risk of moderate/severe steatosis by a factor of 4.31 
(P=0.037).  However, BMI ≥30kg/m did not increase the risk of moderate/severe 
steatosis compared to BMI of 25-29.9 (P=0.144). Raised preoperative 
transaminase levels also increased the risk of moderate/severe steatosis by a 
factor of 3.82 (P<0.001) and raised preoperative alkaline phosphatase 
concentrations decreased the risk by a factor of 0.15 (P=0.001). Hepatic 
steatosis was not associated with liver-directed chemotherapy or other 
biochemical markers of liver dysfunction (pre-operative hypoalbuminemia and 
hyperbilirubinaemia). 
During the study period 94 patients developed a major postoperative 
complication.  Twenty-three patients died within 90 days of surgery (4.6%) and 
71 patients who survived beyond 90 days suffered a major complication 
(14.1%).  The most common cause of mortality was liver failure (nine patients). 
Of patients who developed Grade IV complications 34/64 (53.1%) developed 
PHLF and 31/64 developed renal failure (48.4%). Of the 34 patients who 
developed PHLF 29 had undergone major liver resection. Twenty-three patients 
developed bile leaks, and seven required relaparotomy/relaparoscopy. 
Multivariate analysis revealed that older age, male gender, hypoalbuminaemia, 
synchronous bowel procedures, number of segments resected, and blood 
transfusion were independent risk factors for major postoperative complications 




Table 6.2 Analysis of factors associated with major complications following liver resection in 504 patients. 





P-value Odds ratio (95% CI) P-value 
Median age (range) 64 (21-90) 67 (32-88) 0.015* 1.03 (0.99-1.07) 0.004** 
Gender (%) 
Male 211 (51.5) 67 (71.3) 
0.001* 
2.36 (1.34-4.17) 0.028** 
Female 199 (48.5) 27 (28.7)   
Pathology (%) 
Benign 34 (8.3) 6 (6.4)    
Primary 83 (20.2) 23 (24.5) 0.622   
Secondary 293 (71.5) 65 (69.1) 0.308   
Liver directed chemotherapy (%) 130 (31.7) 33 (35.1) 0.608   
Pre-existing chronic liver disease (%) 10 (2.4) 1 (1.1) 0.666   
Preoperative jaundice (≥50micromol/L) (%) 6 (1.5) 3 (3.2) 0.266   
Hypoalbuminaemia (<35g/L) (%) 9 (2.2) 8 (8.5) 0.004* 2.97 (1.01-8.74) 0.047** 
Raised preoperative alkaline phosphatase (%)  95 (23.2) 24 (25.5) 0.721   
Raised preoperative transaminase (%) 74 (18.0) 21 (22.3) 0.320   
Preoperative glomerular filtration 
rate (%) 
≤90ml/min 274 (66.8) 63 (67.0) 0.892   
Median preoperative haemoglobin (g/dL) (range) 13 (9-17) 13 (9-16) 0.025*  0.439 
Median preoperative white cell count (/L) (range) 7 (3-17) 7 (3-25) 0.422   
Diabetic status (%) 
Non-diabetic 370 (90.2) 78 (83.0) 
0.014* 
 0.912 
Non-insulin dependent (vs non-diabetic) 32 (7.8) 9 (9.6) 
Insulin dependent diabetes (vs non-
insulin dependent and non-diabetics) 
8 (2.0) 7 (7.4) 3.86 (1.17-12.75) 0.028** 
Body mass index (kg/m2) (%) 
<25 139 (33.9) 28 (29.8) 
0.697   25-30 167 (40.7) 42 (44.7) 
>30 99 (24.1) 24 (25.5) 
American Association of 
Anesthesiologists (ASA) grade 
(%) 
1 vs 2 
1 46 (11.2) 6 (6.4) 
0.198* 
 0.611 
2 266 (64.9) 58 (61.7) 
2 vs 3 and 4 
3 95 (23.2) 30 (31.9) 
 0.783 
4 2 (0.5) 0 
Median P-POSSUM physiologic score (range) 16 (12-32) 18 (12-30) 0.003*  0.764 
Operative approach (%) 
Laparoscopic 46 (11.2) 4 (4.3) 
0.065*  0.812 
Open 364 (88.8) 90 (95.7) 
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Table 6.2 continued. 
N=504 
No complication  
(n=410) 
Major complication  
(n=94) 
Univariate Multivariate 
P-value Odds ratio (95% CI) P-value 
Radiofrequency ablation included (%) 18 (4.4) 5 (5.3) 0.698   
Wedge resection included (%) 181 (44.1) 22 (23.4) <0.001*  0.353 
Bile duct reconstruction (%) 34 (8.3) 12 (12.8) 0.246*  0.585 
Synchronous bowel procedure (%) 13 (3.2) 10 (10.6) 0.003* 5.99 (2.25-15.96) <0.001** 
Median number of segments resected (range) 3 (1-6) 4 (1-6) <0.001 1.51 (1.26-1.80) <0.001** 
Repeat operation (%) 31 (7.6) 6 (6.4) 0.861   
Intraoperative blood loss (%) 
<500ml 218 (53.2) 29 (30.9) 
<0.001  0.463 
≥500ml 188 (45.9) 65 (69.1) 
Blood transfusion required (%) 65 (15.9) 41 (43.6) <0.001 2.48 (1.44-4.30) 0.001** 
Steatosis (%) 
<33% 308 (75.1) 70 (74.5) 
1.000   
≥33% 50 (12.2) 11 (11.7) 
 
* Significant at the level of 0.25 for univariate analysis and included in multivariate analysis 





There was no association between NIDDM, BMI or degree of hepatic steatosis 
and major postoperative complications. IDDM more than trebled the risk of 
major complication compared to non-diabetics and those with NIDDM. The 
complications in these groups are shown in Table 6.3.  
The greatest risk however occurred when liver resection was undertaken in 
conjunction with a synchronous bowel procedure, which increased the risk of 
major complication almost six times that of a liver-only resection. Ten of 23 
patients developed major postoperative complications, six of whom had colonic 
resections (three right sided and three left sided), three had small bowel 
procedures and one a gastric resection.  
Of the 299 patients who underwent major resection there was no significant 
difference in the proportion of patients with steatosis ≥33% between patients 
who did (10/64, 15.6%) or did not (23/201, 11.4%) develop major complications 
(P=0.388). Similarly, there was no significant difference in the proportion of 
patients with steatosis ≥33%between patients who did (4/22, 15.6%) or did not 































diabetic Count (%) Count (%) Count (%) Count (%) 





 Liver failure 9 (1.8) 5 (1.1) 3 1 0.023 0.180 
 Sepsis 4 (0.8) 3 (0.7) 1 0 0.296 1.000 
 Malignancy 4 (0.8) 3 (0.7) 0 1 1.000 0.124 
 Pulmonary embolus 1 (0.2) 1 (0.2) 0 0 1.000 1.000 
 Anastomotic leak 1 (0.2) 1 (0.2) 0 0 1.000 1.000 
 Peptic ulcer 1 (0.2) 1 (0.2) 0 0 1.000 1.000 
 Strangulated hernia 1 (0.2) 1 (0.2) 0 0 1.000 1.000 
 Peritonitis 1 (0.2) 1 (0.2) 0 0 1.000 1.000 
 Heart failure 1 (0.2) 1 (0.2) 0 0 1.000 1.000 




Post hepatectomy liver failure (PHLF) 34 (6.7) 30 (6.7) 4 0 0.515 0.613 
Renal dysfunction 31 (6.2) 24 (5.4) 4 3 0.280 0.050 
Respiratory failure requiring Intensive 
Care 
2 (0.4) 2 (0.4) 0 0 1.000 1.000 





Table 6.3 continued. 
Patients may have had more than one complication.

























Bile leak  
Drain 12 (2.4) 11 (2.5) 0 1 0.611 0.330 




Washout 3 (0.6) 1 (0.2) 1 1 0.161 0.064 
Adhesiolysis 2 (0.4) 2 (0.4) 0 0 1.000 1.000 
Defunction for 
anastomotic leak 
1 (0.2) 0 1 0 0.084 1.000 
Small bowel leak 1 (0.2) 1 (0.2) 0 0 1.000 1.000 
Drainage 
Liver abscess 1 (0.2) 1 (0.2) 0 0 1.000 1.000 
Pleural effusion 1 (0.2) 0 0 1 1.000 0.032 





0 0 1.000 1.000 





The principal finding of this study is that although diabetes mellitus and higher 
BMI are risk factors for steatosis in patients undergoing liver resection, the 
majority of cases of steatosis occur in non-diabetic patient with mildly elevated 
BMI (25-30). Secondly, steatosis and elevated BMI are not associated with 
major complications after liver resection, and diabetes is a risk factor for these 
complications only if patients are insulin dependent. Other predictors of major 
complications are older age, male gender, preoperative hypoalbuminaemia, 
synchronous bowel procedures, number of segments resected and requirement 
for blood transfusion. 
The 90-day mortality (4.6%) and morbidity rate (14.7%) rate are similar to 
published series136,137,270, although other series have included minor (Grade I 
and II) complications161,300,301. Composite outcomes similar to the one used in 
this study have been used previously in studies evaluating outcomes following 
gastrointestinal surgery302,303. The present study confirms the association 
between hepatic steatosis and BMI304. Whilst the rate of moderate/severe 
steatosis was greatest in overweight diabetic patients (38.5%), it also occurred 
in patients of normal weight without diabetes (4.4%). This suggests that other 
risk factors may be involved in the aetiology of the disease. Undernutrition 291, 
impaired glucose tolerance305 and genetic factors306 have also been implicated 
in the development of NAFLD. Alcohol consumption is an unlikely cause of 
steatosis in this series as all patients are asked to abstain from alcohol 
consumption prior to surgery, although compliance with this instruction has not 
been assessed.  
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Elevated transaminase levels are associated with hepatic steatosis, but the 
sensitivity of abnormal transaminases in detecting moderate or severe NAFLD 
is poor, as 70% of these patients had normal transaminase levels. This is in 
keeping with other studies307. Interestingly, raised preoperative alkaline 
phosphatase concentration was associated with decreased incidence of 
steatosis. Elevated alkaline phosphatase may be found in cases of biliary 
obstruction and of the 119 patients with this finding 16.8% had 
cholangiocarcinomas compared to only 2.9% of the 380 patients with normal 
alkaline phosphatase. This group is more likely to be systemically unwell as a 
consequence of biliary obstruction and to have suffered a period of anorexia 
and weight loss, which may affect the degree of hepatic steatosis.  
Pre-operative chemotherapy was not shown to be associated with steatosis. 
Studies have shown an association between steatohepatitis and irinotecan 
therapy270, which was rarely used in this series. In addition, the policy in this unit 
is to use only four cycles of chemotherapy and to allow a period of recovery 
before undertaking liver resection, to allow resolution of hepatotoxicity. 
Previous studies have shown that steatosis increases the risk of PHLF 111,283. 
The rate of PHLF in this series was low (6.7%), and occurred in 6.6% patients 
with moderate/severe steatosis and 6.1% of the patients with none/mild 
steatosis. The majority of cases of PHLF followed major liver resection (29/34). 
It is possible that there is an independent association between steatosis and 
PHLF, which is not revealed in this study which uses a composite outcome 
including other complications in the multivariate analysis. Steatosis may be a 
risk factor for liver failure in patients undergoing extended hepatectomy, 
although not in major hepatectomy in this series, where the risk of this 
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complication is greatest. Previous studies have recommended liver biopsy to 
investigate the presence of steatosis prior to resection308,309. The current study 
suggests that the risk of this investigation is not justified due to the lack of effect 
of steatosis on outcome. 
The rate of bile leak requiring intervention (4.6%) was not affected by the 
degree of hepatic steatosis suggesting that hepatic steatosis does not make 
parenchymal division more difficult to perform.   
Elevated BMI was not associated with major complications in this series, 
although it may be associated with more minor complications such as wound 
infection which has not been explored in this study. 
Diabetes was an independent risk factor for complications after liver surgery 
which confirms the findings of previous studies60,163,164,282, although 
identification of insulin-dependence as the major risk factor is a novel finding. 
Whilst there was no significant difference in the risk of major complications 
between non-diabetic patients and those with non-insulin dependent diabetes, 
the risk of complications was more than trebled in those with insulin-dependent 
diabetes.  This finding reflects the multi-system nature of diabetic end-organ 
damage. Diabetic nephropathy is a major cause of renal dysfunction310 and was 
the most common complication in patients with IDDM. Renal dysfunction was 
also twice as common amongst patients with IDDM compared to those with 
NIDDM.  
Older age, male gender, preoperative hypoalbuminaemia, number of liver 
segments resected and requirement for blood transfusion have all been 
previously identified as risk factors for postoperative complications136. The 
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finding that performing a synchronous bowel procedures is associated with 
worse outcome is similar to that of a previous study which found that the risk of 
a major complication was 20.4% after a synchronous colonic resection 
compared to 14.9% after a liver only resection311. Although a recent systematic 
review suggested no difference in terms of overall morbidity or mortality 
between synchronous or staged resections312 the results of the present study 
reveal the risk of developing a major complication after a synchronous bowel 
procedure was almost six times that of a liver-only resection. It should also be 
noted that the synchronous procedures included a gastric resection and a 
Whipple’s procedure which may pose different risks to colonic resections.  Most 




The results of this study allow clinicians to advise patients regarding the risks of 
liver resection and to place them in context. In particular, liver surgery in the 
presence of steatosis, elevated BMI and NIDDM does not lead to greatly 
increased operative risk. While insulin dependence is a significant risk factor for 
complications after liver surgery the major risk factors in this series related to 
technical details of the operation, particularly the performance of simultaneous 
bowel procedures. Clinicians should counsel patients preoperatively regarding 
their individual risks associated with liver resection so that they can make 





Chapter 7: Serum arterial lactate concentration is 
a useful predictor of mortality and organ 
dysfunction following liver resection  
 
Wiggans MG, Starkie T, Shahtahmassebi G, Woolley T, Birt D, Erasmus 
P, Anderson I, Bowles MJ, Aroori S, Stell DA. (2013) Serum arterial 
lactate concentration predicts mortality and organ dysfunction following 







The aim of this study was to determine if the post-operative serum arterial 
lactate concentration is associated with mortality, length of hospital stay or 
complications following hepatic resection. 
Methods 
Serum lactate concentration was recorded at the end of liver resection in a 
consecutive series of 488 patients over a seven-year period. Liver function, 
coagulation and electrolyte tests were performed post-operatively. Renal 
dysfunction was defined as a creatinine rise of >1.5x the preoperative value.  
Results 
The median lactate was 2.8mmol/L (0.6-16mmol/L) and was elevated 
(≥2mmol/L) in 72% of patients. The lactate concentration was associated with 
peak post-operative bilirubin, prothrombin time, renal dysfunction, length of 
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hospital stay and 90-day mortality (P<0.001). The 90-day mortality in patients 
with a post-operative lactate ≥6mmol/L was 28% compared to 0.7% in those 
with lactate ≤2mmol/L. Pre-operative diabetes, number of segments resected, 
the surgeon’s assessment of liver parenchyma, blood loss and transfusion were 
independently associated with lactate concentration. 
Conclusions 
Initial post-operative lactate concentration is a useful predictor of outcome 
following hepatic resection. Patients with normal post-operative lactate are 
unlikely to suffer significant hepatic or renal dysfunction and may not require 




Despite advances in both operative technique and peri-operative care liver 
resection is associated with postoperative mortality rates of 0-22% (median 
3.7%)136 and morbidity rates of 12.5%- 66% including liver dysfunction186,313, 
renal dysfunction140 and bile leak195,314. Factors associated with peri-operative 
complications and death include patient age146,148 and gender143,153 hospital 
annual number of liver resections undertaken143,145, pathologic origin of liver 
tumour143,145, preoperative liver and renal dysfunction148,153, diabetes163,164, 
chronic liver disease143,146, and the peripheral neutrophil to lymphocyte ratio 
(NLR)168. Operative factors associated with outcome include blood loss148,153 
and transfusion63,167, extent of liver resection63,147, duration of surgery155, 




Therefore, many factors affect outcome after liver surgery which have not been 
incorporated into a single scoring system. The American Society of 
Anaesthesiologists (ASA) grade and Portsmouth Physiologic and Operative 
Severity Score for the enUmeration of Mortality and morbidity (P-POSSUM) 
scores are used in the risk prediction of many types of surgery297,315 including 
liver surgery316. However, these scores may not be applicable to the unique 
stresses of liver resection. One of the main reported causes of mortality 
following liver resection is post-hepatectomy liver failure (PHLF)138. The “50-50 
criteria” of serum bilirubin of >50µmol/L and prothrombin index (laboratory's 
calculated mean normal PT divided by patient's observed PT) of <50% 
measured on the fifth postoperative day has been shown to be associated with 
death due to PHLF186. More recently PHLF has been defined by the 
International Study Group of Liver Surgery (ISGLS) as an increased INR (or 
need of clotting factors to maintain normal INR) and hyperbilirubinaemia on or 
after postoperative day five187. The ability of this newer definition of PHLF, using 
lower measures of dysfunction, to predict mortality is assessed in the next 
chapter but a prediction system based on criteria before postoperative day five 
may be clinically more useful in guiding therapy. Furthermore, failure of multiple 
organ systems may contribute to death following liver resection and there is a 
need for a global peri-operative measure to predict the risk of developing 
significant post-operative morbidity and death. 
Lactic acid is a by-product of anaerobic metabolism which is subsequently 
metabolised in the liver during gluconeogenesis114. Hyperlactataemia has been 
shown to be associated with increased mortality and morbidity in a critical care 
setting118,317, in patients with liver failure119, sepsis120 and following trauma318. 
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Similar relationships have been shown in the postoperative setting following 
pancreatic resection319 and other major abdominal surgery121, cardiac 
surgery320 and after hepatic transplantation321. 
The primary aim of this study was to determine if the first post-operative arterial 
lactate concentration (‘initial lactate’) is associated with adverse outcomes 
following liver resection including 90-day mortality, length of hospital stay (LOS), 
and renal and hepatic dysfunction. The secondary aim was to determine which 
pre- and intra-operative risk factors are associated with initial lactate 




This study was a retrospective analysis of a prospectively maintained database 
of all patients undergoing liver resection since July 2005. Routine patient 
characteristics, laboratory data and intra-operative details were retrieved. Pre-
operative liver-directed chemotherapy was administered to selected patients 
following discussion at a regional multidisciplinary team meeting. A period of 
recovery of at least six weeks was allowed following cessation of chemotherapy 
before undertaking surgery. The POSSUM scoring system was used to 
calculate the physiological score297. Prior to resection the operating surgeon 
makes a visual assessment of the condition of the liver parenchyma and 
records this as normal or abnormal. Liver resections were performed using 
standard techniques with a Cavitron Ultrasonic Surgical Aspirator® (CUSA) 
dissector. Hepatic inflow occlusion was used in a minority of cases where there 
was excessive blood loss.  Anaesthetic techniques include the routine use of 
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invasive arterial blood pressure monitoring, central venous pressure monitoring 
(using a target CVP of <5cm H20) and epidural anaesthesia. Liver resections 
were defined according to the Brisbane classification17 and the number of 
removed segments recorded. Intravenous fluid replacement was minimised 
during the resection phase to decrease venous pressure. After removal of the 
surgical specimen a pause in surgical activity is routinely planned to allow 
haemostasis and intra-venous volume replacement with 0.9% Saline or 
Hartmann’s solution at the anaesthetist’s discretion. Patients are usually 
returned to the High Dependency Unit (HDU) after surgery with full invasive 
monitoring, except for minor resections in fit patients who are returned to the 
general ward.  
The serum lactate was recorded from an arterial blood sample taken 
immediately prior to abdominal closure or immediately on arrival in the HDU. 
The arterial lactate in the normal population is below 1.6mmol/L whereas in a 
critical care setting <2mmol/L is more commonly accepted in acutely stressed 
patients322. 
Serum biochemistry tests and coagulation assays were performed on all 
patients in the first 24 hours post-operatively and the tests repeated according 
to clinical course. The peak measurement of bilirubin and prothrombin time (PT) 
were recorded and used for analysis. A PT index of <50% corresponds to a 
PT>24s. Similarly peak postoperative creatinine levels were obtained and renal 
dysfunction was defined according to RIFLE criteria298. Renal dysfunction in 
categorical analyses was defined as any increase in serum creatinine of ≥1·5-
fold from the preoperative baseline. The length of hospital stay was measured 
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from the day of surgery to day of discharge and was expressed as a natural 
logarithm. Ninety-day mortality was recorded.  
The association between initial serum lactate concentration and continuous 
outcomes was investigated using a multiple linear regression model as well as 
Spearman’s rank correlation. To overcome increasing variance with the mean a 
natural log transformation was used. Binary variables were investigated using 
univariate regression. Potential associations between initial lactate 
concentration and pre- and intraoperative factors were tested using univariate 
regression or chi-square test at the level of P<0.25229, as appropriate. 
Significant variables in the univariate analysis were included in the multivariate 
regression model and were considered to be significant if P<0.05.  All analyses 
were carried out using the statistical package R 2.1.14230.  
Confirmation was obtained from the regional health research authority that 
under the harmonized Guidance Approval for Research Ethics Committees 
(REC), REC review was not required because patient data were collected 
during their normal hospital care and was anonymised for research purposes. 




In the study period 501 patients underwent liver resection for whom an initial 
lactate measurement was available in 488. The indications for surgery, pre-
operative and operative details are shown in Table 7.1. Results of blood tests 
are shown in Table 7.2 and the main post-operative outcome measures are 
summarised in Table 7.3. The median number of biochemistry tests performed 
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per patient in the first five post-operative days was 4 (0-6) and coagulation 
assays was 3 (0-6). It was not necessary to administer clotting factors to any 
surviving patients between postoperative days 1-5. Peak abnormalities in PT 
and bilirubin usually occurred early in the post-operative course and tended to 
improve over five days (Table 8.2). Post-operatively 118 patients (24.1%) had a 
serum bilirubin ≥50µmol/L. Minor abnormalities in PT were commonly noted 
though only 15 patients (3.1%) developed a PT >24s. Although a small number 
of patients remained jaundiced at the time of discharge, only one patient fulfilled 
the “50-50 criteria” at day five. The median length of hospital stay was seven 
days (range 2-78) with 90% of patients having a LOS between two and 15 days. 
Twelve patients (2.5%) died within 30 days of surgery and 23 died within 90 
days of surgery (4.7%). The most common cause of death was liver failure 
which occurred in 11 of 23 patients. Four patients died from on-going 
malignancy (of whom three had undergone non-curative resections) and two 
patients died from sepsis without evidence of liver failure. The remaining deaths 
were attributed to pulmonary embolus, heart failure, anastomotic leak following 







































Age (years) 65  
(21-90) 
 
Gender Female  216 (44.3) 
Male  272 (55.7) 
Pathology of resected 
specimen 
Benign  40 (8.2) 
Primary Hepatocellular 
carcinoma 
 30 (6.1) 
Cholangiocarcinoma  36 (7.4) 
Other  35 (7.2) 
Secondary Colorectal 
metastases 
 291 (59.6) 
Other  56 (11.5) 
Preoperative liver directed 
chemotherapy 
Yes  173 (35.5) 
No  315 (64.5) 
Body Mass Index 26  
(16-54) 
 
POSSUM Physiologic score 16  
(12-32) 
 
ASA Grade 1  49 (10.1) 
2  315 (64.7) 
3  121 (24.8) 
4  2 (0.4) 
Preoperative diabetes Yes  55 (11.3) 
No  433 (88.7) 
Preoperative bilirubin (µmol/L) 9 (2-162)  
Preoperative alkaline phosphatase (U/L) 95  
(34-1190) 
 
Preoperative albumin (g/L) 44  
(10-53) 
 




Filtration Rate (ml/min) 
≤90  158 (33.2) 
>90  318 (66.8) 
Neutrophil to Lymphocyte Ratio (NLR) 2.47 
(0.3-17.3) 
 
Operation number 1st   453 (92.8) 
2nd  30 (6.1) 
3rd   5 (1.0) 
Surgeons assessment of liver 
parenchyma 
Normal  314 (65.3) 
Abnormal  167 (34.7) 
Surgical approach Open  440 (90.2) 
Laparoscopic  48 (9.8) 
Radiofrequency ablation 
(RFA) included 
Yes  22 (4.5) 
No  466 (95.5) 
Operation Right hemihepatectomy  142 (29.1) 
Extended right hemihepatectomy  65 (13.3) 
Left hemihepatectomy  55 (11.3) 
Extended left hemihepatectomy  24 (4.9) 
Left lateral sectorectomy  45 (9.2) 
Wedge resection only  127 (26.0) 
Other  30 (6.1) 
Wedge resection included Yes  182 (37.3) 
No  306 (62.7) 
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Bile duct reconstruction 
included 
Yes  43 (8.8) 
No  445 (91.2) 
Synchronous bowel procedure Yes  22 (4.5) 
No  466 (95.5) 
Curative intent Yes   442 (90.6) 
No   46 (9.4) 




Estimated blood loss <100ml  2 (0.4) 
101-500ml  240 (49.7) 
501-1000ml  167 (34.6) 
>1000ml  74 (15.3) 






















Table 7.3 Postoperative outcomes for 488 patients undergoing liver resection 



























































































N=488 Median (range) Count (%) 
Peak bilirubin (µmol/L) 29 (4-445)  
Peak prothrombin time (s) 17.6 (12.4-200)  
Length of stay (days) 7 (2-78)  
Renal dysfunction 
None 450 (92.2) 
Risk (>1.5x pre-operative creatinine) 17 (3.5) 
Injury (>2x pre-operative creatinine) 12 (2.5) 
Failure (>3x pre-operative creatinine) 5 (1.0) 
90-day mortality  23 (4.7) 
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The median initial lactate concentration was 2.8mmol/L (inter-quartile range = 
1.9-3.9) and 350 patients (72%) had an elevated serum lactate concentration 
(≥2mmol/L) (Figure 7.1).  
 
 
Figure 7.1 Distribution of arterial lactate concentration in 488 patients at the end of liver 
resection 
 
There was no difference in the lactate concentration taken prior to abdominal 
closure (n=380, median 2.8mmol/L, range 0.6-16.0) or immediately on arrival in 
the HDU (n=108, median 2.8mmol/L, range 0.6-14.0). The initial lactate 
concentration was noted to be associated with all recorded outcome measures 










Table 7.4 Univariate analysis of the association between lactate and postoperative 
outcomes for 488 patients undergoing liver resection. 
*Significant at level of P<0.05 
 
 
Although major abnormalities of serum bilirubin and PT were rare in our series 
there was a weak correlation with initial lactate for both bilirubin (coefficient 
0.41, P<0.001) and PT (coefficient 0.37, P<0.001) which was stronger for 
bilirubin. Similarly, there was a weak correlation with length of hospital stay 
(coefficient 0.28, P<0.001). Of note the values for length of hospital stay 
includes only survivors, and therefore excludes some patients who are likely to 
have high post-operative lactate levels. Renal dysfunction after liver resection 
was rare in this series (7.0%) but there was a correlation with lactate 
concentration (Table 7.4). Three of 137 patients (2.2%) with an initial lactate 
concentration less than 2mmol/L who had creatinine measured developed renal 
dysfunction (negative predictive value (NPV) = 0.98) compared to 8 of 29 
(27.5%) patients with an initial lactate greater than 6mmol/L (positive predictive 
value (PPV) = 0.28) (P=<0.001) (Figure 7.2).  
  
N=488 Coefficient ±SD P-value 
Peak bilirubin  0.146 ± 0.017 <0.001* 
Peak prothrombin time  0.055 ± 0.002 <0.001* 
Length of Stay  0.046 ± 0.006 <0.001* 
Renal dysfunction  0.324 ± 0.072 <0.001* 




Figure 7.2 Probability of renal dysfunction after liver resection according to lactate 
concentration in 484 patients 
 
In 322 patients with a lactate concentration ≥2 and <6mmol/L 23 developed 
renal dysfunction (7.1%). 
Similarly, there was a correlation between mortality in the 90-day period 
following liver resection and initial lactate concentration (Table 7.4). One of 138 
patients (0.7%) with an initial lactate concentration <2mmol/L died within this 
period, due to an anastomotic leak following colonic resection (NPV=0.99), 
compared to eight of 29 patients with initial lactate ≥6mmol/L (PPV = 0.28) 





Figure 7.3 Probability of 90-day mortality after liver resection according to lactate 
concentration in 488 patients  
 
The deaths in patients with lactate ≥6mmol/L were due to liver failure in four 
patients, sepsis without liver failure in two patients, cardiac failure in one patient 
and on-going malignancy in the other. Of the remaining 322 patients with lactate 
concentration ≥2 and <6mmol/L there were 14 deaths within 90 days of surgery 
(4.3%). 
Comparison of patients with initial lactate concentrations <2mmol/L and 
≥6mmol/L revealed there were significantly more major resections performed 
(P<0.001) and more patients with preoperative diabetes (P<0.001) in patients 








Table 7.5 Distribution of risk factors and outcomes in 138 patients with lactate <2mmol/L 
and 29 patients with lactate ≥6mmol/L undergoing liver resection  
*Significant at level of P<0.05 
 
There was no significant difference in the use of preoperative chemotherapy 
between these two groups (P=0.351). The proportion of patients with both renal 
dysfunction and who died within 90 days was significantly higher in those with 
lactate concentrations ≥6mmol/L (P<0.001). 
Regression analysis revealed that a preoperative diagnosis of diabetes mellitus, 
the number of liver segments resected, the operating surgeon’s assessment of 
the health of the liver parenchyma, the operative blood loss and number of units 
of red cells transfused were all independently associated with initial lactate 
concentration at closure (Table 7.6). The only preoperative factor associated 
with the post-operative lactate concentration was the presence of diabetes. On 
average, this increased the postoperative lactate concentration at any level by 
20% compared to non-diabetics. 
  




Major resection (%) 26 (18.8) 26 (89.7) <0.001* 
Preoperative chemotherapy (%) 38 (27.5) 5 (17.2) 0.351 
Preoperative diabetes (%) 6 (4.3) 8 (27.6) <0.001* 
Postoperative renal dysfunction (%) 3 (2.2) 8 (27.6) <0.001* 




Table 7.6 Univariate and Multivariate analysis of pre- and intraoperative factors 
associated with serum lactate concentration following liver resection in 488 patients. 
* Significant at the level of 0.25 for univariate analysis and included in multivariate 
analysis  







Factor  P-value Coef +/- SD P-value 
Age    0.246*    0.925 
Gender    0.012*    0.129 




  0.226*    0.878 
Liver directed chemotherapy    0.129*    0.219 
Open or laparoscopic resection    0.009*    0.611 
Radiofrequency ablation    0.191*    0.402 
Wedge resection included  <0.001*    0.086 
Bile duct reconstruction    0.004*    0.651 
Number of segments resected  <0.001* 0.143±0.012 <0.001† 
Synchronous bowel procedure    0.516   
Surgeons assessment of liver  <0.001* 0.185±0.042 <0.001† 
Redo operation 1st v 2nd resection   0.268   
 2nd v 3rd resection   0.654   
Preoperative diabetes  <0.001* 0.204±0.064   0.002† 
Body Mass Index    0.06*    0.905 
ASA Grade 1 vs. 2   0.014*    0.824 
 2 vs. 3   0.709    0.872 
Physiologic score    0.054*    0.221 
Hepatic fibrosis/cirrhosis    0.667   
Preoperative bilirubin    0.320   
Preoperative haemoglobin    0.633   
Neutrophil:lymphocyte ratio    0.400   
Preoperative albumin    0.399   
Preoperative alkaline 
phosphatase 
   0.014*    0.775 
Preoperative creatinine    0.392    
Preoperative Glomerular 
Filtration Rate (GFR) >90ml/min 
   0.042*    0.054 
Blood loss (ml) <500 v 500-999 <0.001* 0.131±0.038   0.013† 
 500-999 v >1000   0.435    0.884 





The principal findings of this study are that higher initial serum lactate 
concentration after liver resection is associated with an increased risk of post-
operative mortality and renal and liver dysfunction. Both the 90-day mortality 
rate and the rate of renal dysfunction in patients with initial lactate 
concentrations greater than 6mmol/L were 28% compared to those patients with 
initial lactate concentrations less than 2mmol/L where they were 0.7% and 2.2% 
respectively. Similarly, higher lactate concentration was associated with higher 
postoperative peaks in serum bilirubin concentration and PT, as well longer 
lengths of hospital stay.  
These findings support and extend those of an earlier study323 by demonstrating 
the association of post-operative lactate with renal and hepatic dysfunction and 
length of hospital stay in addition to mortality. Pre-operative diabetes mellitus, 
the surgeon’s assessment of the liver at laparotomy, the extent of liver 
resection, blood loss and the number of units of blood transfused are also 
shown to be associated with post-operative serum lactate concentration. 
During cellular hypoxia pyruvate is diverted from the citric acid cycle and 
converted to lactate, reducing the amount of ATP generated. This occurs in all 
metabolically active tissues including muscle, gut, liver , brain, erythrocytes and 
skin324–326 and is exacerbated by intra-operative stresses including blood 
loss325, endogenous release of stress hormones327 and administration of 
pressor agents328. Liver ischaemia induced by handling of the liver during 
surgery and temporary inflow occlusion has been shown to lead to a rise in 
lactate329. Serum lactate can also be increased by transfusion of stored blood, 
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which contains a higher concentration of lactate than fresh blood depending on 
length of storage330. Administration of Hartmann’s solution has been shown to 
have a small effect on serum lactate concentration331. A potential weakness of 
this study is that details of pressor agents were not recorded which could affect 
the lactate concentration. Similarly, precise details regarding intravenous fluid 
type and volume of fluid (colloid and crystalloid) were not recorded. 
 
In addition to being a potential source of lactate the liver is the principle location 
of lactate metabolism, where it is converted back to glycogen, accounting for 
70% of whole body lactate clearance325.  No change in lactate metabolism has 
been demonstrated following recovery from partial hepatectomy in either rats 117 
or humans114, implying that the liver has a large functional reserve under 
physiological conditions of lactate production.  However, the effects of intra-
operative stress on hepatic glucose homeostasis have not been assessed, 
particularly when in combination with an extended hepatectomy. It is possible 
that inflow occlusion during resection and intra-operative handling of the liver 
lead to a temporary impairment of the ability of the liver to metabolise lactate. 
The finding of an association between the number of liver segments resected 
and the initial post-operative lactate supports this hypothesis. Diabetes is also 
known to be associated with impaired lactate metabolism via 
gluconeogenesis325 and may account for the strong association with post-
operative lactate in this series. Furthermore the use of metformin in non-insulin 
dependent diabetes has also been shown to increase lactate concentration332. 
The rise in serum lactate at the end of liver resection therefore may be due to a 
failure of lactate metabolism in addition to increased production during surgery. 
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Significantly the use of pre-operative chemotherapy was not shown to be 
associated with elevation of post-operative lactate. This may be due to a policy 
of allowing a period of recovery after completion of pre-operative chemotherapy 
before undertaking surgery. Interestingly the operating surgeon’s assessment of 
the liver parenchyma was associated with the post-operative lactate 
concentration. This finding suggests that patient comorbidity was a more 
common cause of abnormal liver parenchyma than the use of liver-directed 
chemotherapy.  
An important observation of this study is the relative rarity of major hepatic 
dysfunction following liver resection in this series with only one patient fulfilling 
the ’50-50’ criteria186, who subsequently recovered. Despite the infrequency of 
major disturbances of post-operative bilirubin and PT there was an independent 
association with increasing concentration of post-operative lactate, 
demonstrating that even a minor degree of liver injury can lead to impaired 
lactate clearance or increase its production. 
Renal dysfunction was also rare in this series, affecting 34 patients (7%) 
compared to 15% in a similar series188. The risk factors for post-operative renal 
dysfunction are likely to be similar to those in other forms of abdominal surgery, 
including blood loss and sepsis, which are also initiating factors for anaerobic 
metabolism and lactate production. This supports the value of initial lactate as 
an early predictor of renal dysfunction. Of note the risk of renal dysfunction 
appeared to rise more rapidly when the post-operative lactate rose above 
5mmol/L (Figure 7.2). This suggests that the kidneys can tolerate a degree of 




There was a weak association between initial lactate concentration and length 
of hospital stay in the study (Table 7.4). However, this may also be affected by 
other factors such as postoperative complications, particularly bile leaks, and 
degree of social support. 
The strongest association demonstrated was between lactate concentration and 
the risk of mortality. In a similar manner to renal dysfunction there seems to be 
a threshold level of post-operative lactate of approximately 6mmol/l above 
which the risk of 90-day mortality rises rapidly (Figure 7.3). Organ dysfunction 
was a major contributor to mortality in the series and initial lactate concentration 
is a valuable global marker of poor organ function in the early post-operative 




These findings are of value in clinical practice as it may be possible to use the 
initial post-operative lactate concentration to determine the patient pathway in 
the early post-operative period. Patients with an initial post-operative lactate of 
less than 2mmol/L have low rates of mortality and organ dysfunction and may 
not require post-operative critical care. In addition, the correlation of post-
operative lactate with subsequent organ dysfunction and mortality may allow its 





Chapter 8: Renal dysfunction is an independent 
risk factor for mortality after liver resection and 
the main determinant of outcome in post-
hepatectomy liver failure. 
 
Wiggans MG, Shahtahmassebi G, Bowles MJ, Aroori S, Stell DA. (2013) 
Renal Dysfunction Is an Independent Risk Factor for Mortality after Liver 
Resection and the Main Determinant of Outcome in Posthepatectomy 







The aim of this study was to assess the interaction of liver and renal dysfunction 
as risk factors for mortality after liver resection.   
Methods 
A retrospective analysis of 501 patients undergoing liver resection in a single 
unit was undertaken. Post-hepatectomy liver failure (PHLF) was defined 
according to the International Study Group of Liver Surgery (ISGLS) definition 
(assessed on day 5) and renal dysfunction according to RIFLE criteria. 90-day 
mortality was recorded. 
Results 
Twenty-three patients died within 90 days of surgery (4.6%). The lowest 
mortality occurred in patients without evidence of PHLF or renal dysfunction 
(2.7%). The mortality rate in patients with isolated PHLF or renal dysfunction 
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was 20% compared to 45% in patients with both. Diabetes (P=0.028), renal 
dysfunction (P=0.030) and PHLF on day 5 (P=0.011) were independent 
predictors of 90-day mortality. 
Discussion 
PHLF and postoperative renal dysfunction are independent predictors of 90-day 
mortality following liver resection but the predictive value for mortality is 




Despite advances in both operative technique and peri-operative care liver 
resection is associated with mortality rates of 0 to 22% (median 3.7%) and 
morbidity rates of 12.5% to 66% (median 36%)136 including liver186,313 and renal 
dysfunction140. Liver dysfunction is a major contributor to both morbidity and 
mortality with an incidence between 1.2% and 32% in published series137–
139,172,181–184. Renal dysfunction has also been shown to be associated with 
mortality following liver resection188, with a reported incidence between 5 and 
15%140,141. Post-hepatectomy renal failure may occur in conjunction with liver 
failure when maldistributive circulatory changes occur causing intravascular 
hypovolaemia140,190, but is also related to operative stress and blood loss148,152. 
Post-operative liver dysfunction has been defined by the “50-50 criteria” as a 
prothrombin index of less than 50% (mean normal prothrombin time (PT) 
divided by patient's observed PT) and a serum bilirubin of >50µmol/L on the fifth 
postoperative day, which has been shown to predict liver failure and death after 
hepatectomy186. More recently post-hepatectomy liver failure (PHLF) and has 
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been defined by the International Study Group of Liver Surgery (ISGLS) as a 
postoperatively acquired deterioration in the ability of the liver to maintain its 
synthetic, excretory, and detoxifying functions, characterized by an increased 
INR (or need of clotting factors to maintain normal INR) and hyperbilirubinaemia 
on or after postoperative day five187. The ability of this newer definition of PHLF, 
using lower measures of dysfunction, to predict mortality has not been 
thoroughly assessed. 
The aim of this study was to assess the utility of the ISGLS definition of PHLF 
on postoperative day 5 as a predictor of mortality and to determine the 





A retrospective analysis of a prospectively maintained database of all patients 
undergoing liver resection in this unit between July 2005 and September 2012 
was undertaken. Five hundred and one patients were studied. Patient 
characteristics, laboratory data and intra-operative details were retrieved. Liver 
resections were defined according to the Brisbane classification17 and 
undertaken using standard techniques. Prior to resection the operating surgeon 
makes a visual assessment of the condition of the liver parenchyma and 
records this as normal or abnormal. Hepatic inflow occlusion was used in a 
minority of cases where there was excessive blood loss. The POSSUM scoring 
system was used to calculate the pre-operative physiological risk score297.  
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All patients were followed up for a minimum of 90 days and mortality was 
recorded along with details of the cause of death. The cause of death was 
determined from case-sheet review, radiological and laboratory data and from 
death certificates. Patients who died with jaundice and/or radiological evidence 
of ascites and/or encephalopathy in the absence of any other clear diagnosis 
were determined to have died of liver failure. Patients who died within 24 hours 
of surgery were excluded from further analysis as these deaths were most likely 
due to peri-operative complications. Patients were also excluded if no 
postoperative blood tests were available. 
Serum biochemistry tests and coagulation assays were performed on patients 
in the first 24 post-operative hours and the tests repeated according to clinical 
course. The peak measurement of bilirubin, prothrombin time (PT) and 
creatinine were recorded and used for analysis and patients with PHLF were 
identified as having an increased PT and serum bilirubin on postoperative day 
five according to the ISGLS definition 187. In patients with preoperatively 
increased PT or serum bilirubin concentration PHLF was defined as an 
increasing serum bilirubin concentration and increasing PT on postoperative 
day 5 compared with the values of the previous day. Renal dysfunction was 
defined as an increase in serum creatinine of ≥1·5-fold from the preoperative 
baseline within the first five post-operative days, according to RIFLE criteria298. 
To determine potential associations between patient characteristics, operative 
factors and organ dysfunction with 90 day mortality univariate logistic regression 
or chi-square test at the level of P<0.25229 was performed, as appropriate. 
Significant variables in the univariate analysis were included in the multivariate 
logistic regression model and were considered to be significant if P<0.05. 
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Mortality ratios for organ failure were calculated as the proportion of deaths to 
proportion of survivors. All analyses were carried out using the statistical 




Five-hundred and one patients were studied. The indications for surgery, pre-
operative and operative details are shown in Table 8.1. Two patients who died 
within 24 hours of surgery were excluded from further analysis. One patient died 
of heart failure after a partially extended right hepatectomy and one died of 
biliary sepsis and multi-organ failure following an extended right hepatectomy 
































Table 8.1 Preoperative and intraoperative characteristics of 501 patients undergoing 






Age 65 (21-90)  
Gender 
Female  223 (45) 
Male  278 (55) 
Histological diagnosis 





Cholangiocarcinoma  31 (6) 





Other metastases  49 (10) 
Liver directed chemotherapy 
Yes  176 (35) 
No  325 (65) 
Diabetes 
Yes  55 (11) 
No  446 (89) 
BMI 26 (16-54)  
ASA Grade 
1  51 (10) 
2  323 (64) 
3  124 (25) 
4  2 (0.4) 
Not recorded  1 (0.2) 
Physiologic risk score 16 (12-32)  
Operative risk score 24 (14-35)  
Estimated P-Possum mortality (%) 7.7 (0.9-69.3)  
Confirmed fibrosis/cirrhosis 
Yes  22 (4) 
No  479 (96) 
Preoperative bilirubin (µmol/L) 9 (2-162)  
Preoperative haemoglobin (g/dL) 13.2 (8.6-17.0)  
Preoperative white cell count (/L) 6.9 (2.7-25.0)  
Preoperative albumin (g/L) 44 (24-53)  
Preoperative alkaline phosphatase (U/L) 95 (34-1190)  
Preoperative creatinine (µmol/L) 78 (40-430)  
Preoperative Glomerular 
Filtration Rate (GFR) 
>90ml/min  163 (33) 
<90ml/min  326 (65) 
Not measured  12 (2) 
Preoperative neutrophil lymphocyte ratio (NLR) 2.5 (0.3-17.3)  
NLR >5 
Yes  59 (12) 
No  442 (88) 
Open or laparoscopic 
approach 
Open  453 (90) 
Laparoscopic  48 (10) 
Radio frequency ablation 
(RFA) included 
Yes  23 (5) 
No  478 (95) 
Wedge resection included 
Yes  189 (38) 
No  312 (62) 
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Details of twenty-one patients (4.6%) who died within 90 days of surgery are 
shown in Table 8.2. There was no significant difference in the median age of 
patients who died (71 years) and those who survived (65 years). The median 









Right hemihepatectomy  173 (35) 
Extended right hemihepatectomy  34 (7) 
Left hemihepatectomy  64 (13) 
Extended left hemihepatectomy  17 (3) 
Left lateral sectorectomy  48 (10) 
Wedge resection only  133 (27) 
Other  32 (6) 
Bile duct reconstruction 
included 
Yes  46 (9) 
No  455 (91) 
Synchronous bowel 
procedure 
Yes  23 (5) 
No  478 (95) 
Operation number 
1st resection  465 (93) 
2nd resection  31 (6) 
3rd resection  5 (1) 
Number of segments resected 4 (1-6)  
Number of procedures 1 (1-10)  
Surgeon’s assessment of 
liver parenchyma 
Normal  323 (64) 
Abnormal  171 (34) 
Not recorded  7 (1) 
Blood loss 
<500ml  246 (49) 
500-999ml  175 (35) 
≥1000ml  76 (15) 
Not recorded  4 (0.8) 

























Table 8.2 Details of 21 patients who died within 90 days of surgery performed between July 2005 and September 2012 





















11 9 2 
67 
(58-76) 




4 2 2 
58 
(43-76) 





1 1 0 71 0 1 0 0 15 
PE 
 
1 1 0 71 1 0 0 0 7 
Anastomotic 
leak 
1 1 0 80 0 0 0 1 8 
Peptic ulcer 
 




1 1 0 76 0 0 0 1 89 
Peritonitis 
 
1 1 0 76 0 0 0 1 70 
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Of the 499 patients studied, blood tests were available in 495 patients (99.2%). 
Four patients did not have post-operative blood tests, all of whom had minor 
resections (fewer than three segments) and none of whom died within the study 
period and were excluded from analysis.  It was not necessary to administer 
clotting factors to any surviving patients between postoperative days (POD) 1-5. 
A summary of liver and renal function tests in the whole cohort is shown in 






Table 8.3 Postoperative liver and renal dysfunction in 495 patients undergoing hepatic 
resection between July 2005 and September 2012 
 
PHLF occurred in 31 patients of whom two had pre-existing liver failure and 12 
had extended resections. Seven patients in this group died within 90 days of 
surgery. Renal dysfunction also occurred in 31 patients, of whom 11 had 
extended resections.  Seven patients in this group died within 90 days of 
surgery. Among 55 patients with diabetes mellitus renal dysfunction occurred in 
seven patients (12.7%) compared to 24 of 440 patients without diabetes (5.5%) 
(P=0.067). There was no significant difference in the number of diabetic 
patients who developed postoperative renal dysfunction between those with 
normal preoperative renal function (0/12) and those with impaired preoperative 
renal function (7/43) (P=0.326).  
Laboratory parameters at day 5 
(N=495) 
Count (%) 90-day 
mortality (%) 
Death due to 
liver failure 
No PHLF or renal dysfunction 444 (89.7) 12 (2.7) 4  
PHLF alone 20 (4.0) 2 (10) 2 
Renal dysfunction alone 20 (4.0) 2 (10) 2 
Renal dysfunction plus PHLF 11 (2.2) 5 (45.5) 3  
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The lowest mortality (2.7%) occurred in the 444 patients without laboratory 
evidence of PHLF or renal dysfunction at day five, of whom 12 died, compared 
to 9 of 51 (17.6%) patients with either or both of these diagnoses. In the first 
group four of the twelve deaths were due to liver failure compared to seven of 
the nine deaths in the group with evidence of organ dysfunction at POD 5. 
The mortality rate in patients who fulfilled the criteria for PHLF on POD 5 but did 
not have renal dysfunction was identical (2 of 10 patients) to that of patients 
with renal dysfunction without PHLF (2 of 10 patients). All four of these patients 
died of liver failure. Mortality was greatest in the group of eleven patients with 
both PHLF and renal dysfunction of whom five died. Three of these five patients 
died of liver failure, one from anastomotic leak and one from a bleeding peptic 
ulcer. 
Multivariate analysis of potential risk factors for mortality including postoperative 
organ dysfunction (Table 8.4) revealed that the only preoperative factor 
independently associated with 90-day mortality was the presence of diabetes 






Table 8.4 Univariate and multivariate analysis of pre- and operative factors as well 
postoperative blood tests associated with 90-day mortality following liver resection in 
495 patients 
*Significant at the level of 0.25 for univariate analysis and included in multivariate 






Factor (Pre-operative and 
operative factors and 







Age 1.05 (1.01-1.10) 0.029*  0.194 
Gender 2.36 (0.91-6.08) 0.077*  0.196 
Pathology   0.274   
Liver directed chemotherapy  0.356   




BMI  0.444   
ASA grade 
1 vs 2 3.02 (0.70-13.11) 0.139*  0.678 
2 vs 3  0.724   
Physiologic score 1.12 (1.03-1.22) 0.010*  0.544 
Operative score  0.303   
P-Possum mortality 1.04 (1.01-1.07) 0.010*  0.479 
Fibrosis/cirrhosis  0.986   
Preoperative bilirubin 1.01 (1.00-1.03) 0.081*  0.652 
Preoperative haemoglobin 0.71 (0.55-0.93) 0.012*  0.195 
Preoperative white cell count  0.388   
Preoperative albumin 0.90 (0.84-0.96) 0.002*  0.168 
Preoperative alkaline 
phosphatase 
 0.884   
Preoperative creatinine 1.01 (1.00-1.02) 0.098*  0.764 
Preop neutrophil lymphocyte ratio 1.13 (0.98-1.31) 0.086*  0.366 
Preop neutrophil lymphocyte ratio 
>5 
2.18 (0.78-6.11) 0.138*  0.345 
Open or laparoscopic resection  0.987   
Radiofrequency ablation (RFA) 
included 
 0.991   
Wedge resection included  0.588   
Bile duct reconstruction included 2.96 (1.05-8.39) 0.041*  0.383 
Synchronous bowel procedure  0.346   
Operation number  0.549   
Number of segments resected 1.59 (1.18-2.14) 0.003*  0.075 
Number of procedures  0.786   
Surgeons assessment of liver 
parenchyma 
2.14 (0.92-4.96) 0.076*  0.494 
Blood loss (ml) 
<500 vs. 
>500 
2.67 (1.27-5.61) 0.009*  0.716 
>500 vs. 
>1000 
 0.652   
Units of red cells transfused 1.13 (1.02-1.26) 0.023*  0.224 




Renal dysfunction (Creatinine rise 
>1.5x) 






Both PHLF on POD 5 and post-operative renal dysfunction were independently 
associated with 90-day mortality. PHLF at POD 5 increased the risk of 90-day 
mortality by a factor of 4.5 (P=0.011) and renal dysfunction increased the risk 
by a factor of 3.6 (P=0.030). 
The positive predictive value (PPV) for mortality in patients who fulfilled the 
criteria for PHLF (including those with and without renal dysfunction) was 
22.6%. However, within this group the PPV was much lower (10%) if the criteria 
for PLF were fulfilled with normal renal function (Table 8.5). The PPV for 








Table 8.5 Predictive values for 90-day mortality of PHLF and renal dysfunction within first 




The effect of developing renal dysfunction in the context of PHLF is 












No PHLF or renal 
dysfunction 0.027 0.824 
PHLF alone 0.1 0.970 
Renal dysfunction alone 0.1 0.970 




Figure 8.1 Mortality ratio of combined liver and renal dysfunction in 495 patients 




The principle findings of this study are that PHLF on POD 5 as defined by the 
ISGLS and postoperative renal dysfunction are independent predictors of 90-
day mortality following liver resection. The predictive value for mortality is 
significantly higher when failure of both organs occurs, with a PPV of 45% and 




The 90-day mortality (4.6%) in this series is similar to results of other units 136. 
An important observation is that half the post-operative deaths in the series 
occurred between 31 and 90 days after surgery, stressing the importance of 
reporting 90-day rather than 30-day mortality. Of the 21 post-operative deaths 
11 were found to be due to liver failure.  
The study confirms the ability of PHLF to predict 90-day mortality. Interestingly 
most patients who developed PHLF at POD 5 (24 of 31) recovered whilst six of 
the eleven patients who died of liver failure did not fulfil the ISGLS definition of 
PHLF at POD 5. Only one patient in this series fulfilled the “50-50 criteria” of 
post-operative liver dysfunction, who subsequently recovered. Therefore, the 
“50-50” criteria had no value as a predictor of liver failure or mortality in this 
series with a PPV of zero. In comparison, the ISGLS definition of PHLF has 
lower thresholds for abnormal bilirubin and PT and is a more clinically useful 
tool for the prediction of 90-day mortality with a PPV of 23% and NPV 97%. This 
is similar to the findings of the only other study to address this issue, which 
revealed the PPV and NPV of PHLF were 32% and 98% respectively333.  
Simple blood tests therefore have a low positive predictive value for mortality 
due to liver failure. 
Renal dysfunction occurred in 6.3% of patients which is similar to other 
published series140,141. Renal dysfunction following liver resection may occur as 
a consequence of liver failure and hepato-renal syndrome, but may also result 
from hypovolaemia or damage from inflammatory mediators during surgery140. 
This occurs more commonly in elderly patients with atherosclerosis or 
hypertension190. These mechanisms of renal dysfunction may occur 
simultaneously. The use of low central venous pressure (CVP) during resection 
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may also increase the risk of postoperative renal dysfunction334,335. The results 
of this study demonstrate that isolated renal dysfunction is a significant risk 
factor for mortality independent of the development of PHLF. Interestingly the 
two patients with isolated renal dysfunction in the first-five post-operative days 
subsequently died of liver failure. This may be attributed to renal dysfunction 
delaying the onset of hepatic regeneration336. The most marked mortality effect 
of renal dysfunction was seen in conjunction with PHLF, where the mortality 
rate increased by a factor of four. Therefore, although the ISGLS definition of 
PHLF is able to predict mortality due to liver failure the development of renal 
dysfunction in this context is the single most important predictive factor.  
The finding of the significance of diabetes as a risk factor for post-operative 
mortality confirms earlier findings337. Insulin is important for hepatic function and 
regeneration338 and diabetes is also a risk factor for the development of non-
alcoholic fatty liver disease and cirrhosis339 which may lead to higher rates of 
PHLF283. Diabetic nephropathy is also a major cause of renal dysfunction310.  
In conclusion, we have demonstrated that PHLF as defined by the ISGLS on 
postoperative day five and postoperative renal dysfunction are able to predict 
90-day mortality following liver resection, although most patients fulfilling these 
criteria of organ dysfunction will recover. In addition, many patients will 
succumb to liver failure without fulfilling the PHLF criteria in the early post-
operative period. The combination of these two markers of organ dysfunction is 
the best early predictor of mortality following liver resection and we suggest that 
PHLF and postoperative renal dysfunction should be used in conjunction when 
predicting mortality after liver resection. Clinicians should use these findings to 
better assess the postoperative course for patients undergoing liver resection 
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and this information can be used when discussing progress with patients and 




Chapter 9: Extended pathology reporting of 
resection specimens of colorectal liver 
metastases-the significance of a tumour 
pseudocapsule 
 
Wiggans MG, Shahtahmassebi G, Malcolm P, McCormick F, Aroori S, 
Bowles MJ, Stell DA. (2013) Extended pathology reporting of resection 
specimens of colorectal liver metastases: the significance of a tumour 






The aim of this study was to analyse the relative influence of factors reported in 
the minimum histopathology dataset for colorectal liver metastases (CRLM) and 
other pre-operative factors compared to additional data relating to the presence 




Extended histological reporting of liver specimens for CRLM was performed for 
a period of fourteen months and included the presence of pseudocapsules and 






In sixty-six patients there were twenty-seven recurrences within one year. 
Recurrence was associated with a positive resection margin and the absence of 
a pseudocapsule (p<0.05). Pseudocapsules were associated with younger age, 
nodal stage of the primary colorectal tumour and metachronous tumours. The 
association between a pseudocapsule and lower early recurrence occurred in 
patients with synchronous metastases. 
 
Discussion 
These findings demonstrate that histological examination of resection 
specimens can provide significant additional prognostic information for patients 
after resection of CRLM, compared to clinical and radiological data available 
pre-operatively. Our finding that the absence of a pseudocapsule in patients 
with synchronous CRLM is associated with a dramatically worse outcome may 







Although resection of colorectal liver metastases (CRLM) offers overall  five 
year  survival rates ranging from 32-65%40,41 there is a spectrum of outcomes 
following surgery with some individuals remaining disease free and potentially 
being cured, while others will recur early with a poor outcome340,341. A number 
of risk scoring systems exist to stratify patients according to likely five-year 
survival. These systems predominantly use factors measurable pre-operatively 
which have been shown to be markers of prognosis, such as Carcinoembryonic 
Antigen (CEA) estimation236, tumour number236–239,342–348, tumour 
size236,238,239,342,348, resection margin clearance236–238,240,241,345,346,349–351, the 
presence of satellite lesions241 and the ratio of neutrophils to lymphocytes 
amongst white cells in a full blood count measured pre-operatively168. Liver 
specimens are routinely sent for pathological analysis after resection and the 
UK Royal College of Pathologists (RCPath) minimum dataset for liver 
specimens with colorectal metastases includes details of tumour number, size, 
location, resection margin clearance, capsular invasion, degree of 
differentiation, the presence of tumour necrosis, vascular and lymphatic 
invasion, the presence of satellite lesions, invasion of adherent tissue, and 
lymph node status if sampled122. With regards to prognostic factors, the most 
important additional information the pathology report reveals which is not 
available pre-operatively is the resection margin status. However, of the fifteen 
risk scoring systems available, only three have shown the presence of an 
involved resection margin to be a significant prognostic factor352. Therefore, 
histological examination of CRLM specimens may add relatively little additional 
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prognostic information compared to clinical, radiological and laboratory data in 
the currently used scoring systems.  
 
Extended examination of resection specimens may reveal other features whose 
prognostic significance has not been rigorously assessed, including details of a 
fibrous pseudocapsule around the tumour and the degree of tumour necrosis. 
The presence of a pseudocapsule has been associated with better overall 
survival after resection of CRLM123–125. Tumour necrosis can result from 
chemotherapy use126 and is also seen in tumours with high rates of cellular 
turnover in rapidly expanding tumours127. Therefore, tumour necrosis may be 
associated with more aggressive tumours and a worse prognosis. 
 
The aim of this study was to analyse the relative significance of factors reported 
in the minimum histopathology dataset and other pre-operative factors 
compared to additional data relating to the presence of tumour pseudocapsules 




Between March 2010 and May 2011, the Histopathology Department at 
Derriford Hospital performed extended reporting of CRLM specimens as an 
experimental protocol. Histology reports documented the presence or absence 
of a pseudocapsule, as well as how much of each tumour diameter was 
encompassed (zero, <50% or >50%). The presence and degree of necrosis 
observed in each tumour (nil, <33%, 33-66% and complete necrosis) was also 
recorded. Up to a maximum of the three largest tumours in each patient were 
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assessed and relevant features recorded. The pseudocapsule was identified as 
a paucicellular collagenous band present between the tumour cells and the 
adjacent hepatocytes, which measured at least 0.1mm in thickness (Figure 9.1).  
Tumour necrosis was characterised as discrete foci of cellular debris indicative 
of coagulative cell death (Figure 9.2). A proforma was designed and agreed 
within the Histopathology department to standardise reporting of resection 
specimens. In cases of heterogeneity between tumours the amount of 
pseudocapsule in up to the three largest tumours was measured and an 
average figure calculated according to a simple formula (>50% = 2, <50% = 1, 
no pseudocapsule = 0) and used in analyses. The amount of necrosis was 






Figure 9.1 Pathological examination showing a pseudocapsule (PC), non-neoplastic liver 
(NL) and a colorectal liver metastasis (CRLM).  Original magnification x50 using 




Figure 9.2 Pathological examination showing tumour necrosis (TN) in colorectal liver 











All patients underwent tumour staging with CT scan prior to surgery. In addition, 
46 patients had a pre-operative MRI scan and 50 patients a pre-operative PET 
scan, at the discretion of the referring clinician.  
A prospective database is maintained of all patients undergoing resection for 
CRLM and a review of these patients was performed when all had been 
followed up for a minimum of one year. The database holds information on 
primary histology, timing of detection of metastatic disease (synchronous 
tumours were defined as those discovered pre-operatively or within two months 
of primary surgery), the neutrophil to lymphocyte ratio, the use of chemotherapy 
as well as the histological features of the resected CRLM. Details of tumour 
recurrence were identified from surveillance imaging which is performed 
according to published guidelines 122. CEA estimation was not used routinely in 
post-operative surveillance. One patient did not have surveillance imaging in the 
first post-operative year and was excluded from recurrence analysis. One year 
recurrence was chosen as the primary end point because a high proportion of 
CRLM recur within this timeframe and early recurrence is associated with worse 
overall survival340,341.  
 
Potential associations between one year tumour recurrence and clinical and 
histological characteristics were tested initially using univariate logistic 
regression or chi-square test at the level of P < 0.25229, as appropriate. The 
association between clinical and histological characteristics and the presence of 
a tumour pseudocapsule in individual tumours was tested in a similar fashion. 
Significant variables in the univariate analysis were included in the multivariate 
logistic regression model and were considered to be significant if P < 0.05.  All 





Sixty-six patients were identified who underwent surgery for CRLM of whom 65 
were available for recurrence analysis. Additional staging MRI scans were 
performed in 28 of 38 patients with synchronous tumours and 18 of 28 with 
metachronous tumours (P=0.431). Additional staging PET scans were 
performed in 28 of 38 patients with synchronous tumours and 22 of 28 with 
metachronous tumours (P=0.774). The median number of surveillance scans 
performed was one (1-4) in patients who recurred and two (1-5) in patients who 
had not recurred at one year. 
 
In addition to surgery four patients had intra-operative radiofrequency ablation 
(RFA). Six patients died of recurrent cancer in the first year of follow-up. 
Twenty-eight patients (43.1%) developed recurrent cancer within the first year 
of follow-up. Eight of these recurred in the liver only, 12 had extrahepatic 
recurrence only and 8 had both hepatic and extrahepatic recurrence. Patient 






















Table 9.1 Pre-operative details of 66 patients undergoing extended histological reporting 
of resection of hepatic colorectal metastases.  
 
From the total patient group 132 lesions were examined histologically in the 
extended dataset. In two patients three tumours had responded completely to 
chemotherapy and were only identifiable microscopically as areas of complete 
necrosis. In these tumours, the presence of a pseudocapsule could not be 
assessed. Histological details of the resected specimens including the RCPath 
dataset and the presence of a pseudocapsule and degree of tumour necrosis 
for the 65 patients included in the recurrence analysis are shown in Table 9.2.   
  
N=66 Median (Range) Count (%) 
Age 65 (33-84)  
Gender Male  40 (60.6) 
Female  26 (39.4) 
Primary T stage 0  2 (3.0) 
1  3 (4.5) 
2  7 (10.6) 
3  29 (43.9) 
4  23 (34.8) 
Unavailable  2 (3.0) 
Primary N stage 0  34 (51.5) 
1  18 (27.2) 
2  11 (16.7) 
Unavailable  3 (4.5) 
Timing Synchronous  38 (57.6) 
Metachronous  28 (42.4) 
Liver-directed 
chemotherapy 
Synchronous  35 (92.1) 
Metachronous  11 (39.2) 
Neutrophil 
Lymphocyte Ratio 
Less than 5  57 (86.4) 




Table 9.2 Histopathological features and 1-year recurrence of 65 patients undergoing 
extended histological reporting of resection of hepatic colorectal metastases with one 
year follow up. 
In two patients (3 tumours) a complete response to chemotherapy was noted and 





















Satellite lesions Yes (0)  0  0 
No (65)  37  28 
Margin less than 10mm Yes (45)  24  21 
No (20)  13  7 
Margin less than 1mm Yes (22)  9  13 
No (43)  28  15 
Liver capsule smooth and 
intact 
Yes (55)  33  22 
No (10)  4  6 
Invasion of adherent tissue Yes (1)  0  1 
No (64)  37  27 
Differentiation No tumour (3)  2  1 
Well/moderate (62)  35  27 
Vascular invasion Yes (9)  3  6 
No (56)  34  22 
Histological evidence of 
response to chemotherapy 
No response (4)  2  2 
Response (19)  13  6 
Uncertain (7)  4  3 
Not recorded (35)  18  17 
Average amount of 
pseudocapsule 
Nil (36)  17  19 
<50% (17)  12  5 
>50% (10)  7  3 
N/A (2)  1  1 
Amount of necrosis of the 
largest tumour 
Nil (4)  3  1 
<33% (29)  16  13 
33-66% (21)  13  8 
>66% (11)  5  6 
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Heterogeneity in the presence of tumour pseudocapsules in multiple 
metastases was observed in 6 of 27 patients, where pseudocapsules were 
absent in some tumours, and in 5 of 27 patients where a differing amount of 
pseudocapsule was noted between tumours. 
9.4.1 Analysis of factors associated with one-year recurrence in 65 patients. 
 
Univariate analysis of pre-operative and histological factors and one-year 
recurrence revealed potential associations with age, number of metastases, a 
resection margin of less than one millimetre and the presence or absence of a 










Table 9.3 Univariate and Multivariate analysis of pre-operative and histological factors 




* Significant at the level of 0.25 for univariate analysis and included in multivariate 
analysis 
**Significant at the level of 0.05 for multivariate analysis 
 
Multivariate analysis revealed that only the absence of a pseudocapsule and a 
resection margin of less than one millimetre were significantly associated with 








Age 0.025* 0.876  
Sex 0.506   
Max diameter of tumour at histology 0.323   
Number of lesions 0.240* 0.831  
Capsule smooth and intact 0.408   
Margin less than 1mm 0.109* 0.045** 2.89 (1.61– 5.18) 
Margin less than 10mm 0.545   
Histological response to chemotherapy 0.674   
T stage of primary tumour 0.571   
N stage of primary tumour 0.381   
Synchronous vs. metachronous 0.824   
Liver directed chemotherapy (yes/no) 0.710   
Neutrophil Lymphocyte Ratio (>5) 0.320   
Pseudocapsule present 0.114* 0.030** 0.30 (0.174 - 0.524) 
Necrosis of largest lesion 0.886   
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patients with tumour pseudocapsules (8/27) than for patients with no 
pseudocapsule (19/36) (P=0.030). There was no significant difference in tumour 
recurrence rates according to the amount (< or >50%) of pseudocapsule 
present (P=0.750). (Figure 9.3). The recurrence rate in patients with a resection 
margin of <1mm was 13/22 compared to 15/43 in those with a margin of >1mm 
(P=0.045). 
 
Figure 9.3 Probability of 1-year recurrence according to the amount of pseudocapsule 
present for 66 patients undergoing extended histological reporting of resection of 







9.4.2 Analysis of factors associated with the presence of a pseudocapsule in 
132 tumours. 
 
Uni- and multivariate analysis was undertaken and revealed that increasing 
age, nodal status of the primary colorectal cancer and metachronous liver 
metastases were associated with the presence of a tumour pseudocapsule 










Table 9.4 Univariate and Multivariate analysis of factors associated with the presence of 
a tumour pseudocapsule (n=132) in 66 patients undergoing resection of hepatic 
colorectal metastases. 
* Significant at the level of 0.25 for univariate analysis and included in multivariate 
analysis 
**Significant at the level of 0.05 for multivariate analysis 
 
The size of individual tumours was not associated with the presence of a 
pseudocapsule. For each year of age, the incidence of a pseudocapsule falls 








Age (per year) 0.011* 0.005** 0.937 (0.90 - 0.98) 
Sex 0.090* 0.142  
T stage of primary tumour 0.290   
N stage of primary tumour <0.001* 0.025** 0.434 (0.24 - 0.77) 
Metachronous vs. Synchronous 0.004* 0.004** 2.622 (1.13 - 6.09) 
Neutrophil Lymphocyte Ratio 0.348   
Tumour size 0.167* 0.405  





Figure 9.4 Probability of pseudocapsule presence according to age for 132 tumours in 
patients undergoing resection of hepatic colorectal metastases 
 
Similarly, as the N stage increases by 1, the incidence of a pseudocapsule falls 
by 0.566 (Figure 9.5). Pseudocapsules occurred more commonly in tumours 
with a metachronous presentation (25/51) compared to a synchronous 
presentation (20/81) (P=0.004). Resection margin positivity was noted in 11 of 







Figure 9.5 Probability of a pseudocapsule according to N stage of primary colorectal 
tumour for 132 tumours in patients undergoing resection of hepatic colorectal 
metastases. 
 
The presence of a pseudocapsule had no significant association with one-year 
recurrence in patients with metachronous CRLM. However, in individuals with 
synchronous lesions the presence of a pseudocapsule was associated with a 














Table 9.5 Relationship between pseudocapsule and 1-year recurrence in synchronous 
and metachronous lesions in patients undergoing resection of hepatic colorectal 
metastases. 
*Significant at the level of 0.05 on Fisher’s exact test. 
 
 
9.5  Discussion 
 
The principal finding of this study is that a fibrous pseudocapsule is a common 
histological feature in patients undergoing resection of CRLM and is associated 
with a lower one-year tumour recurrence rate. This study extends earlier reports 
by showing that the benefit of a pseudocapsule occurs predominantly in 
patients with synchronous hepatic metastases. In these patients, only one third 
develop a pseudocapsule but have a dramatically reduced incidence of one-
year tumour recurrence (2/12) compared to patients without a pseudocapsule 
(13/23). The study also confirms that the presence of an involved resection 
margin is an independent predictor of early tumour recurrence. These two 
findings demonstrate that histological examination of resection specimens can 
provide significant additional prognostic information for patients after resection 




recurrence   
P-value  No Yes 
Timing Synchronous 
(37) 
Pseudocapsule Absent (23) 10 13 0.026* 
Present (12) 10 2  
N/A (2) 1 1  
Metachronous 
(28) 
Pseudocapsule Absent (13) 7 6 0.521 




The strength of the study lies in its prospective and unselected design, including 
all patients over a defined period with standardisation of reporting within 
predetermined guidelines. Specimens were reported by pathologists with a 
subspecialty interest in gastrointestinal disease who collectively approved the 
experimental protocol. The value of these findings to clinical practice is 
significant as the identification of a tumour pseudocapsule is readily performed 
on standard histology specimens without the need for special stains. A potential 
weakness of the study is that estimation of the extent of the pseudocapsule is 
subjective and semi-quantitative; however, our data show that the extent of the 
pseudocapsule is less important than its simple presence.  
 
Although three previously published studies have shown that the presence of a 
pseudocapsule is associated with improved long-term survival after resection of 
CRLM123–125 it is not commonly reported in this setting. Our series is the first to 
report lower recurrence rates in the presence of a tumour pseudocapsule in a 
Western population and adds further evidence of the benefit of adding this 
finding to the core data set in histology reporting of CRLM. Further follow-up will 
determine if lower early recurrence rates in this group are associated with 
improved survival. 
 
It is not known what stimulates the formation of a fibrous pseudocapsule and 
what role it plays in preventing early recurrence. The capsule develops at the 
interface between tumour tissue and normal liver tissue and the proliferating 
stromal cells in the capsule have been shown to be myofibroblasts 125. It has 
been suggested that CRLM activate hepatic stellate cells to form myofibroblasts 
and that this is a host defence response, similar to an inflammatory response, 
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creating a mechanical and chemical barrier around the tumour preventing 
further vascular and intrabiliary invasion125. Our finding that the absence of a 
tumour pseudocapsule is associated with a more aggressive primary tumour 
with nodal metastases supports this hypothesis, although we did not find any 
association with the neutrophil to lymphocyte ratio among circulating 
leucocytes, which has also been shown to be a marker of an inflammatory 
response to tumour168. It is also possible that older patients are less able to 
generate an inflammatory response to the tumour, accounting for the finding of 
a smaller proportion with tumour pseudocapsules in this age group.   
 
Our finding that the absence of a pseudocapsule in patients with synchronous 
CRLM is associated with higher tumour recurrence may help direct patient-
specific adjuvant treatment and care. For example, these patients may benefit 
from an increased frequency of postoperative imaging surveillance. Although 
postoperative chemotherapy following resection of CRLM has been shown to be 
of limited value353, future trials of this modality may be developed to target 
treatment to high-risk groups, such as patients with synchronous tumours with 
no pseudocapsules. 
 
Further research needs to be undertaken to confirm the potential association of 
a lower tumour recurrence rate in patients with tumour pseudocapsule in larger 
series, in addition to correlating this finding with improved survival. Further data 
may allow the development of a risk scoring system incorporating this finding. 
This may help clinicians and patients make informed decisions regarding post-
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Chapter 10: Influence of social-economic 
deprivation on likelihood of undergoing liver 
resection for hepatic colorectal metastases and 
outcome following surgery. 
 
Wiggans MG, Shahtahmassebi G, Aroori S, Bowles MJ, Stell DA. (2014) 
Socioeconomic deprivation influences the likelihood of undergoing liver 








The aim of this study was to compare the socioeconomic profile of patients 
undergoing liver resection for colorectal liver metastases in a regional 
hepatopancreatobiliary unit with that of the local population. A further aim was 
to determine if degree of deprivation is associated with tumour recurrence after 
resection. 
Methods 
A retrospective analysis of patients undergoing liver resection for colorectal liver 
metastases was performed. Geodemographic segmentation was used to divide 
the population into five categories of socioeconomic status (SES). 
Results 
During a seven-year period 303 patients underwent resection for colorectal liver 
metastases. The proportion of patients in the two least deprived categories 
undergoing resection was greater than that of the local population (50.2% vs. 
40.2%) and the proportion in the two most deprived categories was lower 
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(18.3% vs. 30.1%) (P<0.001). There was no difference in recurrence rate 
(P=0.867) or disease-free survival among categories of SES (P=0.913). 
Multivariate analysis demonstrated no association between SES and tumour 
recurrence (P=0.700). 
Discussion 
Liver resection for colorectal metastases is performed more commonly among 
the least socioeconomically deprived population than among the most deprived. 
However, degree of deprivation was not associated with tumour recurrence 




The incidence of primary colorectal cancer is associated with low 
socioeconomic status (SES) in the UK, where the age standardised incidence is 
11% higher in men living in the most deprived areas of England compared with 
those living in the least deprived132, although no difference has been 
demonstrated in women. Similar associations have been found in the USA, 
where individuals with higher levels of deprivation have been found to have a 
greater risk for the development of colorectal cancer even when other risk 
factors are controlled for354. Population studies have also shown that low SES is 
associated with worse outcome amongst patients with colorectal cancer133–135.  
Approximately a quarter of patients with colorectal cancer will develop colorectal 
liver metastases (CRLM) at the time of presentation122 and a further 25-30% will 
develop CRLM within two to three years of diagnosis355. Little is known of the 
impact of SES on the risk for CRLM and on outcomes of liver resection: a single 
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UK study demonstrated no association between social class and long term 
outcome following resection356. However, this study did not account for potential 
bias caused by patient selection for liver surgery. Patients with primary 
colorectal cancer often present symptomatically and are at risk of colonic 
obstruction, and population studies have shown that 60-80% of patients with 
primary colorectal cancer will be offered surgery357. However, the proportion of 
patients with CRLM who are offered surgery is far lower, at 10-20%254,255. 
Patients who develop CRLM must overcome a number of potential obstacles 
before undergoing liver surgery. They must survive surgery for primary 
colorectal cancer; they require long term surveillance imaging to detect 
metachronous lesions; they must be referred to a hepatobiliary unit; they must 
be medically fit for surgery, and their metastases technically resectable. 
Socioeconomic factors may influence a patient’s ability to overcome these 
obstacles following surgery for primary colorectal cancer, which may potentially 
skew the population of patients submitted to surgery for CRLM in comparison 
with that of the population suffering primary colorectal cancer. A crude 
comparison of outcomes according to SES may therefore be less valid for 
CRLM as patients may be more stringently selected than those undergoing 
surgery for primary colorectal cancer.  
The primary aim of this study was to compare levels of socioeconomic 
deprivation in patients undergoing liver resection for CRLM in a regional 
hepatopancreatobiliary (HPB) unit with those of the local population. A 







A retrospective analysis was undertaken of a prospectively maintained 
database of all patients submitted to liver resection for CRLM between July 
2005 and March 2012. Patient details, laboratory data and operative details 
were retrieved. Synchronous metastases were defined as those diagnosed prior 
to or within two months of primary surgery. All patients underwent tumour 
staging with computed tomography (CT) scan prior to liver surgery. Pre-
operative magnetic resonance imaging (MRI) and positron emission 
tomography (PET) scans were performed at the discretion of the referring 
clinician. The physiological score was calculated using the POSSUM 
(Physiological and Operative Severity Score for the enUmeration of Mortality 
and morbidity) scoring system297. Post-operative surveillance CT scans were 
performed at six-monthly intervals for three years after liver resection and 
annually for another two years. All patients included in disease-free survival 
analysis underwent a minimum of one surveillance CT scan performed and the 
date of tumour recurrence was recorded. 
Socioeconomic status was calculated using ACORN®358, a commercially 
available geodemographic segmentation tool. This tool divides UK households 
into five categories in order of increasing deprivation, characterised as 
representing: wealthy achievers; the urban prosperous; the comfortably off; 
those of moderate means, and the hard pressed. The smallest unit of 
population for which information is available is based on postcode. Full 
postcodes allow accurate geographical breakdown because the median size of 
a residential postcode in the UK is 13 households, or 31 residents358. The 
deprivation category is based on data collected from multiple sources including 
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property value, type, occupancy and usage. Further information relating to 
residents is obtained and includes data on date of birth, ethnicity and receipt of 
social benefits, along with data on spending habits and lifestyle. Population 
density data are obtained from the National Census. 
Patient survival curves were constructed using the Kaplan-Meier method and 
differences in survival were assessed using the log-rank method. Patients were 
excluded from survival analysis if they underwent planned non-curative 
resections or did not receive surveillance imaging. Comparisons between 
groups according to SES were performed using the chi-squared test or Mann-
Whitney U-test, as appropriate. Potential associations between pre- and intra-
operative factors, as well as histological outcome and tumour recurrence, were 
tested using univariate logistic regression or the chi-squared test, as 
appropriate. Variables in the univariate analysis for which differences achieved 
a P-value of <0.25 were included in the multivariate regression model229. 
Differences were considered to be significant at P<0.05.  Univariate and 
multivariate analyses were carried out using the statistical package R 2.1.14230. 
Patient consent was not required for this study following confirmation from the 
South West Health Research Authority that under the harmonised Guidance 
Approval for Research Ethics Committees (REC), REC review is not required 
because patient data were collected during normal hospital care and was 







Data relating to 303 liver resections performed for CRLM over a period of seven 
years were analysed. Clinicopathological characteristics and operative details of 



































Table 10.1 Preoperative and operative characteristics of 303 patients undergoing liver 
resection for CRLM. 
N=303 Median (Range) Count (%) 
Age 67 (33-90)  
Gender 
Female  113 (37.3) 
Male  190 (62.7) 
T stage of primary 
0  3 (<1) 
1  7 (2.3) 
2  19 (6.3) 
3  174 (57.4) 
4  91 (30.0) 
Unavailable  9 (3.0) 
N stage of primary 
0  133 (43.9) 
1  101 (33.3) 
2  64 (21.1) 
Unavailable  5 (1.7) 
Site of primary 
Colonic  152 (50.2) 
Rectal  151 (49.8) 
Timing 
Synchronous  144 (47.5) 
Metachronous  159 (52.5) 
Preoperative MRI 
Yes  166 (54.8) 
No  137 (45.2) 
Preoperative PET 
Yes  208 (68.6) 
No  95 (31.4) 
Preoperative liver directed 
chemotherapy 
Yes  151 (49.8) 
No  152 (50.2) 
Preoperative diabetes 
Yes  28 (9.2) 
No  275 (90.8) 
Body Mass Index (BMI) 27 (16-54)  
ASA Grade 
1  24 (7.9) 
2  211 (69.6) 
3  68 (22.4)                          
Neutrophil lymphocyte ratio 2.58 (0.50-17.25)  
Preoperative albumin (g/d/L) 44 (26-52)  
















Wedge resection  79 (26.1) 
Other  13 (4.3) 
Radiofrequency ablation (RFA) 
included 
Yes  19 (6.3) 
No  284 (93.7) 
Wedge resection included 
Yes  122 (40.3) 
No  181 (59.7) 
Number of segments resected 4 (1-6)  
Repeat operation 
Yes  33 (10.9) 
No   270 (89.1) 
Curative resection 
Yes  284 (93.7) 
No  19 (6.3) 
Number of tumours 1 (1-10)  
Maximum diameter of tumours (mm) 35 (3-155)  
Resection margin 
R0  232 (76.6) 
R1  71 (23.4) 
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The proportions of residents of Devon and Cornwall in the first and second 
(least deprived) (40.2%) and fourth and fifth categories (most deprived) (30.1%) 
SES categories differed from those of the UK (37.4% and 35.1% respectively) 











Table 10.2 Distribution of population categorized by socioeconomic status in the UK, in 
Devon and Cornwall, and in those undergoing liver resections for CRLM. 
Socioeconomic status was unclassified for eight patients. (Comparison between the 
proportion of residents of Devon and Cornwall and those undergoing liver resection: 
P<0.001) 
 
Socioeconomic data were unavailable for eight patients undergoing liver 
resection, leaving 295 for analysis. Of these 295 patients submitted to liver 
resection for CRLM, the proportions of patients from the first and second (least 
deprived) categories (50.2%) and fourth and fifth (most deprived) categories 
(18.3%) of SES differed from the proportions in the local population (40.2% and 
30.1% respectively) (P<0.001).  
The clinicopathological and operative characteristics of the 148 least deprived 
(categories 1 and 2) and 54 most deprived patients (categories 4 and 5) are 












1. Wealthy achievers 
(least deprived) 
14 967 871 (24.8) 580 065 (34.6) 137 (46.4) 
2. Urban prosperous 7 594 891 (12.6) 93 708 (5.6) 11 (3.7) 
3. Comfortably off 16 656 466 (27.6) 497 182 (29.7) 93 (31.5) 
4. Moderate means 8 449 324 (14.0) 271 357 (16.2) 31 (10.5) 
5. Hard pressed 
(most deprived) 
12 715 861 (21.1) 232 757 (13.9) 23 (7.8) 
Total 60 384 413 1 676 069 295 
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Table 10.3 Preoperative and operative characteristics of the 148 least (categories 1 and 2) 
and 54 most (categories 4 and 5) socioeconomically deprived patients undergoing liver 
resection for CRLM.  
 
N=202 Least deprived 
categories  
(1 and 2) (n=148) 
Most deprived 
categories  
(4 and 5) (n=54) P-Value 
Median 
(Range) 
Count (%) Median 
(Range) 
Count (%) 
Age 67 (34-88)  67 (33-90)  0.562 
Gender 
Female  56 (37.8)  23 (42.6) 
0.625 
Male  92 (62.2)  31 (57.4) 
T stage of primary 
0  2 (1.4)  0 
0.060 
1  4 (2.7)  1 (1.9) 
2  12 (8.1)  2 (3.7) 
3  71 (48.0)  39 (72.2) 
4  52 (35.1)  11 (20.4) 
Unavailable  7 (4.7)  1 (1.9) 
N stage of primary 
0  64 (43.2)  24 (44.4) 
0.781 
1  50 (33.7)  16 (29.6) 
2  30 (20.3)  13 (24.1) 
Unavailable  4 (2.7)  1 (1.9) 
Site of primary 
Colonic  77 (52.0)  29 (53.7) 
0.874 
Rectal  71 (48.0)  25 (46.3) 
Timing 
Synchronous  71 (48.0)  21 (38.9) 
0.268 
Metachronous  77 (52.0)  33 (61.1) 
Preoperative MRI 
Yes  83 (56.1)  29 (53.7) 
0.873 
No  65 (43.9)  25 (46.3) 
Preoperative PET 
Yes  111 (75.0)  25 (46.3) 
<0.001 









 29 (53.7) 
Preoperative 
diabetes 
Yes  16 (10.8)  3 (5.6) 
0.413 
No  132 (89.2)  51 (94.4) 
Body Mass Index 27 (17-39)  27 (19-54)  0.859 
ASA Grade 
1  16 (10.8)  1 (1.9) 
0.030 2  104 (70.3)  36 (66.7) 
3  28 (18.9)  17 (31.5) 








Preoperative albumin (g/d/L) 44 (29-51)  43 (34-51)  0.102 









 50 (92.6) 
Wedge resection 
included 
Yes  68 (45.9)  21 (38.9) 
0.425 
No  80 (54.1)  33 (61.1) 
Number of segments resected 4 (1-6)  3 (1-6)  0.617 
Repeat operation 
Yes  15 (10.1)  4 (7.4) 
0.786 
No  133 (89.9)  50 (92.6) 
Curative resection 
Yes  136 (91.9)  53 (98.1) 
0.191 
No  12 (8.1)  1 (1.9) 
Number of liver metastases 2 (1-10)  1 (1-8)  0.317 
Maximum diameter of metastases 
(mm) 
30 (3-120) 
 35 (5-120)  
0.063 
Resection margin 
R0  115 (77.7)  44 (81.5) 
0.698 
R1  33 (22.3)  10 (18.5) 
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The use of PET scans was greater in the least deprived than in the most 
deprived group (75.0 vs. 46.3%) and the proportion of patients with American 
Society of Anesthesiologists (ASA) grade 1 status was higher in the least 
deprived (10.8%) compared to the most deprived (1.9%) group. 
Data for 18 patients were excluded from the disease-free survival analysis 
because their resections were non-curative, or they did not complete a staged 
resection. Data for a further 11 patients were excluded because these patients 
died without undergoing surveillance imaging. This left a total of 266 patients for 
analysis. The median length of follow up was 1.07 years (range: 0.14-6.59) in 
the least deprived categories and 1.14 years (range: 0.21-7.36) in the most 
deprived categories (P=0.511). The median number of surveillance scans 
performed was three (range: 1-9) in both the least and most deprived categories 
(P=0.938). Tumour recurrence occurred in 163 patients; there was no difference 
in recurrence rate (77/133, 57.9% v 30/50, 60%) (P=0.867) or median time to 
recurrence between patients in the two least deprived (0.56 years; range 0.14-
2.74 years) and two most deprived (0.61 years; range 0.21-3.91 years) 
(P=0.305). There was no difference among the disease-free survival curves of 





Figure 10.1 Kaplan–Meier disease-free survival curves of 266 patients undergoing 
planned curative liver resections who underwent surveillance imaging according to level 
of socioeconomic deprivation (Log rank P=0.913) 
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Among those patients who underwent planned curative resections and for 
whom socioeconomic data were available, including those in whom no 
surveillance imaging was performed (n=277), there were a total of 96 deaths 
during the study period (34.7%). There was no significant difference in mortality 
rate between patients in the two least deprived categories (42/136, 30.9%) and 
those in the two most deprived categories (18/53, 34.0%) (P=0.729). Twelve 
patients died within 90 days of surgery (4.3%), but there was no significant 
difference in 90-day mortality between patients in the two least deprived (4/136, 
2.9%) and those in the two most deprived (3/53, 5.7%) categories (P=0.403). 
There was no difference in the overall survival curves across categories of SES 





Figure 10.2 Kaplan–Meier overall survival curves of 277 patients undergoing planned 
curative liver resections according to level of socioeconomic deprivation (Log rank 
P=0.190) 
 
Multivariate analysis of factors potentially associated with tumour recurrence 
(Table 10.4) demonstrated no association between SES and tumour recurrence 
(P=0.700). Only the number of liver metastases (P=0.014) and maximum 
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tumour diameter (P=0.001) were associated with tumour recurrence. Each 
additional liver metastasis increased the risk of recurrence by a factor of 1.28, 
and each additional millimetre in tumour diameter had a small effect, increasing 



















Table 10.4 Univariate and multivariate analysis of factors associated with tumour recurrence following liver resection for CRLM in 266 patients. 
 
 












Agea 65 (36-88)  67 (33-87)  0.872    
Gender 
Male  67 (65.0)  105 (64.4) 
0.863    




1 (least)  52 (50.5)  74 (45.4) 
0.700    
2  4 (3.9)  3 (1.8) 
3  27 (26.2)  56 (34.4) 
4  11 (10.7)  19 (11.7) 
5 (most)  9 (8.7)  11 (6.7) 
 T stage of primary 
0,1 or 2  10 (9.7)  18 (11.0) 
0.147b  
0,1,2 vs. 3 0.504 0.79 (0.40-1.56) 
3  61 (59.2)  93 (57.1) 
3 vs. 4 0.706 1.11 (0.68-1.80) 
4  29 (28.2)  47 (28.8) 
N stage of 
primary 
0  50 (48.5)  67 (41.1) 
0.828    1  34 (33.0)  53 (32.5) 
2  18 (17.5)  40 (24.5) 
 Site of primary 
colorectal tumour 
Colon  55 (53.4)  75 (46.0) 
0.389    
 Rectum  48 (46.6)  88 (54.0) 
 Timing 
Synchronous  46 (44.7)  78 (47.9) 
0.584    
Metachronous  57 (55.3)  85 (52.1) 
 Preoperative chemotherapy  47 (45.6)  85 (52.1) 0.412    
Preoperative diabetes  7 (6.8)  15 (9.2) 0.523    
Body mass index (BMI)a 27 (19-54)  27 (16-50)  0.518    
ASA grade 2 (1-3)  2 (1-3)  0.566    
Preoperative albumin (g/dL)a 44 (34-50)  44 (26-52)  0.949    
POSSUM physiological scorea 17 (12-32)  16 (12-32)  0.378    
Neutrophil:lymphocyte ratio (pre-op)a 2.4 (0.5-17.3)  2.6 (0.7-9.1)  0.211b 1.09 (0.95-1.26) 0.079 1.09 (0.94-1.28) 
208 
 











In univariate analysis, continuous variablesa tested with logistic regression. Categorical variables tested with chi square test. bSignificant at the level of 






















Preoperative MRI  59 (57.3)  87 (53.4) 0.640    
Preoperative PET  68 (66.0)  110 (67.5) 0.930    
Wedge resection included  31 (30.1)  67 (41.1) 0.117b  0.062 1.70 (0.98-2.94) 
Radiofrequency ablation (RFA)  6 (5.8)  10 (6.1) 0.959    
Number of segments resecteda 4 (1-6)  4 (1-6)  0.222b 1.10 (0.94-1.28) 0.120 1.00 (0.94-1.07) 
Repeat operation  11 (10.7)  18 (11.0) 0.105b  0.824 1.04 (0.39-2.77) 
Number of tumoursa 1 (1-7)  2 (1-10)  0.007b 1.29 (1.07-1.55) 0.014 1.28 (1.06-1.56) 
Diameter of largest tumour (mm)a 28 (3-155)  35 (6-150)  0.002b 1.02 (1.01-1.03) 0.001 1.0 (1.00-1.04) 





The principal finding of this study is that the SES of patients undergoing liver 
resection for CRLM is not representative of that of the local population because 
the proportion of patients from the least deprived categories is higher than 
expected and that of patients from the most deprived categories is lower than 
expected. Amongst patients undergoing liver resection for CRLM, the degree of 
socioeconomic deprivation had no effect on tumour recurrence after resection. 
The finding that people from the least deprived categories of SES account for a 
higher proportion of patients undergoing liver surgery for CRLM than they do in 
the local population is significant and in keeping with the present authors’ 
clinical observations. The comparison is subject to bias as the incidence of 
colorectal cancer is influenced by SES and the disease is more common in 
populations with the greater levels of deprivation132. This would tend therefore 
to increase the differences observed in the proportions of the different 
population categories submitted to liver surgery in comparison with those within 
the local population because CRLM would be expected to occur more 
commonly amongst patients of lower SES. There are many potential reasons 
why patients with the least deprivation are more likely to undergo surgery for 
CRLM, despite being at lower risk for development of colorectal cancer. 
Patients with higher levels of deprivation are more likely to suffer post-operative 
complications and death following primary colorectal cancer surgery359 and are 
likely to have more or more severe comorbidities that render them unfit for 
further surgery. Socioeconomic status is associated with educational 
attainment360, and patients with greater deprivation may be less aware of the 
potential benefits of treatment for metastatic disease. This may affect patients’ 
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willingness to engage with long-term surveillance to detect metachronous 
disease and to seek referral to an HPB unit. There is also an element of 
discretion by clinical practitioners in many stages of the patient pathway prior to 
surgery for CRLM, which may be influenced by perceptions of degree of 
socioeconomic deprivation. 
Interestingly, there was a large disparity in the use of staging PET scans, which 
were performed in 74.5% of patients from the least deprived groups compared 
with only 30.4% of patients from the most deprived. This may be partly 
explained by the higher incidence of T4 primary tumours amongst the least 
deprived patients, which is one of the indications for PET scans in national 
guidelines122, but is not otherwise explicable by the other measures of disease 
burden used in this study.  
There was no difference in objective measures of health between patients in the 
highest and lowest categories of SES as shown by the presence of preoperative 
diabetes, physiological score or body mass index. This may reflect the greater 
selection of patients from more deprived groups, in whom the rate of these 
markers of poor health might be expected to be higher. There was, however, a 
small difference in subjective measures of health as determined by ASA grade. 
To categorize SES, this study used the ACORN® system, which has been used 
in a number of epidemiological studies361–364. This system has advantages in 
that economic data are drawn from a wide range of sources in addition to 
property values. Other studies addressing the influence of SES on healthcare 
outcomes have used the Income Domain of the Index of Multiple Deprivation 
(IMD) score 365 and the Townsend index 366. These systems have been used 
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simultaneously in previous studies367,368 and neither method has been shown to 
be superior. Moreover, the difficulties of analysing and interpreting 
socioeconomic data have been described369. However, the systems allow for 
the valid and simultaneous comparison of different populations in contexts in 
which potential bias and inaccuracy will affect the populations under study 
equally. 
In a manner reflecting the findings of previous work356 degree of socioeconomic 
deprivation was not shown to be associated with either 90-day mortality or 
disease recurrence. The most likely explanation for this to be derived from the 
present data is not that SES does not affect these outcomes, but that greater 
selection occurs amongst patients of lower SES to favour patients who are likely 
to have better outcomes.  
The difference in the rates of liver resection for CRLM according to SES may 
reflect selection based on objective health measures. However, further study 
however is required to confirm this and to ensure equity of access to specialised 
hepatobiliary services within a publicly funded healthcare system. Similar 
differences may be found in other countries, especially those with systems of 
predominantly private health insurance, and selection of patients for surgery 
based on SES may influence the comparison of outcomes between countries. 
Further research is needed to understand the reasons why patients from more 
deprived groups are less likely to be referred for liver resection. Liver surgeons 
should ensure that other specialists and general practitioners understand the 
role of liver resection for colorectal liver metastases to avoid patients being 
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Chapter 11 : Thesis Summary and Conclusion 
 
This thesis follows the pathway of patients from referral to a regional 
hepatopancreaticobiliary unit through to postoperative surveillance. Over a 
seven-year period 504 liver resections were performed. 
The key findings of this thesis are as follows; 
1. Approximately 10% of patients proceeding to surgery following MDT 
discussion have inaccurate diagnoses and 5% are understaged despite 
an increase in the number of imaging modalities used.  
2. In the staging of patients with CRLM, the use of MRI in addition to CT 
showed no association with lower rates of  post-operative intra-hepatic 
tumour recurrence or disease-free survival.  
3. There was no association between tumour doubling time prior to surgery 
and post-operative survival. 
4. Disease-free survival is determined by tumour behaviour during 
treatment and not by change in size after completion of chemotherapy.  
5. The major complication rate was 18.7% and was significantly associated 
with age, male gender, insulin-dependent diabetes, hypoalbuminaemia, 
synchronous bowel procedures, the extent of resection and requirement 
for blood transfusion.   
6. Post-operative serum lactate predicted the 90-day mortality rate (28% 




7. The 90-day mortality rate was 2.7% in patients without post-hepatectomy 
liver failure or renal dysfunction, 20% in patients with single organ 
dysfunction and 45% in patients with both.  
8. Recurrence rates following liver resection for CRLM were lower in 
patients when a fibrous tumour pseudocapsule was present.  
9. Liver resection for CRLM was performed less frequently among the most 
socioeconomically deprived population. However, socioeconomic 
deprivation was not associated with tumour recurrence. 
 
The beginning of the patient journey begins with discussion of patients at a 
regional multidisciplinary team meeting. Over a six-year period there had been 
a 50% increase in the number of imaging modalities used during the 
assessment of patients put forward for liver resection. This increase in imaging 
modalities was due to the increased use of MRI and PET scans but this did not 
correlate with a reduction in the rate of non-resection or rate of discrepant 
diagnosis. Around 5% of patients still undergo unnecessary surgery for benign 
lesions. 
Overall 10% of patients proceeding to surgery are subsequently shown to have 
inaccurate diagnoses. The highest rate of discrepant diagnoses occurred in the 
group of patients with focal liver lesions but no history of chronic liver disease or 
primary cancer (38%). In this group multimodality imaging should be considered 




Interestingly, whilst investigating the impact of social deprivation in patients 
undergoing liver resection for CRLM it was noted that the use of PET scans was 
significantly greater in patients from the least deprived group (74.5%) compared 
to those patients from the most deprived (30.4%). This may be explained by 
either selection bias or the higher incidence of more advanced primary tumours 
in the least deprived group which is one of the indications for PET in national 
guidelines, although this had no impact on tumour recurrence.  
MRI scans with diffusion-weighted imaging have only been available within the 
region since 2011 and this may explain their increased use during the study 
period. Not only did the increased use of MRI lead to no improvement in the 
assessment of liver lesions in general, it was also demonstrated that in those 
patients with CRLM there were similar rates of accuracy in identifying the 
number of liver metastases in patients staged with CT and those with additional 
MRI. Moreover, MRI tended to overstage patients in terms of tumour number 
with the potential for patients to be denied liver surgery if lesions are falsely 
identified. The use of MRI was also associated with a delay in the time to 
surgery which may result in tumour progression prior to resection which many 
patients would find increasingly stressful. 
Significantly, the additional use of MRI conveyed no benefit in terms of tumour 
recurrence or disease-free survival in patients undergoing resection for CRLM 
when intraoperative ultrasound is used. The role of MRI in national guidelines is 
not clearly defined in this context but the findings of this study suggest that the 
use of MRI should not be mandatory in the assessment in patients with both 
CRLM and other potentially resectable liver lesions as the cost and delay 
associated with the scan outweigh the potential small benefit in terms of 
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improved sensitivity. This is however dependent on the use of IOUS which can 
be performed at low cost and not impact on time to surgery. 
Although scoring systems have been developed for the prediction of outcome 
following liver resection167,188,316,370,371 this thesis has demonstrated several 
novel findings as well as supporting those of previous studies. There was a 90-
day mortality rate of 4.6% in this series and of the 21 postoperative deaths 11 
were due to PHLF. The “50-50” criteria186 has previously been advocated as a 
predictor of PHLF and mortality but in this series, it had no value as a predictor 
of PHLF or mortality following liver resection. However, the ISGLS definition of 
PHLF defined as a post-operatively acquired deterioration in the ability of the 
liver to maintain its synthetic, excretory and detoxifying functions, characterized 
by an increase in INR and hyperbilirubinaemia on or after postoperative day 
five187, was shown to be an independent predictor of 90-day mortality with a 
PPV of 23% and a NPV of 97% in keeping with a previous study333. The 
presence of PHLF on postoperative day five increased the risk of mortality by a 
factor of 4.5.  
Postoperative renal dysfunction occurred in between six and seven percent of 
patients and was also an independent predictor of 90-day mortality following 
liver resection, increasing the risk by a factor of 3.6. A novel finding is that the 
PPV of PHLF as a predictor of 90-day mortality is significantly higher when it 
occurs alongside renal failure with a PPV of 45% and NPV of 97%. Therefore, 
although the ISGLS definition has been validated as a predictor of mortality, the 
development of renal dysfunction in this context is the single most important 
predictive factor and we suggest that PHLF and postoperative renal dysfunction 
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should be used in conjunction when predicting 90-day mortality following liver 
resection. 
Preoperative factors shown to be associated with 90-day mortality included 
older age, male gender, preoperative hypoalbuminaemia and diabetes mellitus 
in accordance with previous findings136,337. The presence of diabetes mellitus 
was also an independent risk factor for major complications after liver surgery 
which is again in keeping with previous studies60,163,164. However, another novel 
finding is that insulin dependence is the major risk factor rather than diabetes 
itself.  
Along with increased BMI, diabetes was associated with hepatic steatosis, 
although steatosis itself did not increase the risk of major complications after 
surgery. Postoperative renal dysfunction was twice as common in patients with 
insulin dependent diabetes compared to those not requiring insulin therapy, 
which itself was a predictor of 90-day mortality. The major risk factors in this 
series related to the surgery itself. Extent of resection and requirement for blood 
transfusion were independently associated with postoperative complications as 
previously demonstrated136. In contrast with a previous systematic review which 
suggested it is safe to perform synchronous bowel resections312 the findings of 
this study suggest that the risk of developing a major complication after a 
synchronous bowel resection was almost six times higher than when liver 
resection was performed alone.  
A key finding of this thesis is that initial serum lactate is a predictor of renal and 
hepatic dysfunction as well as 90-day mortality. The incidence of both renal 
dysfunction and mortality in patients with initial lactate concentrations greater 
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than 6mmol/L were 28% compared to 0.7% and 2.2% in patients with normal 
lactate concentrations <2mmol/L. Operative factors associated with a raised 
initial lactate concentration included extent of resection, blood loss and 
requirement for blood transfusion. There was also an association with diabetes 
mellitus. These findings are of value in clinical practice as those patients with 
initial lactate concentrations <2mmol/L are at low risk of organ dysfunction and 
mortality and therefore may not need post-operative critical care which may 
have significant financial and operational benefits for healthcare systems. 
In patients undergoing liver resection for colorectal liver metastases it was clear 
that the socioeconomic status of patients is not representative of that of the 
local population with more patients form the least deprived categories and fewer 
from the most deprived categories undergoing resection. There were no 
significant differences in the presence of diabetes, BMI or POSSUM 
physiological score between groups which would normally be expected in the 
general population, suggesting greater selection amongst the most deprived 
groups in whom these markers of poor health are more common. Importantly 
there was no association between the degree of socioeconomic deprivation and 
either 90-day mortality or disease recurrence which once again suggests that 
patient selection occurs to favour patients who are likely to have improved 
outcomes. 
In contrast to other solid tumours including colorectal lung metastases the rate 
of growth of untreated CRLM prior to liver resection had no impact on tumour 
recurrence or disease-free survival. In this context, the rate of growth of CRLM 
should therefore not be regarded as a predictor of poor outcome in terms of 
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recurrence and disease-free survival when patients are discussed at the MDT 
pre- or post-operatively. 
Where patients do receive liver-directed chemotherapy prior to liver resection 
for CRLM this study has demonstrated that in many patients the treatment 
effect is transient, and tumours continue to grow in the period between finishing 
chemotherapy and undergoing liver resection. However, it is their initial 
response to treatment that predicts disease-free survival despite rapid rebound 
growth in the interval before surgery, which has no association with disease-
free survival. This is the first study to address this rebound phenomenon and 
may be useful when addressing the timing of surgery. Patients are often 
concerned about the potential delay in proceeding to surgery because of the 
risk of further tumour growth. The results of this study can be used to counsel 
such patients both pre- and postoperatively where there may have been 
considerable increase in size of tumours at the time of resection. 
Aside from continuing in surveillance programmes, the final part of the patient 
journey occurs when the histopathology report of the resected specimen is 
discussed at the MDT. Both the number of metastases and maximum diameter 
of metastases are measured in the histology report. Although these are 
important prognostic indicators this information is often available from 
preoperative imaging and is of little additional benefit. A positive resection 
margin appeared to be an important prognostic factor in one of the multivariate 
analyses performed whilst investigating the presence of pseudocapsules. 
However, this analysis included cases of recurrence at the cut surface of the 
liver and when these patients were excluded from analysis no association 
between resection margin status and tumour recurrence was demonstrated. 
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The finding that in patients undergoing resection for synchronous CRLM the 
presence of a fibrous pseudocapsule may be a predictor of lower early 
recurrence is, however novel and warrants further investigation. This may have 
clinical significance for patients with synchronous CRLM who are found to lack 
the presence of a pseudocapsule and further treatment or surveillance may be 
tailored for this group. 
 
11.1 Overall conclusion 
This work can aid clinicians in the decision making and patient selection for liver 
resection. The findings may be used to effectively counsel patients 
preoperatively regarding the risks and benefits of liver resection. Furthermore, 
some of the findings may have a real impact upon healthcare provision in this 
patient group. In a public health service with ever increasing demand and costs 
careful patient selection is essential.  
Although the studies in this thesis are historical cohort studies (level 4 evidence) 
they have allowed us to ask novel questions regarding the pathway of patients 
undergoing liver resection and have revealed questions that can be further 
examined in other ways. Clinicians should use this evidence to further assess 
and analyse current local and national practices to ultimately improve patient 
care. It is recommended that clinicians could; 
1. Consider multimodality imaging in the diagnosis of hepatic tumours, but 




2. Further evaluate the role of preoperative MRI in the preoperative staging 
of colorectal liver metastases as new technology and protocols evolve 
and assess the impact on patient outcomes rather than simply the ability 
to detect lesions. 
3. Not  use rate of growth of colorectal liver metastases as a predictor of 
poor outcome in terms of tumour recurrence and disease-free survival 
when patients are discussed at MDT pre- or post-operatively until this 
has been further assessed. 
4. Use the evidence that preoperative patient factors such as older age, 
male gender, preoperative hypoalbuminaemia and diabetes mellitus are 
associated with morbidity to counsel patients regarding their individual 
risks associated with liver resection prior to embarking on surgery. 
5. Measure the initial lactate postoperatively to guide decision making 
regarding the level of postoperative care required such as ITU or HDU. 
6. Use the ISGLS definition of PHLF and  in combination with renal 
dysfunction to make assessments of patients’ clinical progress to guide 
the level of postoperative care required and to better inform patients and 
their relatives of clinical progress. 
7. Encourage routine histopatholoical reporting of the presence of 
pseudocapsules surrounding colorectal liver metastases to enable further 
assessment of this feature and its association with tumour recurrence 
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